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 Frontotemporal lobar degeneration (FTLD) is a devastating dementia disorder 
that causes profound changes in personality, behavior, and language abilities. Major 
breakthroughs in the past decade have advanced the understanding of the molecular 
genetics and pathological mechanisms underlying this disease, in particular the most 
common subtype, FTLD-TDP. Several causative and risk modifying genes have been 
identified which implicate defects in protein degradation and RNA metabolism 
pathways. The work presented here can be split into two main projects. In the first, I 
examine the physical properties of TDP-43 aggregation, which is a hallmark of FTLD-
TDP. Specifically, I characterize the role that phosphorylation plays in mediating the 
aggregation propensity of TDP-43 in a mammalian cell culture system. I further show 
that TDP-43 aggregates are cleared by the autophagy lysosome and ubiquitin 
proteasome systems, with the ubiquitin binding adaptor protein, p62/SQSTM1 
facilitating this process. In the second project, I sought to characterize the recently 
identified FTLD-TDP risk factor, TMEM106B. Using cell culture model systems, I 
demonstrate that TMEM106B overexpression causes specific defects in lysosome size, 
morphology, and degradative capacity. I also ruled out the effect of a small coding 
variant associated with the TMEM106B risk allele when the proteins are highly 
expressed at the same level, indicating that increased TMEM106B levels are the likely 
cause of defects seen in certain cases of FTLD-TDP. I have also identified a putative 
  
degradation pathway implicating lumenal lysosomal enzymes and a membrane bound 
intramembrane protease, SPPL2a, in the sequential proteolysis of TMEM106B. This 
pathway may represent a novel therapeutic target for controlling TMEM106B levels in 
vivo. Overall, my work has contributed significant findings to the field of FTLD-TDP 
related research and has increased the body of knowledge regarding the cellular and 
molecular mechanisms that contribute to this terrible disease.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Frontotemporal lobar degeneration 
 Frontotemporal lobar degeneration (FTLD) describes the neurodegenerative 
process that occurs in the prefrontal and anterior temporal cortex of the human brain, 
which causes a class of dementia disorders known as frontotemporal dementia 
(FTD)(1). Despite similar patterns of neurodegeneration, the molecular and genetic 
basis of FTLD is diverse. Furthermore, FTLD is commonly co-morbid with 
amyotrophic lateral sclerosis (ALS), which is characterized by degeneration of upper 
and lower motor neurons (2,3). Nevertheless, recent progress in the field has led to a 
new level of understanding of these complex disorders and common pathways that are 
disrupted in them have become evident. This chapter will provide an overview of the 
current knowledge regarding FTLD and its associated pathology. 
 
1.1.1 Epidemiology 
 FTLD is the third leading cause of all dementia cases after Alzheimer’s disease 
and vascular dementia and the second leading cause of presenile dementia, defined as 
cases with an age of onset earlier than 65 years (4,5). FTLD accounts for ~5-10% of 
all dementia cases (6). Estimates of FTLD prevalence based on multiple population 
based studies are approximately 10-20 per 100,000 with an incidence between 3.5-4.1 
per 100,000 person-years in the 45-64 year age group (5,7-9). At least 50% of FTLD 
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cases are sporadic, meaning there is no family history, however FTLD is familial in 
approximately 35-50% of cases, which are usually inherited in an autosomal dominant 
pattern (10). FTLD is incurable and has a median disease duration of 6-8 years (11-
13).  
 
1.1.2 Clinical subtypes and symptoms 
 Generally, FTLD is characterized by profound changes in personality and 
social behavior and is frequently associated with deficits in interpreting and producing 
language. Clinically, it is divided into three subtypes: behavioral variant FTD 
(bvFTD), semantic dementia (SD), and progressive non-fluent aphasia (PNFA). 
Subtypes are defined by the predominant early symptoms; however, as the disease 
progresses there is often significant overlap in symptomology correlated with 
increased neurodegeneration in the affected brain regions (reviewed in (14,15)).  
 bvFTD is the most common subtype, accounting for approximately two thirds 
of FTLD diagnoses (16). bvFTD manifests with drastic changes in personality and 
anti-social behavior with impairments in executive function, blunting of emotional 
affect, loss of insight, and loss of empathy. It is also associated with changes in food 
preference and inability to control appetite as well the development of stereotyped and 
ritualized behaviors (17,18).  
 The other two subtypes of FTLD, SD and PNFA, primarily affect language 
abilities. SD is characterized by anomia, which consists of the loss of the ability to 
recall words and names. This is due to defects in conceptualizing categories including 
objects and faces. Less common words are not understood and the ability to associate 
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specific words with pictures or concepts is lost. Patients may repeat phrases and words 
without being aware of their meaning. Grammatical rules, non-verbal problem solving, 
and memory are frequently spared in SD during the early course of the disease 
(19,20).  In cases of PNFA, by comparison, word meanings and object recognition 
abilities are relatively intact; however, patients have impairments in motor speech 
fluency and grammatical construction. Phonological aspects of language are affected, 
with patients exhibiting difficulty in producing the right sounds and ordering of words 
in spoken language (21,22). 
 
1.2  Molecular pathology and genetics 
 The last decade has seen incredible progress in the understanding of the 
molecular pathology and genetic causes of FTLD. Current models of pathophysiology 
recognize four principle subtypes, defined by the predominant proteinacious 
inclusions observed in the brains of affected patients. Generally speaking, each 
subtype has specific known causal mutations which result in the observed phenotype; 
however, new genetic causes and risk modifying genes continue to be identified. (23), 
(reviewed in (15,24)). Table 1.1 provides a list of the current known causes and risk 
factors for various classes of FTLD and the major molecular pathology present in each 
case. 
 
1.2.1 FTLD-Tau 
 The first type of FTLD to have a causative mutation linked to it was FTLD-
Tau, characterized by inclusions of the microtubule associated protein tau encoded by  
 4 
 
Table 1.1 Known genetic causes and risk factors for FTLD 
Gene Protein Pathological 
subtype 
Clinical 
phenotype 
Protein functions Locus 
TARDBP 
 
TDP-43 TDP-43 ALS1 mRNA Splicing and 
transcription, mRNA 
transport and stabilization, 
miRNA biogenesis, stress 
granule formation 
1p36 
MAPT Microtubule 
associated protein 
Tau 
Tau FTD Stability of axonal 
microtubules 
17q21 
Grn Progranulin TDP-43 FTD Growth factor, pro/anti-
inflammatory, cell 
migration, lysosomal 
functions? 
17q21 
Ubqln2 Ubiquilin 2 TDP-43 ALS, ALS-
FTD, FTD2 
Protein degradation 
(adaptor for UPS, 
autophagy) 
Xp11 
VCP p97/Valosin-
containing protein 
TDP-43 IBMPFD 
(FTD), ALS 
Protein degradation 
(adaptor for ERAD, UPS, 
and autophagy), 
membrane fusion 
9p13 
C9orf72 Chr.9 Open reading 
frame 72 
TDP-43, UPS ALS, FTD-
ALS, FTD 
unknown, related to 
DENN proteins 
9p21 
TMEM106B TMEM106B TDP-43 FTD, ALS
3 Lysosomal membrane 
protein, lysosome 
morphology,  function 
7p21 
CHM2B Charged 
multivesicular 
body protein 2b 
UPS FTLD, ALS4 component of ESCRTIII 
complex, MVB biogenesis 
and autophagy-lysosome 
degradation 
3p11 
FUS FUS/TLS FUS ALS, FTD-
ALS, FTD 
Splicing and transcription, 
DNA repair, maintenance 
of genome integrity 
16p11 
SQSTM1 p62/Sequesto-
some1 
TDP-43 FTD, FTD-
ALS 
Protein degradation 
(adaptor for UPS, 
autophagy), scaffold for 
NF-kB signaling  
5q35 
hnRNPA1 Heterogeneous 
nuclear 
ribonucleoprotein 
A1 
TDP-43 IBMPFD 
(FTD), ALS 
packing and transport of 
mRNA, interaction with 
splicing machinery 
12q13 
hnRNPA2/
B1 
Heterogeneous 
nuclear 
ribonucleoprotein 
A2/B1 
TDP-43 IBMPFD 
(FTD), ALS 
packing and transport of 
mRNA, interaction with 
splicing machinery 
7p15 
 
                                               
Table adapted from ref.31. 
1 Mutations present in rare cases of FTLD 
2 Mainly associated with ALS, mutations in different protein region linked to FTLD 
3 Risk modifier for FTLD with Grn mutations, associated with cognitive impairment in ALS 
4 Mainly associated with FTLD 
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the gene MAPT. Approximately 45% of all FTLD cases belong to this molecular 
subtype (24). In 1998, mutations in MAPT were identified to cause FTLD-Tau (25). 
To date, over two dozen mutations in the MAPT gene have been identified, with most 
of them mapping to the C-terminal portion of tau, interfering with microtubule 
assembly and regulatory activity of the protein (26). Genetic variants in the tau kinase 
GSK-3β may also be associated with FTLD-Tau (27). 
 
1.2.2 FTLD-TDP 
 Along with FTLD-Tau, the other major molecular subtype of FTLD, and the 
focus of this dissertation, is FTLD-TDP. Accounting for ~45% of all FTLD cases, 
FTLD-TDP is characterized by pathological inclusions of the multifunctional RNA 
binding protein, TDP-43 (24). Prior to the discovery of TDP-43 in FTLD, all non-
tauopathy cases of FTLD were referred to as FTLD-U due to characteristic 
ubiquitinated protein inclusions seen in post-mortem patient brains (23). TDP-43 was 
identified in 2006 as the major ubiquitinated protein present in the inclusions of 
FTLD-U and ALS patients by two groups simultaneously (28,29).  
 In FTLD-TDP brains, TDP-43 is truncated from a 43 kDa protein into C-
terminal fragments of ~35 and ~25 kDa. TDP-43 pathological inclusions are also 
extensively ubiquitinated, hyper-phosphorylated, and redistributed from the nucleus to 
the cytoplasm, although nuclear aggregation is also observed in many cases 
(23,30)(reviewed in (31)). While TDP-43 is the major pathological protein in FTLD-
TDP brains, it is also present in the inclusions of many other neurodegenerative 
disorders, most prominently in ALS, in which it is present in ~97% of cases, both 
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hereditary and sporadic. The remaining 3% of ALS cases contain FUS or SOD1 
inclusions and are generally negative for TDP-43 (32). Further, TDP-43 inclusions 
have been reported in post-mortem brains from patients with Alzheimer’s disease, 
Huntington’s disease, spinal cerebellar ataxia 3, and even some cases of FTLD-Tau 
(33-37). While, mutations in the gene for TDP-43, TARDBP, are known to be 
causative for a fraction of FTLD and many ALS cases, the fact that TDP-43 inclusions 
are observed in so many neurodegenerative diseases raises the possibility that TDP-43 
inclusions may also be a consequence of, in addition to a cause of neurodegeneration 
and this idea is a matter of considerable debate. Proper regulation of TDP-43 levels 
appears to be critical as TDP-43 overexpression animal models in C. elegans, 
Drosophila, and mice exhibit neurodegenerative phenotypes (38-40). Conversely, too 
little TDP-43 may drive a toxic loss of function phenotype, as TDP-43 knockout mice 
are embryonic lethal (41,42). 
 TDP-43 is a 414 amino acid protein localized primarily to the nucleus, but with 
known roles both in the nucleus and in the cytoplasm. Major features include a 
bipartite nuclear localization signal (NLS) from amino acids 82-98, dual RNA 
recognition motifs (RRMs), which bind both UG rich RNA and TG rich DNA 
sequences. A nuclear export signal (NES) is located within the second RRM domain. 
Finally, the C-terminal region from amino acids 274 to 414 remains relatively 
unstructured and likely mediates various protein-protein interactions necessary for 
proper protein function. The C-terminal domain (CTD) also contains a small 
glutamine and asparagine (Q/N) rich prion-like domain which may account for the 
aggregation prone properties of TDP-43. The entire CTD is also very glycine rich and 
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intrinsically unstructured, further accounting for its aggregation prone properties. The 
vast majority of pathogenic mutations in TDP-43 occur in this CTD (reviewed in 
(31)). These features and their major functional roles are laid out in a schematic of the 
TDP-43 protein in Figure 1.1. 
 
1.2.2.1 Physiological roles of TDP-43 
 TDP-43 has extensive known functions involved in RNA transcription, 
splicing, processing, transport, and metabolism. First discovered as a DNA binding 
protein to the transactive response (TAR) DNA of chromosomally integrated HIV-1, 
TDP-43 was shown to act as a transcriptional repressor (43). Its DNA binding and 
transcriptional repression activity has since been demonstrated for an endogenous 
human gene as well (44). One of the best characterized functions of TDP-43 is 
regulation of RNA splicing, dependent on the preferential binding of its RRM motifs 
to UG repeats in single stranded RNA. TDP-43 has been shown to specifically 
enhance or suppress splicing in a large number of transcripts. TDP-43 dependent exon 
skipping activity has been reported for cystic fibrosis transmembrane conductance 
regulator exon 9, apolipoprotein AII exon 3, eukaryotic translation termination factor 
1, and retinoid x receptor gamma (45-47). Conversely, TDP-43 enhances splicing of 
other transcripts including BRCA1 and the polymerase delta interacting protein/S6 
kinase 1 Aly/REF-like target (47,48). In total, TDP-43 is estimated to regulate the 
splicing of over 950 transcripts. TDP-43 also has an autoregulatory splicing role. One 
of the over 1,000 3’UTR binding targets of TDP-43 is its own transcript. When levels 
of TDP-43 are too high, it catalyzes a splicing event leading to the selection of an  
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Figure 1.1: Schematic of TDP-43 domain structure, adapted from ref. 31. TDP-43 
contains an N-terminal region required for many of its cellular functions. TDP-43 
contains an NLS and NES essential for its functions in shuttling RNA species in and 
out of the nucleus. Loss of the NLS when TDP-43 is cleaved promotes cytosolic 
aggregation. RRM1 and RRM2 are essential for TDP-43’s many regulatory roles 
governing RNA metabolism and transport and may be important in mediating TDP-43 
toxicity in disease states. The C-terminal domain is intrinsically unstructured and 
contains a Q/N rich prion-like domain. These regions mediate TDP-43 aggregation 
into stress granules and toxic aggregates during disease pathogenesis. These regions 
are also important for TDP-43 functions and mediate numerous protein-protein 
interactions. Abbreviations: NLS, nuclear localization signal; NES, nuclear export 
signal; RRM, RNA recognition motif, Q/N, Glutamine/asparagine; UTR, untranslated 
region.  
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alternative, cryptic polyadenylation site. This has been proposed to result in less TDP-
43 through the introduction of a premature stop codon resulting in non-sense mediated 
decay and/or nuclear retention of the TDP-43 transcript (49,50). 
 In addition to its splicing regulatory role, TDP-43 has been shown to bind the 
introns and 3’UTRs of numerous transcripts without affecting their splicing patterns. 
Recent, genome-wide studies of TDP-43 depleted mice performed by Polymenidou 
and colleagues demonstrated that TDP-43 binds to close to one third of the entire 
transcriptome, including over 6,000 brain enriched RNA targets (49). It is thought that 
this action may be essential for the long term stability of many of these transcripts, 
particularly those with introns >100kb, many of which are highly enriched in the 
brain. 
 TDP-43 has roles in binding other non mRNA targets in the nucleus as well. It 
has been demonstrated to bind to a variety of regulatory RNAs known as long non-
coding RNAs (lncRNA), which are >200bp and may account for up to a fifth of the 
human genome (51). Two of these lncRNA TDP-43 targets include metastasis-
associated lung adenocarcinoma transcript 1 (MALAT1) and nuclear-enriched 
autosomal transcript 1 (NEAT1) implicating potential roles in chromatin remodeling 
and cell-cycle progression (52). TDP-43 may also have roles in micro RNA (miRNA) 
biogenesis, as certain miRNAs have been reported by Burratti and colleagues, to be 
differentially up or down-regulated in response to reduced TDP-43 levels (53). 
Further, TDP-43 has been reported to bind both the Drosha microprocessor and Dicer 
complexes required for miRNA processing and maturation and these associations are 
dependent on its RRM domains and C-terminal tail (54-56) . 
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 TDP-43 has both a nuclear localization and nuclear export signal. While the 
vast majority of TDP-43 resides in the nucleus at steady state, it can also dynamically 
shuttle various RNA targets between the nucleus and cytoplasm through its RRM 
domains (57). TDP-43 associates and traffics with various RNA containing granules in 
the cytosol such as P-bodies which contain RNA degradation machinery, stress 
granules which can sequester RNAs in times of cellular stress through interaction with 
aggregates of the prion like protein TIA-1, and transporting RNP granules which may 
facilitate proper localized translation of mRNA targets, for example at the synapse 
(58,59). A summary of TDP-43’s many annotated roles is summarized in Figure 1.2. 
 
1.2.2.2 Genetics of FTLD-TDP 
 The genetic causes of FTLD-TDP are varied and relatively complex compared 
to the other molecular classes of FTLD with more than a half dozen genes implicated 
as direct causes of or risk modifiers for disease progression. Mutations identified in 
2004 in the gene encoding valosin containing protein (VCP) were found to result in a 
rare multisystem form of FTLD, known as inclusion body myopathy with Paget 
disease of bone and frontotemporal dementia (IBMPFD), which was later shown to 
contain TDP-43 inclusions (60,61). VCP is a member of the AAA ATPase family with 
many functional roles involved in ubiquitin dependent protein degradation through 
multiple pathways including endoplasmic reticulum associated degradation (ERAD), 
the ubiquitin proteasome system (UPS), and the autophagy-lysosome pathway (62). 
Further roles include mediating vesicle trafficking and homotypic membrane fusion 
events, mitotic events, and maintenance of genome stability (63,64).   
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Figure 1.2: Physiological functions of TDP-43, adapted from ref. 24. In the nucleus, 
evidence exists for TDP-43 binding single stranded DNA and regulating transcription 
(1) regulation of numerous mRNA alternative splicing events (2). TDP-43 controls the 
levels of numerous mRNAs, including its own transcript, through an autoregulatory 
mechanism in the 3’UTR (3). TDP-43 stabilizes mRNA species with long introns, 
which are highly enriched in the nervous system (4). TDP-43 is associated with 
several species of lncRNA (5) and is implicated in miRNA processing events (6). 
Cytosolic functions of TDP-43 include transport of mRNA for localized translation 
(7), particularly at synapses, 3’ UTR binding of mature RNA (8), which may stabilize 
some transcripts and mediate sequestration into stress granules (9). Abbreviations: 
lncRNA, long non-coding RNA; miRNA, microRNA  
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 Perhaps the most commonly mutated gene that causes a clinically “pure” 
FTLD-TDP phenotype is GRN, which encodes the multifunctional secreted growth 
factor progranulin (PGRN). This major finding was simultaneously reported by two 
independent research groups in 2006 (65,66). GRN mutations are responsible for an 
estimated 5-10% of total FTLD cases, 20% of familial FTLD cases, and 20% of 
familial and sporadic FTLD-TDP cases (67,68). The vast majority of disease causing 
GRN mutations result in premature stop codons, resulting in nonsense mediated decay 
of PGRN mRNA, however other causative mutations include certain missense 
mutations, splice site mutations, and mutations in the signal sequence resulting in 
impaired secretion (69-71). The net result of all of these mutations is reduced levels of 
active PGRN, resulting in an autosomal dominantly inherited haploinsufficiency. 
 The mechanism by which PGRN haploinsufficiency causes FTLD-TDP is 
poorly understood, but it has been suggested that loss of PGRN results in caspase 
dependent TDP-43 cleavage into the pathogenic 35 and 25 kDa fragments (30,72). 
PGRN is secreted as a pro-protein consisting of seven and a half granulin motifs, each 
of which contain a characteristic pattern of 12 disulfide bonded cysteine residues (73). 
Additionally, PGRN can be cleaved by multiple proteases including, elastase, 
proteinase-3, MMP-14, and ADAMTS-7, to yield individual granulin motifs each of 
which may be functionally distinct (73-77). PGRN cleavage can also be inhibited by 
the secretory leukocyte protease inhibitor (SLPI) and full length PGRN has been 
shown to be endocytosed into neurons by the trafficking receptor sortilin where it is 
targeted to lysosomes (74,78,79). Progranulin is secreted in large amounts in response 
to injury by immune cells such as microglia, suggesting that it may act on neurons in a 
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cell non-autonomous manner, although neurons do produce some PGRN as well 
(80,81). Individual granulins have been shown to mediate inflammatory events while 
full length PGRN has been shown to exert anti-inflammatory activity, potentially 
through antagonizing TNFR1 and TNFR2, although this latter point remains 
controversial (73,82,83). Finally, PGRN promotes cellular migration and acts as a 
survival signal by activating the AKT and ERK1/2 signaling pathways through an 
unknown mechanism (84,85). 
 Patients with FTLD-TDP caused by PGRN mutations may have vastly 
different clinical outcomes, even when presented with identical mutations, suggesting 
that other genes or environmental effects may be affecting disease progress (86). A 
genome wide association study (GWAS) by Van Deerlin and colleagues, published in 
2010, identified single nucleotide polymorphisms in the TMEM106B gene as a risk 
factor for FTLD-TDP (87). These results were later replicated in further GWASs with 
different cohorts which showed that the major allele of TMEM106B is associated with 
worse outcome in patients with GRN mutations (88-91). In particular, the risk allele of 
TMEM106B was associated with a mean decrease in the age of onset of FTLD by 13 
years. Additionally, the TMEM106B risk allele was associated with cognitive 
impairment in ALS patients and was also shown to be a risk factor for Alzheimer’s 
disease (92-94). TMEM106B is a type II single pass transmembrane protein of 
unknown function (95). The TMEM106B risk allele may correlate with increased 
expression in patients, either through enhanced mRNA stability, differential response 
to a specific miRNA, through slower degradation kinetics due to a variant in a 
consensus glycosylation site, or some combination of these mechanisms (87,96,97). 
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There appears to be a correlation with decreased serum PGRN and mRNA levels in 
patients with the TMEM106B risk allele and increased expression of TMEM106B in 
cell culture models appears to raise the levels of intracellular PGRN (88,96,98). The 
relationship between GRN mutation status and TMEM106B mRNA levels remains 
controversial with some groups claiming TMEM106B mRNA is elevated while others 
say only the protein levels are affected and will be a matter of ongoing investigation.  
 
1.2.3 FTLD-FUS 
 The second class of FTLD-U to be identified was FTLD-FUS, so named for 
the inclusions of the Fused in sarcoma protein (FUS). Mutations in FUS were co-
discovered in 2009 as a cause of both FTLD and ALS and account for approximately 
9% of total FTLD cases and less than 1% of total (5% of familial) ALS cases 
(24,99,100). Like TDP-43, FUS is an RNA binding protein with an aggregation prone, 
prion-like domain. It is involved in many of the same ontological cellular processes as 
TDP-43, including stabilization of long intron containing transcripts, binding of 
lncRNA, biogenesis of miRNA, transcriptional inhibition, mRNA transport, and stress 
granule formation. Additionally, FUS has roles associated with the general 
transcription machinery and in maintaining genome stability (24,101). Despite these 
similarities, there is little overlap in the RNA targets recognized by TDP-43 and FUS, 
suggesting that they play disparate roles within the cell (49,52,102).  
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1.2.4 FTLD-UPS 
 The final distinct molecular subtype of FTLD, is referred to as FTLD-UPS due 
to the presence of ubiquitinated inclusions. A single predominant pathological protein 
has yet to be identified for this subtype, if one exists (23). FTLD-UPS accounts for 
~1% of all FTLD cases and is associated with familial mutations, best characterized 
by a Danish pedigree (24,103). FTLD-UPS is caused by mutations in the charged 
multivesicular body protein 2B (CHMP2B), a component of the endosomal sorting 
complex required for transport (ESCRT)-III complex. The ESCRT-III complex is a 
large multiprotein complex that serves to concentrate ubiquitinated cargoes for 
packaging into the intralumenal vesicles (ILVs) of late endosomes, also referred to as 
multivesicular bodies (MVBs), prior to fusion with lysosomes. The ESCRT-III 
complex also plays a role in recruiting deubiquitinating enzymes (DUBs) that remove 
ubiquitin moieties from cargo destined for degradation. Finally, the ESCRT-III 
complex recruits the AAA ATPase VPS4/Skd1, which disassembles the complex 
(reviewed in (104,105)). 
 
1.2.5 FTLD is part of a clinico-pathological disease spectrum with ALS 
 There is significant overlap in terms of molecular pathology, disease 
mechanisms, and clinical presentation between patients with FTLD and ALS, 
particularly in those cases characterized by TDP-43 inclusions (reviewed in (15,24)). 
As many as 50% of FTLD and ALS patients share some symptoms of both diseases, 
while up to 15% of affected patients can be said to meet the clinical criteria of both 
diseases, hereafter referred to as FTLD-ALS (106-109). Hence, it is increasingly 
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recognized that FTLD and ALS may represent opposing sides of a disease spectrum. 
Nevertheless, different mutations in different genes have different propensities for 
causing either FTLD or ALS, with some causing clinically “pure” phenotypes, while 
others tend to have more mixed pathology. A summary of some of the more common 
causes of FTLD and ALS and their relative contributions to this disease spectrum are 
highlighted in Figure 1.3. 
 Several GWASs had previously demonstrated a major locus mapping to 
chromosome 9p21, associated with both FTLD and ALS (87,110-112). In 2011, two 
groups simultaneously reported the presence of expanded (~700-1,600 repeats) 
GGGGCC hexanucleoitde repeats within the first intron of the C9ORF72 gene 
(113,114). Patients with these repeat expansions have particularly high incidences of 
co-morbidity with FTLD and ALS. This abnormality in C9ORF72 is the single largest 
genetic contributing factor to FTLD and ALS identified, accounting for 10-30% of 
FTLD-TDP cases, 5-20% of sporadic ALS cases, 20-50% of familial ALS cases, and 
as much as 80% of FTLD-ALS cases (115-121). The C9ORF72 protein has an 
unknown function, but bioinformatic analysis reveals the presence of a DENN 
(differentially expressed in normal and neoplastic cells) domain, which are known to 
function as Rab-GEFs, suggesting a potential role in regulating membrane trafficking 
events (122). 
 Mutants in VCP cause IBMPFD, which includes features of Paget disease, 
FTLD, and ALS. Recently, mutations in two other RNA binding proteins in the same 
family as TDP-43, hnRNPA1 and hnRNPA2/B1, were also found to be causative of 
IBMPFD/ALS (123). Mutations in CHMP2B are most strongly associated with FTLD;  
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Figure 1.3: FTLD and ALS represent a disease continuum, adapted from ref. 24. (a) 
Certain mutations have propensities for one side of the continuum. Additionally, many 
mutations are capable of producing cases with clinical features of both diseases 
(FTLD-ALS). * indicates genetic causes of disease with TDP-43 proteinopathy. (b) 
Relative frequencies of the different pathological subtypes observed in FTLD. Note, 
that many of the genetic causes of FTLD-TDP and FTLD-FUS are also capable of 
causing ALS.  
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however, they can also cause ALS in some cases (124,125). Conversely, mutations in 
TDP-43 are nearly always linked to ALS, however, rare cases have been reported in 
which TDP-43 mutations cause FLTD-ALS or even pure FTLD (126-129). Two other 
proteins which are mutated in some cases of familial and sporadic ALS are the 
ubiquitin-binding adaptor proteins p62/SQSTM1 and ubiquilin 2 (UBQLN2). Like 
TDP-43, these can also cause FTLD-TDP in certain cases (130-132). In the case of 
UBQLN2, mutations that cause ALS are typically concentrated in its proline rich PXX 
domain, while FTLD-TDP causing mutations are located in other conserved regions of 
the protein (133).  
 
1.3 Impaired proteostasis and RNA metabolism in FTLD-TDP 
 When reviewing the genetic causes and risk factors for FTLD, it is clear that 
pathways regulating protein homeostasis and various aspects of RNA homeostasis and 
metabolism are strikingly affected. It has been recognized for some time, that impaired  
proteostasis is a general feature of aging and neurodegeneration in particular, with 
post-mitotic neurons being particularly vulnerable to disruptions in protein 
degradation and quality control (134). The cell has two major pathways for the 
degradation of misfolded, aggregated, or otherwise unnecessary proteins: the ubiquitin 
proteasome system (UPS) and the autophagy-lysosome system. Furthermore, these 
two  systems engage in a dynamic cross-talk with each other, and disruptions in one or 
both have far-reaching implications for the overall health of the cell (135). More 
recently, it has been realized that large-scale defects in RNA homeostasis are also 
implicated in a number of neurodegenerative disorders, most prominently FTLD and 
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ALS. Current models of neurodegeneration in FTLD and ALS hold that defects in any 
one of these major processes regulating protein and RNA homeostasis may drive 
further impairments in the other systems, causing a feedback loop of dysregulated 
protein and RNA processing, ultimately resulting in cell death (24,136). Figure 1.4 
displays a cartoon schematic of the pathological conversion of TDP-43 in FTLD-TDP 
and the known causative mutations and risk factors which disrupt these critical 
processes in diseased neurons.  
 
1.3.1 Proteostasis defects in the ubiquitin-proteasome and autophagy-lysosome 
systems 
 One of the hallmarks of FTLD-TDP is the aggregation of cleaved, 
ubiquitinated, and hyperphosphorylated TDP-43. It has been demonstrated that TDP-
43 overexpression and TDP-43 aggregates are directly cytotoxic in a number of cell-
based and animal models (38,39,137-140). In fact, aggregates of TDP-43 have been 
demonstrated to be cytotoxic even in yeast, which have no TDP-43 homolog. This  
toxicity is dependent on both the RNA binding and C-terminal aggregation prone 
regions of TDP-43 (141). TDP-43 aggregates are extensively ubiquitinated and 
removal by the 26S proteasome, with the aid of the chaperones Hsp70 and Hsp90,  has 
been demonstrated to be one  mechanism for removing these cytotoxic aggregates in 
vitro (139,142,143). The vast majority of ALS and to a lesser extent FTLD, disease 
linked TDP-43 mutations are concentrated in the aggregation prone C-terminal region 
and can enhance the aggregation propensity of TDP-43, further suggesting a potential 
gain of function toxicity caused by TDP-43 aggregation (144). 
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Figure 1.4: Proposed sequence of events in pathological conversion of TDP-43 in 
FTLD-TDP, adapted from refs. 24, 31. The known FTLD-TDP genetic causes and  
risk factors and the pathways they disrupt are shown in red. Question marks indicate a 
role in that pathway, but insufficient evidence to conclude a causal effect on 
pathogenicity in disease states. Note, C9ORF72 RNA expansion disruption is thought 
to originate in the nucleus, but these cases also exhibit TDP-43 inclusions and likely 
cytosolic RNA disruption as well. 
  
 23 
 
 In addition to the UPS, the other major protein degradation mechanism in the 
cell is the autophagy-lysosome system, which is critical for the degradation and 
recycling of a large variety of protein substrates. Membrane proteins from the 
endocytic pathway destined for degradation are internalized into late endosomes, 
typically in a mono-ubiquitin dependent manner and are trafficked to the lysosomes, 
while bulk cytoplasmic degradation of large protein aggregates and organelles is 
mediated by sequestration of substrates within a double-membrane autophagic 
vacuole, which then fuses with lysosomes for degradation of its contents (145). The 
importance of functioning endo-lysosomal and autophagy-lysosome pathways in 
neuronal health is illustrated by the case of lysosomal storage disorders (LSDs). LSDs 
are a large group of ~50 metabolic disorders characterized by primary defects in 
lysosomal function, which are frequently associated with progressive 
neurodegenerative and dementia-like phenotypes (146,147). Not surprisingly, 
increasing evidence points to lysosomal dysfunction as playing a crucial role in the 
pathogenesis of many late-onset neurodegenerative diseases as well (146,148). The 
critical importance of autophagy in the maintenance of neuronal health was 
demonstrated in a seminal 2006 study, in which conditional, neuronal-specific,  
ATG5
-/- 
mice were generated. The neurons of these mice are unable to complete the 
process of autophagosome formation which causes neurodegeneration by three weeks. 
Remarkably, these mice develop progressive behavioral and motor deficits 
accompanied by ubiquitinated protein inclusions within their neurons much like those 
seen in FTLD and ALS (149). 
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 The proteins UBQLN2 and p62 are mutated in some cases of FTLD-TDP and 
ALS and belong to a class of ubiquitin binding adaptor proteins capable of binding 
ubiquitinated proteins and linking them to the proteasome for degradation (150). 
UBQLN2 can bind ubiquitinated proteins through its ubiquitin associated (UBA) 
domain and may bridge these substrates through direct binding to the proteasome 
through its ubiquitin like domain (UBL) (151). UBQLN2 disease linked mutations 
have been shown to impair ubiquitin mediated proteasomal degradation (132). 
Polymorphisms in the structurally similar protein, p62 have also been associated with 
FTLD-TDP and ALS and p62 positive inclusions are present in range of 
neurodegenerative conditions including Alzheimer’s and Parkinson’s diseases as well 
as FTLD-ALS caused by C9ORF72 repeat expansions (130,152,153). Recently, it was 
shown that p62 directly binds to TDP-43 in the brains of FTLD-TDP patients to 
facilitate the degradation of the 35 kDa fragment, and p62 binds to TDP-43 less 
efficiently in the brains of FTLD-TDP patients compared to non-diseased controls 
(154).  
 In addition to their roles in linking ubiquitinated proteins to the proteasome for 
degradation, the proteins UBQLN2 and p62 are also implicated in facilitating the 
autophagic degradation of ubiquitinated proteins. Overexpression of UBQLN2 
protects cells from starvation-induced cell death, likely by promoting autophagic 
protein recycling and is observed within autophagic vacuoles and lysosomes via 
immunofluorescence and electron microscopy (155). The functionally and 
evolutionarily related protein, p62, has a similar domain architecture as UBQLN2, and 
likely mediates similar functions in both the UPS and autophagy pathways. The p62 
 25 
 
protein contains an N-terminal PB1 domain, homologous to the UBL domain of 
UBQLN2, which mediates polymerization. In combination with its C-terminal UBA 
domain, p62 is thought to sequester ubiquitinated proteins into aggregates for 
autophagic clearance (150). Further, p62 contains a small domain known as the LC3-
interacting region (LIR) that can directly bind to the autophagic membrane protein 
LC3 to facilitate aggregate removal (156). Cell culture studies show that p62 is 
capable of surrounding aggregated huntingtin and promoting its recruitment to 
autophagosomes and that depletion of p62 significantly increases cell death caused by 
these aggregates (157). Both UBQLN2 and p62 commonly co-localize with aggregates 
in diseased brains and have been shown to bind TDP-43, further highlighting the 
similar roles these two proteins have in maintaining cellular proteostasis at the 
intersection of the UPS and autophagy-lysosome pathways (150).  
 Another protein functionally linked with proteasome function, which is 
impaired in some cases of FTLD-TPD is VCP, which has two well documented roles 
related to proteasomal function. In ERAD, VCP, in cooperation with derlin-1 plays a 
role in extracting misfolded proteins from the endoplasmic reticulum (ER) for 
proteasome mediated degradation (158). Secondly, VCP has been shown to physically 
associate with multiple components of the UPS, including E3/E4 ubiquitin ligases, 
DUBs, and polyubiquitin (159). These associations are likely critical for its roles in 
mediating the ubiquitin-dependent degradation of numerous cytosolic proteins 
(62,160,161). It is important to note that there is little direct evidence that disease 
causing mutations in VCP specifically cause defects in the UPS, but considering the 
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extensive role VCP plays in this regard, it is conceivable that certain UPS functions 
may be subtly affected in disease states. 
 Like UBQLN2 and p62, VCP has annotated roles in both the UPS and 
autophagy-lysosome system, among others. Interestingly, there is much stronger 
evidence that disease causing VCP mutants impair the autophagy-lysosome system 
than the UPS. VCP plays an important role in the fusion of autophagosomes with 
lysosomes, with disease causing mutants leading to an accumulation of fusion-
defective autophagosomes (162). In addition, autophagic dysfunction caused by VCP 
leads to the cytoplasmic accumulation of TDP-43 in cells and in mice, recapitulating 
one of the key pathological features of IBMPFD/ALS (163,164). A recent study used a 
proteomic approach to identify a VCP binding cofactor, UBXD1 which mediates the 
mono-ubiquitin dependent trafficking of caveolin-1 to lysosomes. The interaction 
between UBXD1 is abrogated by disease linked VCP mutants, while ERAD and UPS 
functions are preserved (165). These studies highlight the importance of VCP’s roles 
in ubiquitin mediated membrane trafficking events in the endo-lysosomal and 
autophagy-lysosome pathway. 
 One of several potential pathogenic mechanisms by which C9ORF72 causes 
FTLD-ALS is through the unconventional translation of long, aggregating dipeptides 
in a process known as repeat-associated, RNA-encoded, non-ATG translation (RAN 
translation). RAN translation was first demonstrated in the case of the CAG repeat 
neurodegenerative disease, spinocerebellar ataxia type 8 in the ATXN8 gene and 
results in a long polyglutamine peptide which is translated in a non-ATG dependent 
manner (166). RAN translation may be a common feature of a number of other 
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trinucleotide repeat diseases as well and may result in the buildup of toxic protein 
aggregates (167). Two recent reports demonstrate that dipeptides encoding Gly-Ala 
(GA), Gly-Pro (GP), and Gly-Arg (GR), are produced by the three reading frames of 
the GGGGCC repeats of C9ORF72, respectively (168,169). These dipeptide 
aggregates have been produced in vitro and are found in the neurons of patients with 
C9ORF72 repeat expansions. Furthermore, an anti-sense transcript is also purported to 
be produced, further increasing the repertoire of potentially toxic dipeptide aggregates 
that can be produced by GGGGCC repeat expansions (169). While the mechanism of 
dipeptide aggregate toxicity is poorly understood, one possibility is that massive 
amounts of abnormal aggregated protein may simply overwhelm the normal 
degradative capacity of the proteasome causing a generalized disruption of 
proteostasis and downstream toxicity. 
 Although its function is not known at this point, C9ORF72 itself may play a 
role in the autophagy-lysosome pathways. FTLD-TDP and ALS caused by C9ORF72 
repeat expansions is associated with an approximately 50% reduction in the mRNA of 
both major isoforms of C9ORF72, suggesting haploinsufficiency as a potential disease 
mechanism (113,170). This mechanism is supported by a zebrafish model of ALS in 
which antisense knockdown of C9ORF72 levels causes neurodegeneration coupled 
with locomotor deficits (171). Since C9ORF72 contains a DENN domain, which has 
Rab-GEF activity and is highly associated with vesicular trafficking events, it is 
tempting to speculate that C9ORF72 may have an important role in late endosome or 
autophagosome trafficking to lysosomes, much like other known causes of FTLD and 
ALS (122,172). Finally, it should also be noted that the RAN associated dipeptides 
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seen in C9ORF72 repeat expansion carriers may similarly play a general role in 
disrupting autophagic clearance of proteins on a global level, although this remains 
hypothetical at this time. 
 The ESCRT-III component, CHMP2B is implicated in familial forms of 
FTLD-UPS and has a well described role in the trafficking of ubiquitinated membrane 
proteins into late endosomes/MVBs for eventual lysosomal degradation (173). Various 
splice site and nonsense mutations in the CHMP2B protein result in C-terminal 
truncations. These truncations remove an autoinhibitory domain from CHMP2B, 
causing it to constitutively bind late endosome membranes and thus the ESCRT-III 
complex cannot be disassembled by VPS4/Skd1. These mutations have been shown in 
cell culture models to prevent MVB and autophagosome fusion with lysosomes and 
result in an accumulation of p62 and ubiquitinated proteins (174-177). A recently 
described transgenic mouse model containing an intron 5-retention disease mutant 
exhibits progressive neurodegeneration and increased mortality, whereas loss of 
CHMP2B has no phenotype, suggesting a toxic gain of function in the endo-lysosomal 
pathway (178). 
 Mutations in the gene encoding PGRN invariably cause FTLD-TDP through a 
haploinsufficiency mechanism. PGRN is best known as a pleiotropic secreted growth 
factor with neurotrophic, cell migration, and pro- and anti-inflammatory functions (6). 
PGRN has not traditionally been ascribed a role in lysosomal function; however, 
several converging lines of evidence from recent studies have begun to hint at a 
potential role in this organelle. We have recently shown that sortilin promotes 
lysosomal trafficking of PGRN through its interaction with the extreme C-terminus of 
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full length PGRN (78,79). Furthermore, bioinformatic analysis reveals PGRN is 
transcriptionally co-regulated with a multitude of other lysosomal genes (179). PGRN, 
ranks among the top regulated targets by the Coordinated Lysosomal Expression and 
Regulation (CLEAR) network, under control by the master lysosomal transcription 
factor, TFEB (180). PGRN knockout mice exhibit tissue vacuolization, ubiquitinated 
protein inclusions, and accumulate the lysosomal waste byproduct, lipofuscin (181). 
Finally, a recent case report of siblings harboring homozygous PGRN mutations 
revealed diagnoses of neuronal ceroid lipofuscinosis (NCL), a much more severe and 
early onset neurodegenerative LSD (182). While the exact role of PGRN in lysosomes 
remains unknown, the available evidence points to a lysosomal function, which merits 
further investigation. The FTLD-TDP risk factor, TMEM106B is strongly associated 
with PGRN mutant carriers and has recently been shown to localize to late endosomes 
and lysosomes (95). Like PGRN, the function of TMEM106B in lysosomes remains 
unknown, but its localization and genetic association with PGRN further suggests an 
important role in lysosome function and is the subject of much of this dissertation. 
 
1.3.2 Disruption of RNA homeostasis 
 Disrupted RNA metabolism has been recognized as a major feature of FTLD-
TDP and ALS (as well as FTLD and ALS caused by FUS mutations). In addition to 
models that propose a gain of function toxicity from TDP-43 aggregation, another 
likely contributing factor in disease pathogenesis is loss-of function of TDP-43 caused 
by cleavage and sequestration of the active protein product. Genome-wide studies of 
TDP-43’s RNA targets in mouse and human brains reveal numerous RNAs whose 
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levels and splicing are critically regulated by TDP-43 (49,52). Many of these RNA 
targets have important implications for overall neuronal health and survival. A few of 
the notable mRNAs of the ~1500 whose levels and splicing are affected by loss of 
TDP-43 include the FTLD disease linked genes encoding Tau, CHMP2B, VCP, p62, 
and PGRN, along with the PGRN receptor sortilin (49,183). Interestingly, TDP-43 
mediated sortilin splicing is necessary for a functional protein and a loss of TDP-43 
results in a non-functional sortilin product, potentially impairing PGRN transport to 
lysosomes (184). TDP-43 also regulates the levels of ATG7, which is essential for 
autophagy induction. Genes encoding proteins associated with other 
neurodegenerative diseases are also affected and include amyloid precursor protein 
(APP), presenilin, huntingtin, α-synuclein, and survival of motor neuron (SMN) 
protein among many others (49,183).  
 An additional explanation for the toxicity of cytoplasmic of TDP-43 
aggregates is through the binding and sequestration of critical RNAs in the cytoplasm, 
preventing their proper localization and translation. A yeast suppressor screen showed 
that loss of the RNA intron lariat debranching enzyme Dbr1 rescues TDP-43 
aggregate toxicity (185). It is hypothesized that the accumulation of RNA lariats may 
act as decoys which can bind TDP-43 aggregates in the cytosol, allowing normal RNA 
species to escape sequestration and remain functional. 
 Altered RNA metabolism is also likely one of the mechanisms by which 
C9ORF72 repeat expansions cause pathogenesis in FTLD-ALS. GGGGCC containing 
RNA foci have been reported in the nuclei of postmortem CNS tissue and induced 
pluripotent stem cells differentiated into neurons (iPSN) from C9ORF72 repeat 
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expansion carriers (113,186). The RNA-binding proteins hnRNPA3 and Pur-α have 
been shown to bind GGGGCC repeats in vitro and are part of some protein inclusions 
seen in tissue from C9ORF72 patients (187,188). A recent study using iPSNs 
demonstrated that GGGGCC repeats cause toxicity by sequestering a number of RNA 
binding proteins such as the RNA editing enzyme ADARB2, which contributes to 
glutamate excitotoxicity by preventing RNA editing of the glutamate receptor subunit 
GluR2 (186). This same study also showed that C9ORF72 repeat expansions cause 
changes in the expression of hundreds of genes, similar to the effects seen by TDP-43 
depletion and antisense mediated knockdown of C9ORF72 RNA caused a reduction in 
toxicity. 
 
1.3.3 Current models: impaired proteostasis and defects in RNA metabolism 
drive loss and gain of function toxicity  
 It is interesting to note that a large number of the genes regulated by TDP-43 
are in turn required for optimal proteostasis, including the removal of excess 
aggregated TDP-43, further strengthening the link between proteostasis and RNA 
homeostasis. As mentioned earlier, TDP-43 also negatively regulates its own 
transcript, and loss of TDP-43 function caused by mislocalization and aggregation 
could feasibly drive a feed-forward loop driving excess TDP-43 translation, and 
exacerbating the problem of TDP-43 proteostasis. Taken together, it is increasingly 
apparent that disrupted proteostasis and RNA homeostasis are intimately linked in a 
give and take relationship, with defects in one system driving defects in the other. 
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1.4 Contents of this dissertation 
 This dissertation explores several mechanisms by which FTLD-TDP and ALS 
pathogenesis may occur and is split up into three main chapters and several 
appendices.  
 Chapter 2 explores the mechanisms governing TDP-43 aggregation and 
clearance in cell culture models. In it, I explore the role of the C-terminal domain in 
mediating aggregation and how phosphorylation affects aggregation and clearance. In 
my experiments, I show that phosphomimetic mutations in the aggregation prone C-
terminus of TDP-43 actually suppress aggregation in vitro. This is in contrast to many 
models which correlate phosphorylated TDP-43 with increased insolubility and more 
aggregation. My work supports a model in which phosphorylation of the C-terminal 
region of TDP-43 sends a “stop” signal to halt further aggregation. Because these 
phosphomimetic mutants are present from synthesis, the TDP-43 aggregates have little 
chance to aggregate in the first place. This finding was confirmed by another paper 
which came out shortly after our’s was published (189). Additionally, I report a role of 
p62 in facilitating the clearance of aggregated TDP-43 fragments in vitro and 
demonstrate that this occurs through both the UPS and autophagy pathways, with the 
autophagy pathway playing a more prominent role in our experiments. This model of 
cooperation between the UPS and autophagy pathways in clearing TDP-43 has been 
reported by other groups at around the same time. Shortly after this was published p62 
was identified to bind TDP-43 less effectively in the brains of FTLD-TDP patients 
compared to healthy controls, strengthening the case for p62 in mediating the 
clearance of TDP-43 in vivo (143,154).  
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 Chapters 3 and 4 explore the basic biochemical and cell biological properties 
of the recently identified FTLD-TDP risk factor, TMEM106B, in order to ascertain a 
function for this previously unstudied membrane protein. Chapter 3 characterized the 
localization of TMEM106B to late endosomes/lysosomes and supports a role for 
TMEM106B in regulating lysosome morphology and number, with elevated levels 
leading to lysosome dysfunction in our cell culture model system. These results were 
mostly supported by several papers released at around the same time (95-97). 
Interestingly, we also observed a correlation between increased TMEM106B levels 
and increased full-length PGRN, but not PGRN mRNA, potentially due to defects in 
lysosomal degradation of PGRN. This remains controversial as elevated TMEM106B 
levels are thought to be correlated with decreased PGRN in patients carrying the risk 
allele of TMEM106B (88,89). Nonetheless, my results were supported by two of the 
recently mentioned reports on TMEM106B, and further implicate both PGRN and 
TMEM106B as playing important roles in regulating lysosome functions (96,97). 
 Chapter 4 reports TMEM106B as a substrate for regulated intramembrane 
proteolysis (RIP) by an unidentified lysosomal enzyme(s) and the intramembrane 
cleaving protease (i-CLIP), SPPL2a. These results are significant because 
TMEM106B levels are thought to be increased in disease and this identifies a potential 
cellular mechanism for controlling TMEM106B levels in vivo. Additionally, this study 
contributes to the small, but growing list of transmembrane protein substrates that are 
known to be cleaved by the SPPL2 family of i-CLIPs. These results have also led the 
project to new directions which are actively being pursued in the lab in order to further 
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characterize the trafficking, degradation, and functional roles of TMEM106B. As of 
the time of this writing, these results are being revised for submission and publication. 
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CHAPTER 2 
 
REGULATION OF TDP-43 AGGREGATION BY PHOSPHORYLATION AND 
p62/SQSTM1
1
 
 
2.1 Summary 
TAR DNA-binding protein-43 (TDP-43) proteinopathy has been linked to several 
neurodegenerative diseases, such as frontotemporal lobar degeneration with ubiquitin-
positive inclusions and amyotrophic lateral sclerosis. Phosphorylated and 
ubiquitinated TDP-43 C-terminal fragments have been found in cytoplasmic 
inclusions in frontotemporal lobar degeneration with ubiquitin-positive inclusions and 
amyotrophic lateral sclerosis patients. However, the factors and pathways that regulate 
TDP-43 aggregation are still not clear. We found that the C-terminal 15 kDa fragment 
of TDP-43 is sufficient to induce aggregation but the aggregation phenotype is 
modified by additional sequences. Aggregation is accompanied by phosphorylation at 
serine residues 409/410. Mutation of 409/410 to phosphomimetic aspartic acid 
residues significantly reduces aggregation. Inhibition of either proteasome or 
autophagy dramatically increases TDP-43 aggregation. Furthermore, TDP-43 
aggregates colocalize with markers of autophagy and the adaptor protein 
p62/SQSTM1. Over-expression of p62/SQSTM1 reduces TDP-43 aggregation in an 
autophagy and proteasome-dependent manner. These studies suggest that aggregation 
of TDP-43 C-terminal fragments is regulated by phosphorylation events and both the 
autophagy and proteasome-mediated degradation pathways. 
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The results of this study were published in Brady OA, Meng P, Zheng Y, Mao Y, Hu 
F. J. Neurochem. 2011 Jan;116(2):248-59.  P.M., and Y.Z. assisted with data 
collection and analysis. Y.M. performed secondary structure prediction and 
bioinformatic analysis F.H. generated the ATG5 knockdown cells and took 
immunofluorescence pictures containing FUS/TLS. All other experiments were 
performed by O.A.B. O.A.B. and F.H. wrote the manuscript. 
 
2.2 Introduction 
Abnormal protein aggregation has become a hallmark of neurodegeneration (Ross and 
Poirier 2004). TAR DNA-binding protein-43 (TDP-43), a protein involved in 
transcriptional repression and exon skipping, has emerged as a signature protein in the 
inclusions of a range of neurodegeneration related diseases, including frontotemporal 
lobar degeneration with ubiquitin-positive inclusions (FTLD-U), amyotrophic lateral 
sclerosis (ALS), and recently Alzheimer’s and Huntington diseases (1-10). Mutations 
in the TDP-43 gene have also been genetically linked to ALS, suggesting that TDP-43 
proteinopathy alone can cause neurodegeneration (11-14)  
TDP-43 is a 43-kDa protein that contains two RNA recognition motifs (RRMs), and a 
glycine rich C-terminal region. Both a nuclear localization signal and nuclear export 
signal have been found in TDP-43, mediating its shuttling between nucleus and 
cytoplasm (15). Also, two potential caspase cleavage sites have been identified in 
TDP-43, which could generate the 35 and 25 kDa C-terminal fragments (16), although 
the TDP-43 fragments identified in disease patients do not exactly match the caspase-
cleaved products (17,18). In patients with FTLD-U and ALS, the 25 kDa fragments of 
TDP-43 form cytoplasmic aggregates that are ubiquitinated and phosphorylated (1,19). 
Although the underlying mechanisms of TDP-43 proteinopathy are still under debate, 
toxicity resulting from aggregation of these fragments is thought to play an important 
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role in neurodegeneration involving TDP-43. Transgenic mice over-expressing wild 
type TDP-43 in neurons display a dose-dependent neurodegeneration phenotype, with 
the 25 kDa fragment aggregates present in the nucleus (20,21). Overexpression of the 
35 and 25 kDa fragments in mammalian cells results in aggregation and cell death, 
suggesting that these fragments of TDP-43 are aggregation prone and mediate TDP-43 
toxicity (22,23). However, the cellular pathways that mediate TDP-43 degradation and 
clearance are still not clear and cellular factors that regulate TDP-43 aggregates 
remain to be explored.  
Here, we show that the C-terminal fragment of TDP-43 mediates its aggregation. The 
15 kDa fragment at the C-terminus of TDP-43 is sufficient to induce TDP-43 
aggregation but the aggregation phenotype is modified by additional sequences. When 
over-expressed in mammalian cells, the C-terminal TDP-43 fragments are 
phosphorylated at serine residues 409/410. Phosphorylation plays an imporant role in 
regulating the aggregation of TDP-43 fragments. Furthermore, we show that these 
fragments are subject to autophagy and proteasome-mediated degradation pathways 
regulated by the adaptor protein p62/SQSTM1. These findings could have important 
implications for TDP-43aggregation seen in many neurodegenerative diseases. 
2.3 Materials and Methods 
Antibodies 
The following antibodies were used in our studies for western blot, 
immunoprecipitations, and immunofluorescence: rabbit anti-TDP-43 (ProteinTech, 
Chicago, IL, USA), rabbit anti-phospho TDP-43 pS409/410 (Cosmo Bio Co., Tokyo, 
Japan), mouse anti-green fluorescent protein (anti-GFP) (Covance, Princeton, NJ, 
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USA), rabbit anti-GFP antiserum (provided by Dr Anthony Bretscher and Dr Scott 
Emr), mouse anti-c-Myc clone 9E10 (Sigma, St Louis, MO, USA), mouse anti-HA.11 
clone 16B12 (Covance), mouse anti- p62/SQSTM1 (BD Biosciences, San Jose, CA, 
USA), mouse anti-GAPDH (Novus Biologicals, Littleton, CO, USA), rabbit anti-
ATG5 (Epitomics, Burlingame, CA, USA, and Novus Biologicals) and goat anti-LC3 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Plasmids 
Human TDP-43, mouse p62, and mouse FUS cDNAs in the pCMVSport6 vector were 
obtained from Open Biosystems (Huntsville, AL, USA). GFP-LC3 construct was 
obtained from Addgene (Cambridge, MA, USA).  
All GFP-tagged TDP-43 constructs were subcloned into pEGFP-C1 (pEGFP-C1 was 
cut with BglII and SalI and ligated to fragments digested with BamHI and XhoI). Site-
directed mutants were created using Quick change mutagenesis kit from Stratagene 
(La Jolla, CA, USA). Full-length TDP-43 was inserted into pcDNA 3.1/myc-His A 
with BamHI and XhoI. HA tagged FUS and p62 were generated in the pCMV-HA 
vector (Clontech, Mountain View, CA, USA) using EcoRI and BglII: FUS was 
inserted as two fragments with a 5’ EcoR1 and 3’ StuI site and a 5’StuI and 3’ BamHI 
site; mouse p62 (accession no.: BC006019) was inserted as EcoR1 and BamHI 
digested fragment. Deletion constructs for p62 [p62 ΔUBA, aa1-357, and p62 ΔLIR 
(Δ323-344: QPEEQMESGNCSGGDDDWTHLS)] were cloned into pCMV-HA using 
EcoRI and BglII. mCherry-LC3 was generated by replacing enhanced green 
fluorescent protein (EGFP) with mCherry in the GFP-LC3 construct by using 
restriction sites NheI and XhoI. mCherry p62 and mCherry-FUS/TLS was created by 
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replacing LC3 with p62 or FUS/TLS coding sequence in the mCherry-LC3 plasmid by 
using restriction enzymes EcoRI and KpnI (FUS) or EcoRI and BamHI (p62).  
The shRNA construct for mouse Atg5 gene was created by annealing the following 
primers (5'-GATCCCCGGCATTATCCAATTGGTTTATTGGTTTATTC- 
AAGAGATAAACCAATTGGATAATGCCTTTTTA and 5’- TCGATAAAAAGGC- 
ATTATCCAATTGGTTTATCTCTTGAATAAACCAATTGGATAATGCCGGG) 
and ligating to the pSuperRetro vector (Oligoengine, Seattle, WA, USA) digested with 
BglII and XhoI. The target sequence was designed according to published shRNAs for 
mouse Atg5 gene that showed effective knockdown (Amaravadi et al. 2007). 
Cell culture and transfection 
HEK293T, COS-7, NIH3T3 and N2A cells were grown in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum, 1% penicillin–
streptomycin at 37º C in a 5% CO2 atmosphere. All cell lines were obtained from 
ATCC. Cells were transiently transfected with polyethlyeneimine as described (24). 
Stable N2A cells with pSuperRetro control or pSuperRetro-shRNA (Atg5) were 
selected with 2 µg/mL puromycin. 
Immunofluorescence studies 
Cells were fixed in 3.7% formaldehyde, 20% sucrose in phosphate buffered saline 
(PBS) for 15 min, permeabilized and blocked with 0.1% Triton X-100, 5% bovine 
serum albumin in PBS for 15 min, and incubated with primary antibody for 4 h at 20º 
C or overnight at 4º C. Secondary antibodies conjugated to Alexa Fluor-488 or -568 (1 
: 500) (Invitrogen, Carlsbad, CA, USA) were then applied. Nuclei were stained with 
Hoechst or Syto63 (Invitrogen). Images were taken with an ImageXpress Micro 
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automated fluorescent microscope and analyzed with MetaXpress software (Molecular 
Devices, Palo Alto, CA, USA). For confocal microscopy, cells were plated on glass 
coverslips. Coverslips were mounted onto microscope slides with Fluoromount-G 
(Southern Biotech, Birmingham, AL, USA). Images were acquired either on an 
Intelligent Imaging Innovations CSU-X spinning disc microscope with 63X 1.4 NA 
objective and Photometrics Quant EM or HQ2 CCD camera. Images were acquired 
with a Nikon Eclipse TE-2000U microscope. Images were processed with Slidebook 
5.0 (3i). 
Cell fractionation 
Sequential protein extractions were performed to separate protein extracts by 
solubility. Cells were washed with PBS, scraped and lysed in ice cold RIPA buffer (50 
mM Tris pH 7.3, 150 mM NaCl, 1% Triton, 0.1% sodium dodecyl sulfate, 0.5% 
Deoxycholic acid, 1 mM EDTA) with protease and phosphatase inhibitors (Roche 
Complete Mini, EDTA-free Protease Inhibitor, 10 µM MG-132, 5 mM NaF, and 10 
mM β-glycerol-phosphate). Cell lysates were centrifuged at 18 000 g for 15 min at 4º 
C and the supernatant saved as the RIPA soluble fraction. The RIPA-insoluble pellets 
were extracted with urea buffer (7 M urea, 4% 3-[(3-cholamidopro-
pyl)dimethylammonio]-1-propanesulfonate, 30 mM Tris, pH 8.5) and centrifuged at 
18 000 g for 15 min at 4º C and the supernatant was saved as the RIPA-insoluble, 
urea-soluble fraction. 
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Western Blot Analysis 
Protein samples in sodium dodecyl sulfate sample buffer containing β-
mercaptoethanol were boiled 10 min and centrifuged 1 min at 10,625 g. Samples were 
run on 12% polyacrylamide gels and transferred to Immobilon-FL polyvinylidene 
fluoride membranes (Millipore Corporation, Bedford, MA, USA). Membranes were 
blocked with 5% non-fat milk in PBS for 1 h followed by incubation with primary 
antibodies for 2 h at 20º C or overnight at 4º C. Membranes were washed for 5 min 
three times in Tris-buffered saline with 0.1% Tween-20, incubated with secondary 
antibody for 2 h at 20º C and washed three more times with Tris-buffered saline with 
0.1% Tween-20. Blots were imaged using an Odyssey Infrared Imaging System (LI-
COR Biosciences, Lincoln, NE, USA). 
 
2.4 Results 
TDP-43 C-terminal fragments are aggregation prone 
In FTLD-U and ALS, TDP-43 is often cleaved to generate 25 kDa C-terminal 
fragments (1,19). These fragments are ubiquitinated, phosphorylated and are present in 
cytoplasmic inclusions. Secondary structure prediction indicates that the C-terminal 
glycine rich fragment (aa 267-414, 15 kDa) is non-structured and many mutations of 
TDP-43 linked to ALS have been mapped to this region (13,14). To establish a 
cellular TDP-43 aggregation model for further characterization, we made expression 
constructs of GFP fused to TDP-43 full length or C-terminal 35, 25 and 15 kDa 
fragments (CTD fragments) (Figure 2.1A). When expressed in HEK293T cells, GFP-
TDP-43 full- length protein resides mostly in the nucleus with occasional nuclear 
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aggregates and cytoplasmic localization (Figure 2.1B). Around 8% of transfected cells 
expressing the 35 kDa fragment exhibit visible aggregates of  ~4 µm in size, often 
close to the nucleus (Figures 2.1B and C). However, the 25 and 15 kDa fragments of 
TDP-43 readily form aggregates ranging from small punctuate structures to larger 
ones several micrometers in size (Figure 2.1B and C). About 28% of cells expressing 
the 25 kDa fragment exhibit large aggregates of ~7 µm in size, whereas 14% of cells 
expressing the 15 kDa fragment exhibit aggregates with an average size of ~4 µm. The 
15 kDa expressing cells tend to have smaller but more aggregates per cell than the 25 
kDa fragment (Figure 2.1C). Although cytoplasmic aggregates were observed most of 
the time, nuclear aggregates were also often detected when the 25 or 15 kDa TDP-43 
fragments were over-expressed, suggesting that the aggregation can propagate into the 
nucleus under certain conditions. Distinct aggregation phenotypes were also seen 
when these fragments are over-expressed in COS-7 cells, with a dramatic aggregation 
phenotype of 25 and 15 kDa but minimal aggregation of the 35 kDa fragment (Figure 
S2.1A). These distinct aggregation phenotypes suggest that although the presence of 
the 15 kDa fragment is sufficient to cause aggregation, the presence of additional 
sequences could modify the characteristics of the aggregates formed. Similar 
aggregation phenotypes were also seen in the neuroblastoma cell lines M17 and N2A 
(our unpublished observation), although the percentage of aggregation observed was 
lower. This could be due to lower levels of protein expression in these cells. 
Regulation of TDP-43 aggregation by phosphorylation 
The TDP-43 C-terminal glycine rich region is enriched with serine residues and 
several antibodies specific for phosphorylated forms of TDP-43 have been developed  
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Figure 2.1: The residues 267–414 of TDP-43 (15 kDa fragment) are sufficient for 
aggregation. (a) Schematic representation of the constructs used in this study. All 
constructs used have an N-terminal EGFP tag unless otherwise noted. NM fragment 
appears much like FL (data not shown). (b) Confocal microscopy of HEK293T cells 
transfected with GFP fused TDP-43 constructs. Images were acquired 2 days after 
transfection. Scale bar = 10 lm. (c) Quantification of the average size of the aggregates 
and the number of cells exhibiting aggregates with the expression of the 35, 25, and 15 
kDa fragments in HEK293T cells. The average number of aggregates per positively 
scored cell transfected with 25 and 15 kDa fragments was also quantified. Images 
were acquired using the ImageXpress system and analyzed using the MetaXpress 
software. (~1000-3000 cells counted per trial, mean ± SEM, n = 3–6). (d) The 25 and 
15 kDa fragments of TDP-43 expressed in N2A cells are phosphorylated at serines 
409/410 in the RIPA-insoluble urea soluble fraction. R, RIPA fraction; U, urea 
fraction. Similar results were seen in HEK293T and COS-7 cells. 
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(25,26). Casein kinase was shown to phosphorylate several serine residues in the 
glycine rich region of TDP-43 in vitro (27), although whether it is responsible for 
TDP-43 phosphorylation in vivo is still unclear. Phosphorylation of serines 409/410 
were observed in FTLD-U patients (28,29), suggesting that TDP-43 phosphorylation 
could play a role in the disease mechanism. To determine whether aggregated TDP-43 
fragments are phosphorylated, we fractionated cell lysates into RIPA-soluble (R) and 
urea-soluble (U) fractions. GFP-tagged TDP-43 full-length protein and 35, 25 and 15 
kDa fragments expressed in N2A and COS-7 cells were detected in both RIPA and 
urea fractions, with the 25 and 15 kDa fragments showing increased insolubility in 
RIPA (Figure 2.1D and Figure S2.1B). We also found that the 25 and 15 kDa 
fragments expressed in these cells showed much more phosphorylation of serine 
409/410 in the RIPA insoluble fraction than the full-length TDP-43 or the 35 kDa 
fragment when blotted with antibodies specific for phospho-409/410 (Figure 2.1D). 
This suggests that the level of phosphorylation is directly correlated with the degree of 
aggregation. Phospho-409/410 detected a band that migrates more slowly than the 
unphosphorylated form of TDP-43 (Figure 2.1D), indicating that additional 
phosphorylation or ubiquitination might be involved in the mobility shift. However, 
phosphorylated species only represent a small portion of RIPA-insoluble and urea-
soluble proteins, even in the case of 25 and 15 kDa fragments (Figure 2.1D).  
To determine the effect of phosphorylation on aggregate formation, we mutated serine 
residues at 409 and 410 (SS) to aspartic acid (DD) to mimic its phosphorylated state or 
to alanines (AA) to a non-phosphorylatable state. The AA mutant has a slightly 
reduced (by 15%) aggregation compared with wild-type (Figure 2.2A–C), suggesting 
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that phosphorylation is not an absolute requirement for aggregation. Surprisingly, we 
found that the phosphomimetic DD mutation dramatically reduces (by 60%) the 
aggregation of the 25 and 15 kDa fragments (Figure 2.2A–C). Biochemical 
fractionation revealed that the DD mutant is much more soluble in RIPA buffer than 
the wild-type and the AA mutant (Figure 2.2D and E). Similar results were found in 
N2A cells, although aggregation and insoluble protein levels were lower overall in 
N2A cells. These results indicate that phosphorylation could play a critical role in 
regulating aggregation. 
TDP-43 aggregates are substrates of autophagy 
The ubiquitin proteasome system and autophagy are the two main pathways for 
protein degradation in the cell. To determine which pathway is involved in clearing 
TDP-43 aggregates, we treated N2A and HEK293T cells expressing TDP-43 
fragments with MG-132, an inhibitor of the 26S proteasome or 3-methyladenine (3-
MA), a drug that inhibits the class III PI3-kinase, VPS34, which is required for 
autophagosome formation (30). Although MG-132 treatment led to an increase of 
TDP-43 aggregation compared with untreated control, the effect of 3-MA treatment 
was more pronounced, especially in the case of the 15 kDa fragment (Figure 2.3A). 
This suggests that autophagy might be the dominant pathway for clearing TDP-43 
aggregates, especially for the 15 kDa fragment. Moreover, 3-MA treatment 
dramatically increased the buildup of the TDP-43 full-length protein and fragments in 
the RIPA insoluble fractions and the phosphorylation at 409/410 residues (Figure 2.3C 
and D). As 3-MA might have non-specific effects, we generated N2A cells stably 
expressing shRNAs against Atg5, a gene essential for autophagosome formation (31).  
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Figure 2.2: Effects of phosphorylation on aggregation of TDP-43 fragments. 
(A) Representative examples of HEK293T cells transfected with the 25 or 15 kDa 
fragment fused with GFP. Images were acquired using the ImagXpress system. Scale 
bar = 20 lm. (B) The S409D S410D (DD) and S409A S410A (AA) mutations reduce 
the aggregation of 15 and 25 kDa fragment in HEK293T cells. Cells were transfected 
with GFP-tagged TDP-43 fragments and percentages of cells with aggregates were 
scored 2 days after transfection using the ImageXpress imaging system. (~1000-2000 
cells counted per trial, mean ± SEM, n = 6, *p < 0.05, **p < 0.01, paired Student’s t-
test). (C) Representative examples of HEK293T cells transfected with the 25 or15 kDa 
fragment. Images were acquired using confocal microscopy with nuclei in blue. Scale 
bar = 10 lm. (D) The DD mutant is more RIPA soluble than the SS and AA fragments. 
HEK293T cells transfected with various constructs as indicated were lysed 2 days 
after transfection and fractionated into RIPA (R) and urea (U) soluble fractions. The 
lysates were blotted with antibodies against GFP or phosphorylated 409/410. (E) 
Quantification of panel (D) was performed using densitometry with Odyssey Infrared 
Imaging software (for the 15 kDa fragment). Data were presented as the percentage of 
urea fraction of total protein (RIPA + urea fractions) (mean ± SEM, n = 3, *p < 0.05, 
**p < 0.01, paired Student’s t-test). 
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Atg5 shRNA effectively reduced Atg5 expression in N2A cells compared to control 
shRNA (Figure 2.3E), which resulted in a significantly increased aggregation of TDP-
43 C-terminal fragments (Figure 2.3F). This result confirms a critical role of 
autophagy in clearing TDP-43 aggregates in all cell types, including neurons.  
 To further confirm the role of autophagy in TDP-43 regulation, we examined 
the colocalization of autophagy markers with the TDP-43 aggregates using confocal 
microscopy. We failed to detect the colocalization of small aggregates with ubiquitin 
or the autophagy marker LC3 (Figure 2.4A). However, it appears that at later stages of 
aggregation, the TDP-43 fragments get ubiquitinated and become substrates of 
autophagy. Colocalization of GFP tagged TDP-43 fragments with HA-ubiquitin and 
mCherrytagged LC3 was observed in larger aggregates that were irregularly shaped 
and had poorly defined edges compared with aggregates without ubiquitin and LC3 
colocalization (Figure 2.4A and B). This may indicate that a critical size threshold 
must be reached before aggregates can be ubiquitinated and recognized by autophagy 
proteins. In most cases, biquitin and LC3 signals appeared like a shell surrounding the 
TDP-43 aggregates tagged with GFP, with the GFP signal becoming much dimmer in 
some cases. To avoid the potential problems of protein over-expression, we also 
examined the localization of endogenous ATG5 protein in the aggregates. Consistent 
with ubiquitin and LC3 localization, endogenous ATG5 forms a shell-like structure 
around the irregularly shaped aggregates (Figure 2.4C). 
Reduction of TDP-43 aggregation by p62/SQSTM1 overexpression 
UBA domain containing adaptor proteins play important roles in protein degradation 
(32). p62, also known as sequestosome 1 (SQSTM1), contains both a UBA domain  
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Figure 2.3:  Autophagy inhibition increases aggregate formation of TDP-43 C-
terminal fragments.  
(A) HEK293T cells transfected with GFP-tagged 25 and 15 kDa fragments exhibit 
increased aggregation when treated with a proteasome inhibitor (2 µM MG-132) and 
an autophagy inhibitor (10 mM 3-MA). Cells were treated 24 h after transfection for 
an additional 24 h with MG-132 or 3-MA (~1000-3000 cells counted per trial, mean ± 
SEM, n = 6, *p < 0.05, **p < 0.01, paired Student’s t-test). (B) Autophagy inhibition 
in N2A cells also leads to accumulation of TDP-43 aggregates. N2A cells expressing 
GFP-tagged 25 or 15 kDa fragments were treated with 10 mM 3-MA for 24 h and the 
percentages of cells with aggregates were scored (> 400 cells scored per trial, mean ± 
SEM, n = 3, *p < 0.05, **p < 0.01). (C) Autophagy inhibition decreases the solubility 
of GFP-tagged TDP-43 proteins in N2A cells. N2A cells transfected with indicated 
constructs were treated with 10 mM 3-MA for 24 h and fractionated into RIPA (R) or 
urea (U) fraction. Phosphorylation at 409/410 is also increased in the presence of 
autophagy inhibition, as indicated by western blotting using phospho-specific 
antibodies. (D) Levels of the RIPA-insoluble, urea-soluble fraction of the 15 kDa 
mutants are increased under conditions of autophagy inhibition in N2A cells. N2A 
cells transfected with indicated constructs were treated with 10 mM 3-MA for 24 h 
and fractionated into R or U fraction. (E) Western blot of ATG5 protein in N2A cells 
stably expressing shRNAs against Atg5 compared with pSuper control. (F) Atg5 
knockdown in N2A cells leads to increased aggregation of the 15 kDa fragment with 
no change in the average number of aggregates per cell. Images were acquired using 
the ImageXrpess system and analyzed using the Metaexpress software (~1000-2000 
cells counted per trial, mean ± SEM, n = 3, **p < 0.01). 
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that can bind to ubiquitinated proteins and an LC3-interacting region (LIR) that can 
bind to LC3 and thus was proposed to be an adaptor protein for the autophagy 
pathway (33). To determine whether p62 is associated with TDP-43 aggregates, we 
performed confocal colocalization studies with antibodies to endogenous p62. Similar 
to our results with ubiquitin and LC3, we failed to detect a colocalization of the small 
aggregates with p62. However, the larger and irregularly shaped aggregates were 
positive for p62 staining (Figure 2.4D). The same results were seen with mCherry-
tagged p62 (data not shown), but not with mCherry-tagged FUS/TLS (Figure S2.3), 
suggesting that the recruitment of p62 to TDP-43 aggregates is specific. 
To delineate a function for p62 in TDP-43 aggregation, we determined the effect of 
p62 over-expression on TDP-43 solubility and aggregation. We found that over-
expression of p62 in N2A cells leads to less insoluble TDP-43 or TDP-43 fragments 
(Figure 2.5A) and significantly less TDP-43 aggregation (Figure 2.5B), thus increased 
levels of p62 could reduce TDP-43 aggregation. In addition to targeting ubiquitinated 
substrates to autophagy, p62 has also been reported to shuttle protein cargoes to the 
proteasome (34,35). To determine whether p62 over-expression affects proteasome 
activity in our system, we examined the turnover of a reporter construct, global protein 
stability (GPS) (36). GPS contains EGFP fused with mutant of the ornithine 
decarboxylase degron (d1GFP) with a half-life of the GFP around 1 h. GPS also 
contains Discosoma red fluorescent protein (DsRed) expressed under the same 
promoter with d1GFP (DsRed-IRES-d1GFP), with DsRed serving as an internal 
control. When the GPS construct was expressed in N2A cells, MG-132 but not 3-MA  
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Figure 2.4: Colocalization of the 25 and 15 kDa fragments with autophagic markers 
and adaptor proteins in COS-7 cells.  
(A) LC3, an autophagosomal membrane marker, forms a shell around the bigger 25 
and 15 kDa TDP-43 aggregates, but is only sparsely associated with the smaller 
aggregates. COS-7 cells were co-tranfected with mCherry-LC3 and GFP-tagged TDP-
43 fragments. Confocal images were acquired 2 days after transfection. (B) Ubiquitin 
forms a shell around the irregularly shaped aggregates of the 25 and 15 kDa 
fragments. Cells were co-transfected with HA-ubiquitin and GFP-TDP-43 fragments 
and stained with anti-HA antibodies. (C) The autophagy protein ATG5 also showed a 
shell-like structure around the big and irregular aggregates. Cells were transfected 
with GFP-TDP-43 fragments and stained for endogenous ATG5. (D) The adaptor 
protein p62 surrounds bigger aggregates of GFP-tagged TDP-43 fragments but is 
absent from the smaller aggregates. Cells were transfected with GFP-TDP-43 
fragments and stained for endogenous p62. Images were taken using confocal 
microscope. Scale bar = 10 µm. 
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treatment led to robust accumulation of the GFP protein with DsRed unchanged, 
confirming that d1GFP protein level could be used as an indicator of proteasomal 
activity (Figure 2.5C). When p62 is over-expressed, the d1GFP signal was 
dramatically reduced, indicating that p62 over-expression does stimulate proteasomal 
activity (Figure 2.5C). We also examined the effect of p62 on autophagy using the 
modification of LC3-I to LC3-II as an indicator. LC3-II is the lipidated form of LC3 
that associates with the autophagosome membrane. The ratio of LC3-II/I has been 
widely used as an indicator of autophagy activity (37). Over-expression of p62 in N2A 
cells led to more LC3-II, confirming that p62 over-expression also stimulates 
autophagy (Figure 2.5C). Thus, stimulation of both proteasomal and autophagy 
activity is likely to contribute to the effect of p62 over-expression on TDP-43 
aggregates. To test this, we treated N2A cells expressing p62 and GFP-15 kDa 
fragments with MG-132 or 3-MA. Both treatments led to a significant increase of 
TDP-43 aggregates in the p62 over-expressed cells (Figure 2.5D), confirming that 
increase in both proteasome and autophagy activities is responsible for decreased 
TDP-43 aggregation when p62 is over-expressed. A role of autophagy in TDP-43 
clearance in p62 over-expressing cells was also confirmed in N2A cells with Atg5 
expression knocked down with shRNAs. The effect of p62 on TDP-43 C-terminal 
aggregates was much reduced in Atg5 shRNA expressing cells compared with control 
cells, although some p62 activity was still detectable, which is likely caused by the 
stimulation of proteasome activity by p62 (Figure 2.5E).  
This result is further confirmed by examination of p62 deletion mutants. Over-
expression of p62 mutants with the UBA or the LIR domain deleted (p62ΔUBA or 
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p62ΔLIR) resulted in a significantly reduced effect on TDP-43 aggregation compared 
with full-length p62, indicating that both domains are important for its activity (Figure 
S2.2). This effect of p62ΔUBA on TDP-43 aggregation also indicates that p62 might 
have ubiquitin-independent regulation of autophagy and possibly the proteasome 
pathway, as shown by other studies (38). Likewise, the effect of p62ΔLIR on TDP-43 
aggregation is likely caused by stimulation of the proteasome pathway, as indicated by 
the results of the GPS assay (Figure 2.5C).  
Aggregation of TDP-43 does not sequester FUS/TLS protein 
Recently mutations in another RNA-binding protein FUS/TLS have also been 
genetically linked to ALS (39,40). Aggregates of FUS protein were also observed in 
ALS patients (39,40). Whether TDP-43 and FUS could co-aggregate is still under 
debate. Several studies suggested aggregates of TDP-43 and FUS occur in distinct 
patients (41,42), whereas other studies demonstrated co-aggregation of these two 
proteins (43-45). Physical and functional interactions of TDP-43 and FUS have also 
been reported (46,47). To determine whether FUS and TDP-43 could co-aggregate 
with each other in our cell-culture model, we co-expressed GFP-tagged TDP-43 25 
kDa fragment with mCherry-tagged FUS. FUS remains in the nucleus in the presence 
of TDP-43 25 kDa fragment (Figure S2.3), indicating that TDP-43 aggregation does 
not affect the homeostasis of FUS. When FUS/TLS is over-expressed together with 
TDP-43 full-length protein or TDP-43 fragments, FUS does not affect the solubility of 
TDP-43 (Figure 2.5A), suggesting FUS and TDP-43 aggregation are independent of 
each other. 
  
 74 
 
 
 
 
 
 
 
 
 
 75 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Over-expression of p62 decreases TDP-43 aggregation.  
(A) p62 reduces the insoluble portion of full-length TDP-43, the 25 kDa fragment, and 
the 15 kDa in N2A cells. N2A cells were cotransfected with vector control (Vect), 
HA-p62 or HA-FUS together with GFP tagged TDP-43 constructs as indicated. Cell 
lysates were fractioned 2 days after transfection. (B) p62 over-expression decreases 
aggregate formation of the 15 kDa fragment and its mutants in N2A cells. Cells were 
co-transfected with GFP-15 kDa fragments or its mutants together with vector control 
or HA-p62. Aggregates were scored 2 days after transfection (> 400 cells counted per 
trial, mean ± SEM, n = 5, *p < 0.05, **p < 0.01). (C) Effect of p62 and its ΔUBA and 
ΔLIR mutants on proteasome and autophagy activity. N2A cells were co-transfected 
with the GPS-d1GFP construct and vector control, HA-p62 or p62 deletion mutants. 
Duplicates of vector transfected cells were treated with 10 µM MG-132 or 10 mM 3-
MA for 24 h the next day after transfection. Cells were lysed in sodium dodecyl 
sulfate (SDS) sample buffer and blotted for GFP, DsRed or LC3 as indicated. (D) 
Both MG-132 and 3-MA lead to an increase in the percentage of cells with aggregates 
in N2A cells co-transfected with HA-p62 and the 15 kDa fragment. The average 
number of aggregates per positively scored cell did not change significantly under any 
of the conditions tested. Cells were treated for 24 h with 10 µM MG-132 or 10 mM 3-
MA. Only live cells were counted (> 200 cells counted per trial, mean ± SEM, n = 3, 
*p < 0.05, **p < 0.01). (E) Knockdown of Atg5 expression reduces the effect of p62 
expression on TDP-43 15 kDa fragment. N2A cells stably transfected with pSuper or 
pSuper-shRNA (Atg5) were co-transfected with HA-p62 and GFP-15 kDa. Images 
were acquired and analyzed two days later with the ImageXpress system. No 
significant changes were detected in the average number of aggregates per positively 
scored cell (~1000-2000 cells counted per trial, mean ± SEM, n = 3, *p < 0.05, **p < 
0.01). 
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2.5 Discussion 
Sequence determinant of TDP-43 aggregation 
Our data suggest that the 15 kDa fragment of TDP-43 containing the glycine-rich 
region (aa 267–414) is sufficient to form aggregates when over-expressed as a GFP 
fusion protein in mammalian cells. This fragment of TDP-43 does not possess any 
recognizable secondary structure and thus is presumably non-structured. According to 
IUPRED, a software that predicts non-structured regions in proteins (48), amino acids 
260–304 and 335–385 are predicted to be intrinsically unstructured regions. These 
correspond roughly to the glycine-rich domain and the C-terminal tail, both of which 
are part of the 15 kDa fragment used in these studies, which may correlate with the 
minimal sequence required for TDP-43 aggregation. This region has also been 
implicated in mediating interactions between TDP-43 and other RNAbinding proteins 
(49). It is possible that in full-length TDP-43, the 15 kDa fragment is buried inside of 
the protein or protein complex, and thus not exposed. Cleavage of TDP-43 into 25 
kDa or smaller fragment may expose this aggregation prone fragment resulting in its 
aggregation. Although the 15 kDa fragment is sufficient to cause aggregation, the 
presence of additional sequences could change the aggregation rates and morphologies 
seen in the larger fragments. We have observed bigger and less numerous aggregates 
per cell formed by the 25 kDa fragment (Figure 2.1C), which has part of the second 
RRM motif in addition to the 15 kDa fragment. However, the 35 kDa fragment of 
TDP-43, which contains two intact RRM domains in addition to the 15 kDa region 
forms very few aggregates when over-expressed, indicative of a moderating effect of 
the two fully intact RRM domains on the extent of aggregation. 
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Regulation of TDP-43 aggregation by phosphorylation 
TDP-43 aggregates seen in neurodegenerative diseases are often phosphorylated and 
ubiquitinated. Specifically, phosphorylation at serines 403/404 and 409/410 is 
observed in disease states (28,29). However, the role of phosphorylation and 
ubiquitination on TDP-43 aggregation is still not clear. Our data suggest the level of 
phosphorylation directly correlates with the degree of aggregation. The aggregation 
prone 25 and 15 kDa fragments have dramatic phosphorylation at 409/410 compared 
with the 35 kDa fragment and full-length protein, in direct correlation with the degree 
of aggregation these fragments exhibit (Figure 2.1D). 3-MA treatment increases 
aggregation of the 15 and 25 kDa fragments, which is accompanied by an increase in 
their phosphorylation (Figure 2.3C and D).  
Our analysis of the DD and AA mutants also indicates an important role of 
phosphorylation in regulating aggregation. Although DD and AA mimic the charge of 
the phosphorylated and non-phosphorylatable form of TDP-43 CTD fragment, it is 
hard to judge whether they fully mimic the conformation of the phosphorylated and 
non-phosphorylated form. The fact that the DD mutant is recognized by 
phosphorylation specific antibody suggests that it mimics the phosphorylated state to 
some extent. The fact that the DD mutant mitigates ~60% of aggregate formation 
(Figure 2.2A and B) indeed suggests that having phosphorylated 409/410 when the 
protein is synthesized might reduce aggregation. We propose that phosphorylation 
happens after aggregation as a cellular attempt to reduce aggregation or prevent the 
formation of large aggregates, possibly by electrostatic repulsion. Having the negative 
charges conferred by aspartic acid residues in place of serine when the protein is 
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synthesized could significantly reduce initial aggregation formation or prevent the 
fusion of small aggregates into big aggregates, which has been demonstrated for TDP-
43 fragments in cell culture (50). If phosphorylation of 409/410 prevents aggregation, 
it is puzzling that the AA mutant exhibits slightly reduced aggregation instead of 
having elevated aggregation. Several possible explanations exist. One possibility is 
that compensatory phosphorylation events, such as serine 403/404 could still take 
place in the AA mutant to prevent aggregation. The other possible explanation is that 
phosphorylation plays a dual role in regulating TDP-43 aggregation and clearance: (i) 
to reduce aggregation at early stage (in the case of the DD mutant); and (ii) to prevent 
clearance in the later stage. A recent study suggested that the phosphorylated form of 
TDP-43 CTD fragments are much harder to degrade than the nonphosphorylated form 
(50), consistent with the second model. 
Regulation of TDP-43 clearance by proteasome and autophagy 
The ubiquitin proteasome system and autophagy are the two main pathways for 
protein degradation and clearance. Autophagy is an intracellular degradation process 
which involves the formation of double-membrane autophagosomes around 
cytoplasmic components followed by fusion with lysosomes for degradation (30). 
Autophagy is responsible for the clearance of most long lived proteins, dysfunctional 
organelles and protein aggregates. Decreased autophagy has been implicated in 
various neurodegenerative disorders with protein aggregation. Autophagy deficiency 
in neurons in the neuron specific Atg5 knockout mice causes a neurodegenerative 
phenotype (51). Induction of autophagy enhances the clearance of protein aggregates 
that cause neurodegeneration and confers cytoprotective roles in cell and animal 
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models (52). Many aggregation prone proteins implicated in neurodegeneration have 
been shown to be substrates for autophagy, including alpha synuclein and poly-
glutamine expanded Huntington (52). Our data strongly suggest that TDP-43 
aggregates are substrates of autophagy. We found inhibition of autophagy leads to 
increases in aggregation and insolubility of TDP-43 C-terminal fragments. 
Furthermore, inhibition of autophagy leads to relocalization of TDP-43 from the 
nucleus to cytoplasm (53,54) (Figure S2.4), suggesting that autophagy could regulate 
the balance of TDP-43 nuclearcytoplasmic shuttling. The proteasome-dependent 
degradation pathway also plays a role in clearing TDP-43 aggregates, because 
inhibition of proteasome function by MG-132 leads to increased TDP-43 aggregation 
as well, although not to the same extent as the autophagy inhibitor 3-MA (Figure 
2.3A). 
p62/SQSTM1is a multi-functional adaptor protein that could target ubiquitinated 
substrates to proteasome or autophagy for degradation (55). We found that over-
expression of p62 decreases TDP-43 aggregation and p62 colocalizes with TDP-43 
aggregates at later stages of aggregation. Furthermore, we showed p62 over-
expression enhances both proteasome and autophagy activities (Figure 2.5C). 
Inhibition of either proteasome activity or autophagy activity reduces the effect of p62 
overexpression on TDP-43 aggregation (Figure 2.5D and E). Deleting the UBA or LIR 
domain in p62 also affects the ability of p62 to reduce TDP-43 aggregation (Figure 
S2.2). These data implicate an important role of p62 in the clearance of TDP- 43 
aggregates and further support the involvement of both proteasome and autophagy in 
the clearance of TDP-43 aggregates. 
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A model for TDP-43 aggregation and clearance 
Taking our data together, we propose the following model for TDP-43 aggregation 
(Figure S2.5). Cleavage of TDP-43 generates aggregation prone 25 kDa and smaller 
fragments. These fragments form aggregates in a concentration-dependent manner. 
Phosphorylation happens as a result of initial aggregation as a cellular attempt to 
reduce aggregation. Ubiquitination occurs at a later stage of aggregation as a signal for 
proteasome or autophagy-mediated degradation. Subsequent binding and recruitment 
of p62 to the ubiquitinated TDP-43 aggregates allows degradation of the TDP-43 
aggregates by either the proteasome or the autophagy pathway. More understanding of 
phosphorylation, ubiquitination and ubiquitin-binding proteins involved in the 
aggregation and clearance process will lead to a better view of TDP-43 aggregation 
and clearance, which is important for many neurodegenerative diseases with TDP-43 
proteinopathy. 
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2.7 Supplementary Information 
 
 
 
      
 
Figure S2.1: Aggregation of TDP-43 fragments in COS-7 cells.  
(A) Examples of the full length (FL), 35 kDa, 25 kDa, and 15 kDa fragments of TDP-
43 expressed as GFP fusion protein in COS-7 cells examined under confocal 
microscope. The frequency of various aggregation phenotypes is indicated. Scale bar 
= 10 μm. (B) The 25 kDa and 15 kDa fragments of TDP-43 expressed in COS-7 cells 
are phosphorylated at serines 409/410 in the RIPA insoluble urea soluble fraction. R: 
RIPA fraction; U: Urea fraction. 
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Figure S2.2: Overexpression of full length p62, p62ΔUBA or p62ΔLIR mutants 
decreases TDP-43 15kDa fragment aggregation. (A,B) N2A cells were co-transfected 
with the 15kDa fragment and vector control, HA-tagged p62 or p62 deletion mutants. 
Full length p62 more potently reduced the percentage of cells exhibiting aggregation 
than either the ΔUBA or ΔLIR mutant. No change was detected in the average number 
of aggregates per positively scored cell. (>200 cells counted per trial, mean+/-SEM, n 
= 3-4, *p<0.05, **p<0.01). (C) Representative examples of N2A cells co-transfected 
with the 15kDa fragment and either vector control, HA-tagged p62 or p62 ΔUBA and 
ΔLIR mutants. Images were acquired using the ImageXpress system. 
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Figure S2.3: TDP-43 C-terminal aggregates do not sequester FUS/TLS. GFP-TDP-
43-15kDa or 25 kDa fragment and mCherry tagged FUS/TLS were co-transfected into 
HEK293T cells (A) or COS-7 cells (B). Images were taken using confocal 
microscope. Scale bar=10 μm 
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Figure S2.4: Autophagy inhibition results in shuttling of TDP-43 to the cytosol. (A) 
3T3 cells were treated with 10mM 3-MA for 24 hours and stained with rabbit anti-
TDP-43 antibodies. (B) Quantification of experiment in (A) (>1000 cells per trial, 
mean+/-SEM, n=3). 
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Figure S2.5: A model for the role of phosphorylation, ubiquitin, p62, autophagy and 
proteasome in regulating TDP-43 aggregation and clearance. 
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CHAPTER 3 
 
THE FRONTOTEMPORAL LOBAR DEGENERATION RISK FACTOR, 
TMEM106B, REGULATES LYSOSOMAL MORPHOLOGY AND FUNCTION
1
 
 
3.1 Summary 
Haplo-insufficiency of Progranulin (PGRN), a gene encoding a secreted glycoprotein, 
is a major cause of frontotemporal lobar degeneration with ubiquitin positive 
inclusions (FTLD-U). Single nucleotide polymorphisms in the TMEM106B gene were 
recently discovered as a risk factor for FTLD-U, especially in patients with PGRN 
mutations. TMEM106B is also associated with cognitive impairment in ALS patients. 
Despite these studies, little is known about TMEM106B at molecular and cellular 
levels and how TMEM106B contributes to FTLD. Here we show that TMEM106B is 
localized in the late endosome/lysosome compartments and TMEM106B levels are 
regulated by lysosomal activities.  Ectopic expression of TMEM106B induces 
morphological changes of lysosome compartments and delays the degradation of 
endocytic cargoes by the endolysosomal pathway. Furthermore, overexpression of 
TMEM106B correlates with elevated levels of PGRN, possibly by attenuating 
lysosomal degradation of PGRN. These results shed light on the cellular functions of 
TMEM106B and the roles of TMEM106B in the pathogenesis of FTLD-U with PGRN 
mutations. 
1
The results of this study were published in Brady OA, Zheng Y, Murphy K, Huang 
M, Hu F. Hum. Mol.Genet. 2013 Feb 15;22(4):685-95. Y.Z., K.M., and M.H. assisted 
with data acquisition and analysis. All experiments were performed by O.A.B. O.A.B. 
and F.H. wrote the manuscript. 
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3.2 Introduction 
Frontotemporal lobar degeneration (FTLD) is one of the most prevalent forms of early 
onset dementia, second only to Alzheimer’s disease (1,2). Mutations in the 
Progranulin (PGRN) gene were recently shown to be the major cause of FTLD with 
ubiquitin positive inclusions of TDP-43 (FTLD-U) (3-5). Most PGRN mutations result 
in a decrease in the amount of PGRN expressed or secreted, rather than a gain of 
toxicity (3,4). Thus, progranulin haplo-insufficiency is strongly associated with 
FTLD-U. PGRN encodes an evolutionarily conserved, secreted glycoprotein of 88 
kDa involved in would healing, inflammation, tumorigenesis and neuronal survival 
(6). A member of the VPS10 family, sortilin, was recently identified as a binding 
partner for PGRN (7). Sortilin regulates PGRN trafficking by mediating PGRN 
endocytosis and targeting to lysosomes, thus controlling PGRN levels in the brain 
(7,8). 
However, PGRN mutation carriers show a high variability in age of onset and 
pathological presentation, even with identical mutations, suggesting that 
environmental influences or additional genetic factors modify the disease 
manifestation (9). Recent genome-wide association studies by several groups have 
pinpointed TMEM106B, a gene encoding a transmembrane protein of unknown 
function, as a bona fide risk factor for FTLD-U, especially in patients with PGRN 
mutations (10-13). TMEM106B is also associated with cognitive impairment in ALS 
patients (14). However, studies with samples from FTLD patients have obtained 
conflicting results on the effect of TMEM106B polymorphisms on TMEM106B 
function and on the relationship between TMEM106B and PGRN. First, it is not clear 
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whether TMEM106B mRNA levels are affected by TMEM106B SNPs (11,12). 
Secondly, it is not known whether the protein function of TMEM106B is altered by 
SNPs within the coding region of TMEM106B (10,11,13). Studies have identified a 
T185S coding variant in TMEM106B associated with the protective allele (10,11,13) 
and suggested T185S to be in perfect linkage disequilibrium with the strongest SNP 
associated with FTLD-U, rs1990622 (10,13). However, whether and how T185S 
affects TMEM106B function remains unknown. Finally, it is still under debate 
whether TMEM106B polymorphisms affect PGRN levels, although the T185S allele 
was reported to be protective and was correlated with higher plasma PGRN levels 
(10,11,13). Thus, despite a strong genetic linkage, the role of TMEM106B in FTLD-U 
and the relationship between TMEM106B and PGRN are not completely understood 
from these studies (10-17). 
TMEM106B encodes a transmembrane protein of unknown function. To address the 
role of TMEM106B in FTLD-U with PGRN mutations, we investigated cellular 
functions of TMEM106B. Consistent with recent findings (18,19), we found that 
TMEM106B is a lysosomal protein and TMEM106B levels are modulated by 
lysosomal activities. We further showed that increased TMEM106B levels result in 
the accumulation of enlarged lysosomes and impair the degradation of endocytic 
cargoes.  Exogenous expression of TMEM106B increases PGRN levels, possibly due 
to its regulation of the endolysosomal pathway.  
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3.3 Materials and Methods 
Cell culture procedures 
T98G, N2A, HEK293T (from ATCC),  NSC34 (20) and BV-2 (21) cells were grown 
in DMEM supplemented with 10% FBS, 1% Penicillin-Streptomycin at 37°C in a 5% 
CO2 atmosphere.  Cells were transiently transfected with polyethlyeneimine (PEI) as 
described (22).  E17 rat cortical neurons were isolated and cultured as described (7).   
Plasmids and siRNAs 
Human TMEM106B cDNA was obtained from Open Biosystems (the ORFome 
collection, T185; in the pCMV-Sport6, S185). FLAG-tagged TMEM106B constructs 
were generated by cloning TMEM106B into p3XFLAG-CMV7.1 vector (Sigma-
Aldrich) using the enzymes HindIII and SalI. TMEM106B-myc was generated by 
cloning TMEM106B into pcDNA3.1myc his A vector (Invitrogen) using the enzymes 
HindIII and XhoI. GFP-TMEM106B was generated by cloning TMEM106B into 
pEGFP-C3 vector (Clontech) using the enzymes HindIII and XhoI/SalI.  GFP tagged 
Rab plasmids are generous gifts from Drs. Bill Brown and Volker Vogt.  PGRN and 
sortilin constructs were obtained as described (7). siRNA against Mouse TMEM106B 
(D-042561-01,-02,-03,-04), mouse SORT1 (D-041713-01,-02,-03,-04), and pooled 
control siRNAs (D-001206-13-05) were obtained from Dharmacon and transfected 
into N2A cells using DharmaFECT according to manufacturer’s instructions.    
Antibodies and chemicals 
The following antibodies were used in the study: sheep anti-mouse PGRN antibodies, 
goat anti-human PGRN antibodies and goat anti-mouse sortilin from R&D systems; 
mouse anti-myc (9E10) and anti-FLAG (M2) antibodies from Sigma-Aldrich; mouse 
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anti-LAMP1 and EEA1 antibodies from BD biosciences; rabbit anti-EGFR, rabbit 
anti-phospho-Erk1/2, and rabbit anti-cleaved caspase 3 antibodies from Cell 
Signaling; rat anti-mouse LAMP1 (1D4B) antibodies from BioLegend; rabbit anti-
TDP 43 antibodies from Proteintech; and mouse anti-GAPDH antibodies from 
Millipore. Rabbit anti-cathepsin D antibodies are a generous gift from Dr. Bill Brown. 
 To generate anti-TMEM106B antibodies, the intracellular domain of 
TMEM106B (residues 1-96) were expressed and purified as GST fusion proteins from 
E. coli. Recombinant proteins were sent to Covance laboratories to generate rabbit 
polyclonal antibodies.  Serum from the final bleed was diluted 1:2000 for western blot 
analysis and 1:250 for immunostaining. Antibody specificity was confirmed via 
Western blot and immunofluorescence by observing overlapping signals between 
FLAG and TMEM106B antibodies for overexpressed FLAG-TMEM106B and by 
decreased signals from cells treated with siRNAs against TMEM106B. The antibody 
does not cross react with the TMEM106B family members TMEM106A and 
TMEM106C (data not shown). 
 The following reagents are used in the study: 3-methyladenine (3-MA), 
chloroquine, ammonium chloride, cycloheximide, and staurosporine from Sigma-
Aldrich; recombinant human epidermal growth factor (EGF) from Promega; 
puromycin from Calbiochem; trichloroacetic acid (TCA) from Acros Organics; MG-
132 from Cayman chemical; bafilomycin A1 (Baf1) from LC Laboratories. 
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Immunofluorescence Microscopy 
Cells were plated on coverslips the day prior to transfection. Cells were fixed with 
3.7% formaldehyde in PBS 24 or 48 hours post-transfection and washed with PBS, 
followed by permeabilization and blocked with PBS containing 3% BSA, 0.1% Triton 
X-100 or 0.05% Saponin. Cells were stained with primary antibody in 1% BSA PBS 
blocking buffer overnight at 4º C. Cells were washed three times with PBS and 
incubated 2 hours at room temperature with a 1:500 mixture of Hoechst and secondary 
antibody (donkey-anti-rabbit/mouse IgG Alexa Fluor488 and 594, donkey-anti-rat 
AlexaFluor568, and donkey anti-sheep AlexaFluor680 Molecular Probes). For dextran 
loading experiments Texas Red labeled dextran (70,000 MW, Lysine Fixable, 
Molecular probes) was used. Cells were either preloaded for 16 hours with 0.5 µg/ml 
dextran, washed, and chased 4 hours in growth medium to label lysosomes, or cells 
were transfected and then loaded and chased. Cells were washed three times with PBS 
and mounted with Fluoromount G (Southern Biotech), then analyzed with a CSU-X 
spinning disc confocal microscope (Intelligent Imaging Innovations) with an HQ2 
CCD camera (Photometrics), or a Zeiss LSM700 confocal microscope with a 
transmission photomultiplier detector. All confocal pictures were obtained through 
63x or 100x objectives. 
Lysosomal scoring and Vacuolization Assays 
For lysosomal scoring, 0.56 µm confocal slices from N2A cells transfected with either 
vector control, WT or the T185S allele of TMEM106B were acquired. Slices were 
obtained through cells to yield the maximum number of lysosomes per field of view. 
Discrete LAMP1, positive vesicles between 0.3-4.0 µm were counted for each cell and 
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measured through the widest part of the vesicle. Large swollen vacuoles greater than 
4.0 µm were not included in these analyses. Histograms were generated using 200 
randomly selected lysosomes from each of these data sets. Analysis was performed 
with Slidebook software (3I). 
 For the vacuolization assay, N2A cells were transfected with indicated 
constructs and treated 24 hours later with any chemicals indicated. Cells were 
photographed with an ImagXpress Micro (Molecular Devices) at 20x and >200 cells 
counted per trial by an observer blind to the conditions. Cells were scored as positive 
by the presence of enlarged (>3µm) phase-lucent vacuoles.  
EGFR Degradation Assay 
T98G cells were transfected with indicated constructs. Cells were washed with PBS 
and media replaced with serum free DMEM after 24 hours. After 24 hours in serum 
free media, cells were stimulated with 100 ng/ml recombinant human EGF in the 
presence of 25 µg/ml cycloheximide to inhibit further protein synthesis and cells lysed 
at indicated time points for Western blot analysis. 
Western-blot analysis   
Protein samples in SDS sample buffer containing β-mercaptoethanol were kept on ice 
or boiled for 2min.  Samples were run on 12% polyacrylamide gels and transferred to 
Immobilon-FL PVDF membranes (Millipore).  Membranes were blocked with 
Odyssey Blocking Buffer (LI-COR Biosciences) for 1 hour followed by incubation 
with primary antibodies overnight at 4°C.  Membranes were washed for 5 min three 
times in Tris-Buffered Saline with 0.1% Tween-20 (TBS-T), incubated with secondary 
antibody for 2 hrs at room temperature and washed three more times with TBS-T.  
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Blots were imaged and quantified using an Odyssey Infrared Imaging System (LI-
COR Biosciences). For quantitation, all immunoreactive bands were normalized to a 
corresponding GAPDH reference band. 
Immunoprecipitation 
Cells were lysed in 50 mM Tris, pH 7.5, 150 mM NaCl, 1mM EDTA, 1%Triton, 0.1% 
sodium deoxycholate, and proteinase and phosphatase inhibitors (Roche). Mouse anti-
FLAG conjugated beads (Sigma) were allowed to immunoprecipitate FLAG-
TMEM106B in the cell lysates. These beads were incubated with cell lysates for 4 
hours at 4°C and washed 4 times with the lysis buffer. 
TCA precipitation of conditioned medium 
One day after transfection, N2A cells were grown in serum free medium. Conditioned 
media was collected 24 hours later and centrifuged at 10,000 rcf for 10 min to remove 
cell debris. Cleared media was incubated with 10% TCA at 4°C.  Protein pellets were 
collected by centrifugation, washed with acetone, and dissolved in SDS sample buffer 
prior to western blot to determine PGRN levels.  
ELISA 
PGRN levels were measured in N2A cells with TMEM106B overexpressed or 
knocked down with siRNAs. Cells were washed 48 hours post transfection and 
incubated 24 hours in serum-free DMEM. Conditioned media was cleared at 10,000 
rcf for 10 min and subjected to a Mouse PGRN ELISA (AdipoGen) according to 
manufacturer’s instructions. PGRN concentrations were converted to percentage of 
control in order to correct for inter-assay variability. Corresponding cell lysates from 
these samples were collected in RIPA buffer for Western blot analysis.  
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RT-PCR 
RNA was purified from cells 48 hours after transfection using TRIzol Reagent 
(Invitrogen). 2 µg total RNA was reverse transcribed using a poly(T) primer and 
SuperScript III Reverse Transcriptase (Invitrogen). qPCR was performed on a 
LightCycler 480 (Roche Applied Science) and transcript levels were calculated using 
efficiency  adjusted ΔΔ-CT. All transcripts were normalized to the geometric mean of 
two reference genes, Tbp, and Actb. The mouse Grn primer pair sequences were 
5’AGTTCGAATGTCCTGACTCCGCCA3’and 
5’AAGCCACTGCCCTGTTGGTCCT-TT3’. Mouse Tbp primers were 
5’CCCCACAACTCTTCCATTCT3’ and 5’GCAGGAGTGATAGGGGTCAT3’ and 
mouse Actb primers were 5’ACGAGGCCCAGAGCAAGAG3’ and 
5’TCTCCAAGTCGTCCCAGTTG3’. 
 
3.4 Results 
TMEM106B is localized in late endosome/lysosome compartments 
TMEM106B is a predicted type II transmembrane protein of unknown function. To 
determine the expression of endogenous TMEM106B, we raised antibodies against the 
intracellular portion of TMEM106B (a.a. 1-96). The polyclonal antibody specifically 
detects a 43 kDa band on SDS-PAGE corresponding to endogenous TMEM106B 
detected in multiple cell lines (Figure 3.1A). Since TMEM106B has 274 residues with 
a predicted molecular weight of 31 kDa, the discrepancy on migration indicates 
potential posttranslational modification, likely glycosylation of this protein (19).  
Consistent with studies by others (18), we found that TMEM106B protein exhibits as  
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Figure 3.1: Expression of TMEM106B in different cell types. (A) Cell lysates from 
HEK293T, NSC-34 and BV-2 were loaded and blotted with anti-TMEM106B and 
anti-GAPDH antibodies. (B) TMEM106B forms homodimers. FLAG-tagged 
TMEM106B WT and T185S variants were co-transfected with GFP-TMEM106B WT 
into HEK293T cells. Anti-FLAG antibodies were used to immunoprecipitate FLAG-
TMEM106B. IP products were blotted for GFP and FLAG as indicated. (C) 
TMEM106B expression in rat cortical neurons. E17 rat cortical neurons were isolated 
and allowed to differentiate for indicated days. Cell lysates were prepared and blotted 
for sortilin, TMEM106B and GAPDH. Cortical neurons were treated with 2 µM Ara-
C after DIV6 in order to inhibit the growth of glial cells. (D)  N2A cells were treated 
with 5mM 3-MA, 50 nM Baf1, 15mM NH4Cl + 100 µM chloroquine or 10 µM MG-
132 for 14 hrs as indicated. Cell lysates were prepared and blotted for TMEM106B 
and GAPDH.  (E) Quantification of data shown in (D), n=4, +/-SEM, * p<0.05, ** 
p<0.01 Student’s t-test.  
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an 86kDa band on SDS-PAGE when the samples are not boiled (data not shown), 
suggesting the presence of a SDS-resistant dimer. This is further confirmed by the co-
immunoprecipitation of GFP-tagged TMEM106B with FLAG-tagged TMEM106B 
(Figure 3.1B). The T185S variant of TMEM106B self-associates to a similar degree as 
wild type TMEM106B.  
With our polyclonal antibodies, we found that TMEM106B is ubiquitously expressed 
in many different cell types, including neurons and microglia cells, with highest 
protein levels detected in neuronal cell lines (Figure 3.1A). Analysis of TMEM106B 
expression levels in cortical neurons showed a positive correlation of TMEM106B 
protein levels with neuronal maturation in vitro (Figure 3.1C). To investigate cellular 
localization of endogenous TMEM106B, we stained neuroblastoma N2A cells with 
our polyclonal antibodies against TMEM106B. We found that a large pool of 
TMEM106B localized in intracellular vesicles (Figure 3.2A). Knockdown of 
TMEM106B expression by siRNA abolished this vesicular staining, confirming the 
specificity of our antibody (Figure 3.2A). To determine the identities of these 
intracellular vesicles, we examined the colocalization of N-terminal FLAG tagged 
TMEM106B with GFP-tagged Rab GTPases. TMEM106B shows strong 
colocalization with late endosome and lysosome markers Rab7 and Rab9, with little 
colocalization with the early endosome marker Rab5 and the recycling endosome 
marker Rab11, suggesting that TMEM106B mainly localizes to late endosomes and 
lysosomes (Figure S3.1A). FLAG-TMEM106B also shows strong colocalization with 
LAMP1, a transmembrane protein localized mainly on the lysosomes (Figure S3.1B). 
We further confirmed this with colocalization of endogenous TMEM106B with 
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Figure 3.2: TMEM106B localizes to late endosomes/lysosomes. (A) Colocalization of 
endogenous TMEM106B with LAMP1 positive vesicles. N2A cells were fixed and 
stained with polyclonal anti-TMEM106B and monoclonal anti-LAMP1 antibodies. 
siRNA knockdown of TMEM106B confirms the specificity of our anti-TMEM106B 
antibody. (B) Colocalization of endogenous TMEM106B with LAMP1 in DIV15 
cortical neurons.  (C) Overexpression of TMEM106B induces enlarged LAMP1 
positive vesicles. Vector control, pCMV-TMEM106B WT and T185S transfected 
N2A cells were stained with anti-TMEM106B and anti-LAMP1 antibodies. Green 
fluorescence exposure time was reduced for cells overexpressing TMEM106B to 
highlight differences in expression levels compared to nearby non-transfected cells. 
Scale bars: 10 µm (2 µm in the inset). (D) Quantification of average number of 
lysosomes per cell and mean lysosome diameter +/-SEM along with best fit curves of 
lysosome size histograms from  cells imaged in (C). A minimum of 200 lysosomes 
were measured from six randomly selected cells in each condition. * p<0.05, ** 
p<0.01, ***p<0.001 Student’s t-test. 
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LAMP1 in N2A cells (Figure 3.2A) and cortical neurons (Figure 3.2B). Endogenous 
TMEM106B in N2A cells shows much better colocalization with LAMP1 than 
overexpressed TMEM106B (Figure 3.2 and Figure S3.1), suggesting that TMEM106B 
overexpression might cause mislocalization of the protein or disturbance of lysosomal 
compartments. In particular, endogenous TMEM106B usually appeared as a granular, 
but relatively evenly distributed coat on the lysosomal limiting membrane with the 
occasional lysosome exhibiting one to several discrete TMEM106B puncta polarized 
on the lysosome surface. When TMEM106B was overexpressed we saw a 
preponderance of this polarized/punctate localization pattern compared to vector 
transfected controls. Overexpressed TMEM106B also frequently appeared within the 
lumen of the LAMP1 positive vesicles. A small pool of TMEM106B was also 
detected at the plasma membrane when overexpressed. These data strongly indicate 
that TMEM106B localization is critically affected by expression level. Live cell 
staining with external antibodies against the myc epitope tag, which is inserted at C-
terminus of TMEM106B, confirms that TMEM106B is a type II transmembrane 
protein with its C-terminus facing extracellularly or to topologically equivalent 
luminal spaces (Figure S3.2).  
Since TMEM106B is mainly localized on lysosomes, we further investigated whether 
protein levels of TMEM106B are regulated by lysosomal activities. Treatment with 
inhibitors of lysosomal acidification, such as bafilomycin (Baf1), ammonium chloride 
or chloroquine, leads to a significant increase in TMEM106B levels in N2A cells, 
suggesting that TMEM106B levels are regulated by the lysosomal degradation 
pathway (Figure 3.1D and E). Treatment with 3-methyladenine (3-MA), an inhibitor 
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of VPS34, a PI3K involved in autophagy and formation of multivesicular bodies (23),  
also increases TMEM106B levels (Figure 3.1D and E). This indicates that 
TMEM106B levels may be regulated by membrane trafficking events. On the other 
hand, treatment with the proteasome inhibitor MG-132 had minimal effects on 
TMEM106B levels, suggesting that the ubiquitin-proteosomal pathway is not a major 
regulator of TMEM106B protein levels 
Increased TMEM106B levels induces enlarged lysosomes 
Close examination of lysosome morphology in TMEM106B overexpressing N2A cells 
revealed an enlargement of lysosomes and a reduction of lysosome numbers (Figure 
3.2C and D). Examination of lysosomal morphology in other cell lines with 
TMEM106B overexpression, including HEK293T, COS-7, T98G and motor neuron 
cell line NSC-34 indicated a much more pronounced lysosomal phenotype in neuronal 
cell lines upon increases in TMEM106B levels, suggesting an enhanced sensitivity of 
neuronal cells to elevations in TMEM106B levels (Figure S3.3). Abnormal 
morphology was also seen in some of the enlarged lysosomes, some of which are 
reminiscent of intermediates of lysosomal fission or fusion (Figure 3.2C). This 
phenotype is also seen with GFP-TMEM106B overexpression,  which tends to give 
higher expression levels and results in large vacuoles positive for LAMP1 but negative 
for the early endosome marker EEA1 (Figure 3.3). These vacuoles are prominent 
under regular phase microscope in GFP-TMEM106B overexpressing N2A cells and 
are present in N2A cells overexpressing untagged TMEM106B when treated with 3-
MA (Figure S3.4). We fail to detect any significant differences between wild type  
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Figure 3.3: GFP-TMEM106B overexpression results in LAMP1 positive vacuoles in 
N2A cells. (A) GFP-TMEM106B expression in N2A cells results in enlarged vacuoles 
that are rimmed by TMEM106B and LAMP1. (B) GFP-TMEM106B induced 
vacuoles are EEA1 negative. (C) Co-localization of PGRN with GFP-TMEM106B in 
some of the vacuoles. Scale bar: 10 µm (2 µm in the inset). 
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and the T185S variant of TMEM106B in inducing abnormalities in lysosomal 
morphology (Figure 3.2 and Figure S3.4). 
To further confirm the origin of these membranes, we preloaded lysosomes with 
dextran and then transfected the cells with TMEM106B constructs. It has been shown 
that preloaded dextran accumulates in lysosomes (24). We found that many of the 
enlarged vesicles induced by TMEM106B overexpression are positive for dextran 
(Figure 3.4A), confirming that these are lysosome derived. Although TMEM106B 
overexpression induces lysosome enlargement, it does not induce apoptosis or TDP-43 
mislocalization or cleavage (Figure S3.5).  
TMEM106B overexpression impairs endolysosomal degradation 
To investigate whether the abnormal morphology of enlarged late 
endosomes/lysosomes induced by TMEM106B impairs endolysosomal function, the 
cellular turnover rate of epidermal growth factor receptor (EGFR) was analyzed. 
T98G cells, which express high levels of endogenous EGFR, were treated with EGF. 
EGF stimulation leads to the activation of EGFR and phosphorylation of ERK1/2. 
EGFR signaling continues after EGFR endocytosis until the receptors are inwardly 
budded into intra-luminal vesicles in MVBs. EGFR is subsequently degraded through 
lysosomal fusion and degradation (25). We found that GFP-TMEM106B expression 
appears to attenuate the rate of EGFR degradation in T98G cells. However, EGF 
downstream signaling, as quantified by the levels of phospho-ERK1/2 is not affected 
(Figure 3.5). These data suggest that TMEM106B may cause a defect in the later 
stages of late endosome/lysosome fusion or lysosomal degradation rather than early  
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Figure 3.4: The fluid-phase marker, dextran, accumulates in TMEM106B positive 
vesicles. (A) N2A cells pre-loaded with dextran were transfected with TMEM106B 
and GFP-TMEM106B. Cells were fixed and stained 24 hrs post-transfection. 
Untagged and GFP-TMEM106B can be seen on the surface of dextran containing 
vesicles. (B) Dextran labeled endosomes are capable of fusion with TMEM106B 
enlarged lysosomes. N2A cells were transfected with vector control, TMEM106B, and 
GFP-TMEM106B.  After 28 hrs, cells were loaded with dextran for 16 hrs, washed, 
and chased 4 hrs in growth medium. Cells were fixed and stained 48 hrs post-
transfection. Scale bars: 10 µm (2 µm in the inset). 
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endocytic trafficking steps or MVB formation. Because the enlarged lysosome 
phenotype induced by TMEM106B overexpression is much more pronounced in 
neuronal bcell lines than in T98G cell, a more severe endolysosomal dysfunction is 
expected in neuronal cell lines. Unfortunately, we were unable to detect eciable 
amounts of endogenous EGFR in N2A cells, making them unsuitable for this assay. 
To determine whether TMEM106B affects endosome/lysosome fusion, we incubated 
N2A cells overexpressing TMEM106B with the fluid-phase marker, dextran and 
chased for 4 hours. Dextran signal is present in TMEM106B enlarged lysosomes to a 
similar extent as in control cells, suggesting that there are no major defects in fusion 
between TMEM106B induced enlarged lysosomes and incoming endosomes (Figure 
3.4B).  
TMEM106B modulates PGRN protein levels. 
Our previous published results have shown that sortilin mediates PGRN trafficking 
into lysosomes and plays a critical role in regulating PGRN levels (7).  We 
hypothesized that TMEM106B may play a role in regulating PGRN levels by affecting 
lysosomal activities. To address this hypothesis, we measured intracellular and 
secreted PGRN levels in cells overexpressing the wild type or T185S allele of 
TMEM106B. Both wild type and T185S alleles of TMEM106B increased endogenous 
PGRN levels in N2A cells (Figure 3.6A-C).  These changes in PGRN levels are not 
due to changes in PGRN mRNA levels as measured by qPCR (Figure 3.6C), 
suggesting that TMEM106B regulates PGRN levels through post-transcriptional 
mechanisms. Sortilin expression levels do not appear to be affected by TMEM106B  
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Figure 3.5: GFP-TMEM106B overexpression results in defects in EGFR degradation. 
(A) T98G cells transfected with vector control or GFP-TMEM106B were serum 
starved and stimulated with EGF in the presence of cycloheximide for indicated times. 
Levels of EGFR, phosphorylated ERK1/2, and GAPDH were quantified by western 
blots. A representative image of 3 experiments is shown. (B) Quantification of EGFR 
levels relative to loading control for experiment in (A). n=3 +/-SEM.             
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Figure 3.6: Regulation of PGRN levels by TMEM106B. (A) Western blot analysis of 
N2A cells overexpressing TMEM106B WT and T185S. Transfected cells were 
changed to serum free medium 24 hrs after transfection. After another 24 hrs, lysates 
and conditioned media (CM) was collected. CM was further concentrated using TCA 
precipitation. (B) Western blot analysis of N2A cells transfected with control siRNA 
pool or siRNA pools against TMEM106B and sortilin. Transfected cells were changed 
to serum free medium 48 hours after siRNA transfection. After another 24 hrs, lysates 
and conditioned media (CM) was collected. CM was further concentrated using TCA 
precipitation. (C) Overexpression of TMEM106B in N2A cells lead to increased 
intracellular and secreted PGRN levels as measured by western blot or ELISA, 
respectively (n=5).  PGRN levels were normalized to the mean of two vector 
transfected controls. No change in PGRN mRNA levels was detected via qPCR (n=3). 
(D) Knockdown of TMEM106B in N2A cells has no effect on intracellular or secreted 
PGRN levels as measured by western blot or ELISA, respectively (n=6). Sortilin 
knockdown leads to increased levels of PGRN in the media. * p<0.05, **p<0.01, 
Student’s t-test. 
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(Figure 3.6A), indicating it is unlikely that TMEM106B regulates PGRN levels 
through sortilin. Furthermore, in cells overexpressing GFP-TMEM106B, 
accumulation of endogenous PGRN, along with the prototypical lysosomal proteinase 
cathepsin D, can be detected in some of the GFP-TMEM106B positive vacuoles 
(Figure 3.3C).  Together these results suggest that TMEM106B may regulate PGRN 
levels through its function in the endolysosomal degradation pathway.   
 We also examined the effect of TMEM106B loss of function on PGRN levels 
by knocking down TMEM106B expression in N2A using siRNA.  siRNA treatment 
resulted  in ~50-70%  reduction of TMEM106B expression (Figure 3.6B and D). In 
order to test the validity of our assay, we knocked down sortilin expression using 
siRNA as a positive control and observed an increase in secreted PGRN (Figure 3.6D). 
However, TMEM106B knockdown did not appear to affect PGRN levels. Further, 
reduced TMEM106B expression does not appear to affect lysosomal size or 
morphology (Figure 3.2A). Thus, either residual TMEM106B expression is enough to 
maintain its function in the lysosomes or TMEM106B loss of function does not 
directly affect lysosomal morphology or function. 
 
3.5 Discussion 
Endolysosomal function is essential for the health of neurons. Several genetic 
mutations found in FTLD, including those in CHMP2B and VCP/p97, result in the 
accumulation of enlarged vacuoles and a defect in endo-lysosomal trafficking or 
autophagosome maturation (26-29). Mutations in the PGRN gene are the main cause 
for FTLD-U (3-5). PGRN has also been implicated in regulating lysosome functions 
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and  is transcriptionally co-regulated with a number of essential lysosomal genes (30). 
PGRN knockout mice accumulate lysosomal byproducts, lipofuscin (31) and 
homozygous PGRN mutant human patients exhibit neuronal ceroid lipofuscinosis 
(32). In this study, we showed that the FTLD-U risk factor TMEM106B is mainly 
localized to late endosome/lysosome compartments and regulates lysosomal 
morphology (Figure 3.2). Overexpression of TMEM106B results in accumulation of 
enlarged lysosomes (Figure 3.2-3.4) and delays the degradation of endocytic cargoes, 
such as EGFR (Figure 3.5). TMEM106B does not affect the termination of EGFR 
signaling (Figure 3.5), suggesting that TMEM106B does not cause defects in 
membrane invagination into multivesicular bodies.   We speculate that TMEM106B 
may regulate the fusion of late endosomes with lysosomes or the fission of the hybrid 
organelle after endosome-lysosome fusion. Our examination of endosome-lysosome 
fusion events using dextran labeling suggested that TMEM106B induced enlarged 
lysosomes are still capable of fusing with incoming endosomes (Figure 3.4). However, 
it is still possible that TMEM106B affects the kinetics of endosome-lysosome fusion, 
which requires detailed analysis of endosome-lysosome fusion using time lapse 
imaging. 
 It is still under debate whether TMEM106B polymorphisms result in changes 
in TMEM106B levels or changes in TMEM106B protein, as one variant, T185S, has 
been reported to be protective and to be in perfect linkage disequilibrium with the 
strongest SNP associated with FTLD-U (10-17). We find no differences between the 
WT and T185S variant of TMEM106B in regards to regulating lysosomal morphology 
and number, or PGRN levels. Our results are consistent with a model in which 
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increased expression of TMEM106B perturbs the endolysosomal pathway. This is 
corroborated by findings of increased TMEM106B mRNA and protein levels in post-
mortem brain samples of FTLD-U patients (12,18). Surprisingly, reduced expression 
of TMEM106B by RNAi treatment does not have any obvious effect on lysosomal 
morphology. It is possible that residual TMEM106B is sufficient to maintain its 
function in the lysosomes or that TMEM106B is not essential for lysosomal function. 
Another possibility is that TMEM106B is functionally redundant and may be 
compensated by other genes, such as TMEM106A and TMEM106C. A complete 
depletion of TMEM106B function using a mouse knockout model might be needed to 
determine TMEM106B function in vivo.  
 Progranulin haplo-insufficiency is strongly associated with FTLD-U. However, 
it is still under debate whether TMEM106B SNPs affects PGRN levels. Previous 
studies with FTLD patient samples resulted in contradictory conclusions on the 
regulation of PGRN by TMEM106B (10-13). Here we show that exogenous 
expression of TMEM106B increases PGRN levels (Figure 3.6) and results in 
accumulation of PGRN in the lysosomes (Figure 3.4C). Our results indicate that 
elevated TMEM106B levels could alter plasma PGRN levels in human patients, 
possibly due to its effect on endolysosomal trafficking. While the majority of the 
increased PGRN observed appears to be intracellular, likely as a result of abnormal 
lysosomal degradation, we do detect a modest increase in the levels of extracellular 
PGRN as measured by ELISA. One potential mechanism to explain this increase in 
PGRN levels is through an overflow of the increased intracellular PGRN into the 
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extracellular space via lysosomal exocytosis, a well described process in which 
lysosomes fuse with the plasma membrane and release their lumenal contents. 
 In summary, our molecular and cellular characterization of TMEM106B and 
studies on TMEM106B and PGRN interaction revealed a relationship between PGRN 
and TMEM106B that converges on regulation of endolysosomal trafficking and 
function. These results will shed light on how PGRN and TMEM106B affect FTLD-U 
pathogenesis and how PGRN and TMEM106B are regulated at the molecular and 
cellular levels. Further studies to monitor the dynamics of endosome-lysosome fusion 
with live imaging, to examine the detailed morphology of TMEM106B induced 
vacuoles with electron microscopy, and to identify TMEM106B binding partners will 
give us insights into mechanisms of endosome-lysosome dynamics regulated by 
TMEM106B 
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3.7 Supplementary Information 
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Figure S3.1: TMEM106B localizes to late endosomes/lysosomes. (A) Colocalization 
of TMEM106B with Rab7 and Rab9 in T98G cells. Flag tagged TMEM106B were co-
transfected with GFP-tagged Rab GTPases as indicated into T98G cells. Cells were 
fixed and stained with anti-Flag antibodies. (B) Colocalization of TMEM106B with 
endogenous LAMP1 in T98G cells. Untagged TMEM106B was transfected into T98G 
cells which were fixed and stained with anti-TMEM106B and LAMP1 antibodies.  
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Figure S3.2: TMEM106B is a type II transmembrane protein. HEK293T cells were 
transfected with N-terminal Flag tagged TMEM106B (Flag-TMEM106B) or C-
terminal myc tagged TMEM106B (TMEM106B-myc). Cells were either incubated 
with anti-Flag or anti-myc antibodies on ice for 2 hours (live) or incubated with these 
antibodies after fixation and permealization (permeablized). Confocal images were 
acquired. Scale bar=10μm.  
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Figure S3.3: GFP-TMEM106B expression in COS7 cells results in enlarged 
lysosomes. (A) Cells were transfected with vector control, fixed and stained with anti-
TMEM106B and anti-LAMP1 antibodies. (B) Cells were transfected with GFP-
TMEM106B, fixed and stained with anti-LAMP1 antibodies.  
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Figure S3.4: TMEM106B overexpression results in enlarged vacuoles in N2A cells. 
(A) 3-MA (5mM for 12 hours) treatment results in enlarged vacuoles with 
TMEM106B overexpression. Cells with vacuoles • 3 μm in diameter were scored as 
positive. n=4 * p<0.05, Student’s t-test. (B) GFP-TMEM106B expression in N2A 
leads the accumulation of vacuoles. Cells with vacuoles • 3 μm in diameter were 
scored as positive. n=4 * p<0.05, Student’s t-test.  
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Figure S3.5: GFP-TMEM106B vacuolization does not perturb TDP-43 nuclear 
localization or cause apoptosis. (A) N2A cells were transfected with GFP control or 
GFP-TMEM106B for 24 hrs and 48 hrs. Cells were fixed and stained with polyclonal 
rabbit anti-TDP 43 antibodies. (B) GFP-TMEM106B expressing cells exhibited 
minimum caspase-3 staining at 24 hrs and 48 hrs after transfection. As a positive 
control, N2A cells were treated with 1 μM staurosporine for 3rs to induce apoptosis as 
indicated by cleaved caspase-3 staining. (C&D) Staurosporine, but not GFP-
TMEM106B expression alone, induces TDP-43 and caspase 3 cleavage in N2A cells.  
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CHAPTER 4 
 
REGULATED INTRAMEMBRANE PROTEOLYSIS OF THE 
FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) RISK FACTOR, 
TMEM106B, BY SPPL2A AND SPPL2B
 1
 
 
4.1 Summary 
The sequential processing of single pass transmembrane proteins via ectodomain 
shedding followed by intramembrane proteolysis is involved in a wide variety of 
signaling processes as well as maintenance of membrane protein homeostasis. Here 
we report that the recently identified frontotemporal lobar degeneration (FTLD) risk 
factor TMEM106B undergoes regulated intramembrane proteolysis. We demonstrate 
that, when overexpressed, TMEM106B is readily processed to the N-terminal 
fragment (NTF) containing the transmembrane and intracellular domain. The NTFis 
further processed into a small, rapidly degraded membrane associated intracellular 
domain (ICD). The GxGD aspartyl proteases SPPL2a, and to a lesser extent, SPPL2b, 
are responsible for this second cleavage event. Additionally, the TMEM106B paralog, 
TMEM106A, is also lysosomally localized and appears to undergo similar proteolytic 
processing; however, it is not a specific substrate of SPPL2a or SPPL2b. Our data 
adds to the growing list of proteins that undergo intramembrane proteolysis and  may 
shed light on the regulation of the TMEM106 family of proteins. 
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performed by O.A.B. O.A.B. and F.H. wrote the manuscript. 
 
4.2 Introduction 
The regulated intramembrane proteolysis (RIP)
2
 of transmembrane proteins has 
emerged as a widespread and evolutionarily conserved mechanism for coordinating 
both extracellular and intracellular signaling events in cells (1). Generally, an initial 
proteolytic event results in the shedding of an ectodomain followed by intramembrane 
processing of the transmembrane stump, liberating an intracellular domain (ICD) and 
a small peptide corresponding to the transmembrane region between the two cleavage 
sites. An increasing number functions have been being ascribed to RIP in health and 
disease, including signaling functions such as transcriptional regulation by ICDs 
liberated from amyloid precursor protein (APP), and Notch, among many others (2,3). 
RIP is also implicated in the processing of MHC-I molecules by signal peptide 
peptidase (SPP) in the ER (4). Finally, RIP may also represent a generalized 
mechanism for regulating the levels of membrane proteins (5).     
 Intramembrane cleaving proteases (iCLiPs) are a diverse group of three major 
protein families: the S2P-metalloproteases, the rhomboid serine proteases, and the 
GxGD-type aspartyl proteases, all of which are capable of cleaving proteins within the 
lipid bilayer (6). The signal peptide peptidase-like (SPPL) class of intramembrane 
proteases is part of the larger family of GxGD aspartyl proteases (7). Within this 
aspartyl protease family, presenilin, has a strong preference for cleaving type I 
transmembrane proteins and  the SPPL family has a strict requirement for type II 
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membrane proteins which corresponds to a topological inversion of the catalytic sites 
within the membrane, relative to presenilin (8,9). Intramembrane cleavage of 
transmembrane proteins by these proteases requires an initial ectodomain shedding 
event in order for the substrate to be accessible (10-12). Each member of the SPPL 
family has a specific subcellular localization and tissue distribution, suggesting that 
each may have unique substrate preferences (9,13).  
 TMEM106B was first identified as a genetic risk factor for frontotemporal 
lobar degeneration (FTLD) caused by mutations in the progranulin gene (14,15). 
TMEM106B is a type II single pass transmembrane protein residing primarily within 
the limiting membrane of late endosomes and lysosomes (16-18). The SNPs 
associated with increased risk for FTLD do not result in mutations in the TMEM106B 
protein, but instead lead to elevated mRNA and protein levels of TMEM106B (14,17). 
Increased TMEM106B  levels have been shown to cause various lysosomal defects 
including altered morphology, impaired acidification, and reduced degradative 
capacity (17,18). Furthermore, a coding variant T185S, in linkage disequilibrium with 
the protective allele of TMEM106B has been proposed to be more rapidly degraded, 
further implicating elevated TMEM106B levels as a potential mechanism underlying 
FTLD risk (19).  
 
4.3 Materials and Methods 
Pharmacological Reagents and Antibodies 
The following antibodies were used in this study: mouse anti-FLAG (M2) from 
Sigma, mouse anti-HA (HA.11) from Covance, mouse anti-GAPDH from Proteintech 
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Group, Mouse anti-v5 from Invitrogen, and rat anti-mouse LAMP1 (1D4B) from BD 
Biosciences. Rabbit anti-TMEM106B was generated against the ICD as described 
(18). 3-methyladenine (3-MA), Phorbol 12-myristate 13-acetate (PMA), leupeptin, 
and ammonium chloride were purchased from Sigma. TAPI-2, GM6001, BACE IV 
inhibitor, and (ZLL)2-ketone were from EMD Millipore.  
Expression Constructs 
Human TMEM106B cDNA was obtained from Open Biosystems in pCMV-Sport6. 
SPPL2b, SPPL2c, TMEM106A, and TMEM106C were obtained from ORFeome 
Collection (kind gifts from Dr. Haiyuan Yu). SPPL2a was obtained from the DNASU 
Plasmid Repository (Arizona State University). All TMEM106 family cDNAs were 
subloned into the p3XFLAG-CMV7.1 vector (Sigma-Aldrich).All SPPL2 family 
cDNAs were subcloned into pCDNA3.1(+)-V5/HisA (Invitrogen). The SPPL2a 
D412A mutant was generated by site directed mutagenesis. HA-TNFα in the pCMV-
Tag 4 vector (Stratagene) was kindly provided by Dr. Hening Lin. 
Cell Culture, DNA Transfection, and Drug Treatment  
Human embryonic kidney HEK293T and mouse N2a cells were maintained in 
Dulbecco’s Modified Eagle’s medium (Cellgro) supplemented with 10% fetal bovine 
serum (Gibco) and 1% Penicillin–Streptomycin (Invitrogen) in a humidified incubator 
at 37ºC and 5% CO2. Cells were transiently transfected with polyethyleneamine as 
described (20). Cells were either treated with 200 nM PMA for 2 hours, or with 50 µM 
TAPI-2, 50 µM  GM6001, 20 µM BACE IV inhibitor, 15 mM ammonium chloride, 
250 µM leupeptin, or 50 µM  (ZLL)2-ketone for 16 hours. 3-MA was used at 5 or 10 
mM for 14 hours. 
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Western Blot Analysis  
Cells were washed with PBS 48 hours post-transfection and whole cell lysates were 
collected in Laemmli sample buffer with β-mercaptoethanol. Whole cell lysates were 
sonicated and kept on ice or heated at 95ºC for 2 minutes. Samples were separated on 
12% SDS-PAGE gels or 16% tricine gels and transferred to Immobilon-FL 
polyvinylidene fluoride membranes (Millipore). Membranes were blocked for 1 hour 
with 5% non-fat milk in PBS and incubated in an equal mix of TBS with 0.1% Tween-
20 (TBS-T) and Odyssey blocking buffer (LI-COR Biosciences) containing primary 
antibodies overnight at 4ºC. Membranes were washed three times with TBS-T, 
incubated with secondary antibodies conjugated to AlexaFluor 680 (Invitrogen) or 
IRDye 800 (LI-COR Biosciences) for 1 hour at room temperature. Membranes were 
washed three more times with TBS-T then imaged and quantified using an Odyssey 
Infrared Imaging System (LI-COR Biosciences). 
Immunofluorescence Microscopy 
Cells on coverslips were washed with PBS 48 hours post-transfection and fixed in 4% 
paraformaldehyde for 15 minutes at room temperature. Cells were washed 3 more 
times with PBS followed by permeabilization and blocking in blocking buffer (0.05% 
Saponin, 3% BSA in PBS) for 1 hour. Primary antibodies were incubated in blocking 
buffer overnight at 4ºC. Cells were washed and incubated in secondary antibodies 
conjugated to CF488A, CF568, or CF660C (Biotum). Cells were washed three more 
times and coverslips mounted on to slides with Fluoromount G (SouthernBiotech). 
Images were acquired on a CSU-X spinning disc confocal microscope (Intelligent 
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Imaging Innovations) with an HQ2 CCD camera (Photometrics) using a 100x 
objective. 
 
4.4 Results 
TMEM106B is proteolytically processed  
When N-terminally FLAG tagged TMEM106B is overexpressed in HEK293T cells, 
we observed a faint band at 20 kDa in addition to the 50 kDa full length TMEM106B 
in Western blot using an anti- FLAG antibody. We hypothesized that the 20 kDa band 
was the N-terminal transmembrane stump remaining after cleavage of the 
TMEM106B lumenal domain. We refer to this product as the N-terminal fragment 
(NTF) (Figure 4.1A). Because ectodomain shedding is a prerequisite for most know 
instances of RIP, we decided to test if this NTF could be further processed by an 
iCLiP to produce an ICD. Note that ectodomain shedding generally refers to the 
extracellular release of a soluble protein domain; however, TMEM106B is almost 
exclusively localized to late endosomes/lysosomes. We will henceforth refer to this 
analogous shedding event as lumenal domain shedding.  
 In order to increase the amount of substrate available to increase our chances 
of detecting an ICD, we treated cells with 3-MA, an inhibitor of the class III PI3 
kinase VPS34. Inhibition of this enzyme prevents the induction of autophagy and 
increases the levels of TMEM106B (18,21). When cells overexpressing FLAG-
TMEM106B were treated with 3-MA, we observed a ~18kDa band in addition to the 
20 kDa NTF and full length TMEM106B, which we predicted to be the TMEM106B 
ICD. The SPP family of iCLiPs has been shown to cleave a number of type II 
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transmembrane proteins at various subcellular locations (13,22-25). Treatment of 
TMEM106B overexpressing cells with the specific SPP class protease inhibitor 
(ZLL)2-ketone led to an increase in the relative amount of TMEM106B NTF 
generated and  a concomitant decrease in the ICD, suggesting that an endogenous SPP 
class protease plays a role in cleaving the TMEM106B NTF in HEK293T cells (Figure 
4.1A).  
 We attempted to reproduce this effect in cells transfected with untagged 
TMEM106B. To our surprise, untagged TMEM106B produced relatively more 
TMEM106B NTF and ICD than the FLAG-tagged construct, indicating that the 
FLAG-tag may be sterically hindering the active protease’s access of the NTF 
substrate. Treatment with (ZLL)2-ketone led to a significant decrease in the amount of 
ICD generated relative to the NTF and full-length TMEM106B. Treatment with 3-MA 
elevated the levels of full-length TMEM106B, the NTF, and the ICD; however, the 
ratios between these fragments when treated with (ZLL)2-ketone were no different 
from those of cells not treated with 3-MA (Figure 4.1C.).  
 In order to narrow down the possible enzymes required for the initial lumenal 
domain shedding event, we screened a number of compounds which are capable of 
inducing or inhibiting various classes of sheddase. Members of the A disintegrin and 
metalloproteinase (ADAM) family are often implicated in the primary ectodomain 
shedding event for transmembrane proteins prior to RIP (26). Cells treated with 
phorbol myristate acetate (PMA), a protein kinase C inducer which stimulates ADAM 
sheddase activity, failed to induce TMEM106B lumenal domain shedding as assessed 
by the levels of NTF produced relative to full-length protein (Figure 4.1B and 4.2A). 
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Figure 4.1: TMEM106B undergoes sequential proteolysis. (A) HEK293T cells 
transfected with FLAG-TMEM106B were treated with 3-MA and/or (ZLL)2-ketone 
for 14 hours as indicated. Whole cell lysates were subject to anti-FLAG western blot, 
which revealed  a 50 kDa monomeric TMEM106B, a 20 kDa membrane-retained NTF 
stub, and an 18 kDa ICD.  (ZLL)2-ketone inhibits the formation of the ICD, resulting 
in an increase in the NTF levels. Vertical black lines indicate where the image was 
cropped from the same blot. (B) Untagged TMEM106B is more susceptible to 
cleavage than FLAG-TMEM106B. Western blots of 293T whole cell lysates 
transfected with TMEM106B and probed with a rabbit anti-TMEM106B ICD 
antibody reveal a 43 kDa full length protein, 19 kDa NTF, and 17 kDa ICD. The levels 
of all of these products are enhanced by treatment with 10 mM 3-MA. Treatment with 
200nM PMA for 2 hours does not enhance lumenal domain shedding and NTF 
formation. Note that the TMEM106B fragment comprising amino acids 1-96 migrates 
slightly faster than the actual ICD. The asterisk indicates a non-specific band. (C) 
Quantitation of the results from (B). The ICD generated was quantitated by 
densitometry and calculated as a ratio relative to full length and NTF TMEM106B. 
Values were normalized to GAPDH intensity (n=3 +/- SEM, *p-value <0.05, *p-value 
<0.01, Student’s t-test). (D) Schematic illustration of regulated intramembrane 
proteolysis of TMEM106B, yielding a released lumenal and a membrane-retained 
NTF which is further processed into an ICD and a small predicted peptide.  
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Treatment with the hydroxamic acid-based inhibitor TAPI-2, a broad spectrum 
inhibitor of sheddases in the matrix metalloproteinase (MMP) and ADAM families, 
failed to inhibit shedding, as assessed by the levels of NTF produced relative to full-
length protein (Figure 4.2A). The related MMP inhibitor GM6001 also failed to affect 
shedding (data not shown). As a positive control for PMA and TAPI-2 activity, we 
treated TNFα expressing HEK293T cells with PMA pretreated with TAPI-2 or vehicle 
control. As expected, PMA induced a large decrease in the levels of full length TNFα 
while TAPI-2 pretreatment prevented this effect (Figure 4.2B). Most ADAM and 
MMP sheddases are primarily active at the cell surface and cleave extracellularly 
facing substrates (27,28). Our data confirms that these are unlikely candidates for 
TMEM106B lumenal shedding. BACE1, the sheddase for amyloid precursor protein 
required for β-amyloid generation, is active in endosomal and lysosomal 
compartments (29). However, treatment with BACE Inhibitor IV also failed to inhibit 
NTF generation (Figure 4.2A). The majority of known sheddases belong to either the 
metalloprotease family (MMP and ADAM) or the aspartic protease BACE family, 
none of which appear to be responsible for TMEM106B processing, suggesting a 
potentially novel mechanism for TMEM106B lumenal domain shedding. Lysosomes 
harbor a wide range of proteases, which can be inhibited by raising the pH of the 
lysosome or by direct inhibition with leupeptin, a protease inhibitor (30). Treatment 
with these lysosomal inhibitors result in a modest decrease in the levels of NTF 
relative to full TMEM106B compared to the other treatments. This suggests that the 
TMEM106B lumenal domain shedding event may occur within the lumen of the 
lysosome by a resident protease 
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Figure 4.2: TMEM106B lumenal domain shedding occurs at the lysosome and its 
NTF is cleaved by SPPL2a and SPPL2b.  (A) TMEM106B lumenal domain shedding 
is not mediated by most known classes of sheddases including ADAMs and MMPs, 
but is slightly reduced by inhibition of lysosomal proteases. HA-TNFα blot is 
provided as a positive control for the effects of PMA and TAPI-2. PMA induces 
ectodomain shedding of full-length TNFα, which is prevented by pre-treatment with 
TAPI-2.  HEK293T cells overexpressing TMEM106B were treated with indicated 
chemicals for 16 hours, except PMA which was treated for 2 hours. Concentrations 
used were 50 µM TAPI-2, 200 nM PMA, 20 µM BACE IV inhibitor, 15 mM 
ammonium chloride, 250 µM leupeptin, and  50 µM  (ZLL)2-ketone. ICD standards of 
different sizes show that the 106 amino acid fragment is closest in size to the ICD 
generated by TMEM106B. Note that the actual ICD appears as a doublet of two very 
closely spaced bands. (B) SPPL2a promotes the conversion of TMEM106B NTF to 
the ICD. This is inhibited by (ZLL)2-ketone treatment (50 µM for 16 hours). The 
catalytically inactive mutant of SPPL2a (D412A) also fails to induce NTF conversion 
to ICD. SPPL2b promotes conversion of NTF to ICD and is somewhat resistant to 
(ZLL)2-ketone inhibition under the conditions tested. SPPL2c fails to promote NTF to 
ICD conversion. The asterisk indicates a non-specific band. (C) FLAG-tagged 
TMEM106B cleavage by SPPL2 family members is similar to untagged TMEM106B. 
HEK293T cells transfected as indicated were treated with 5 mM 3-MA for 14 hours. 
FLAG-tagged TMEM106B NTF and ICD standards of 127 and 96 amino acids are run 
next to these TMEM106B fragments for reference.  
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The TMEM106B NTF is a substrate for intramembrane proteolysis by SPPL2a 
and SPPL2b 
SPPL2a and SPPL2b have recently been implicated in the intramembrane proteolysis 
of several type II membrane proteins. To date, five known substrates have been 
identified: TNFα, Fas Ligand, British dementia protein-2/ITMB2 (Bri2), Transferrin 
Receptor 1, and CD74 (22-25,31-34). In some cases, SPPL2a and SPPL2b appear to 
share a common substrate such as TNFα, and Bri2. To test if TMEM106B could be a 
substrate of either of these enzymes, we co-transfected untagged TMEM106B into 
HEK293T cells with vector control, or expression constructs for SPPL2a, SPPL2b, 
and their paralog, SPPL2c. We found that both SPPL2a and SPPL2b, but not SPPL2c 
were capable of cleaving the TMEM106B NTF to generate smaller ICD fragments and 
this activity was inhibited by treatment with (ZLL)2-ketone (Figure 4.2B and 4.2C). 
Additionally, D412A, a catalytically inactive mutant of SPPL2a failed to induce this 
cleavage, indicating that SPPL2a is indeed an active protease against the TMEM106B 
NTF. 
 SPPL2a has been reported to be primarily localized to late endosomes and 
lysosomes, whereas SPPL2b is primarily expressed at the cell surface (22,35). In order 
to demonstrate the localization of these proteases in TMEM106B expressing cells, we 
analyzed the localization of the v5 tagged SPPL2 proteins in N2a cells along with 
TMEM106B. TMEM106B appears primarily as discrete puncta on LAMP1 positive 
vesicles. SPPL2a as well as the D412A mutant could be detected on a subset of 
vesicles containing both LAMP1 and TMEM106B, indicating that SPPL2a could 
access lysosomal TMEM106B as a substrate (Figure 4.3A and B). SPPL2b localized 
 142 
 
very poorly to these TMEM106B positive vesicles (Figure 4.3C). Instead, SPPL2b 
accumulated in large perinuclear stacks, suggesting that this construct accumulates in 
the Golgi (Figure 4.3C). SPPL2b might process TMEM106B in the Golgi since a 
small population of TMEM106B is also observed in the Golgi at steady state. SPPL2c 
did not co-localize at all with TMEM106B and stained in a reticulated pattern, 
indicative of its localization to the ER, in agreement with a previous report (Figure 
4.3D)(22). In agreement with this, SPPL2C has no activity towards TMEM106B 
(Figure 4.2B and C). 
Determination of the NTF and ICD cleavage sites  
In order to determine the approximate location of the cleavage sites for both lumenal 
domain shedding and intramembrane proteolysis, we generated various C-terminal 
truncations of TMEM106B to determine which species migrated at the same apparent 
molecular weight as the NTF and the ICD by SPPL2a during RIP. The first two 
constructs generated were N-terminally flag tagged and corresponded to amino acids 
1-127 and 1-96. Amino acid 127 is 10 residues C-terminal to the predicted end of the 
transmembrane region while amino acid 96 is the last intracellular residue prior to the 
start of the transmembrane region. FLAG-1-127 migrated at the exact apparent 
molecular weight as the FLAG-TMEM106B induced NTF (Figure 4.2C) while 
FLAG-1-96 migrated slightly faster than the FLAG-TMEM106B induced ICD, 
suggesting that cleavage is indeed occurring within the transmembrane helix as is 
predicted for iCLiP activity. To more accurately estimate the intramembrane cleavage 
site, we generated untagged ICD constructs +5 and +10 amino acids into the 
transmembrane region relative to the 1-96 ICD. These constructs were run as  
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Figure 4.3: SPPL2a localizes to lysosomes along with TMEM106B and its ICD. (A) 
SPPL2a-V5 co-expressed with TMEM106B co-localizes on LAMP1 positive vesicles 
in N2a cells. (B) A catalytically inactive D412A mutant of SPPL2a also localizes with 
TMEM106B on LAMP1 positive vesicles. (C) SPPL2b-V5 localizes poorly with co-
expressed TMEM106B on LAMP1 positive vesicles. Most SPPL2b appears 
accumulated within ER and Golgi compartments. (D) SPPL2c-V5 does not localize 
with co-expressed TMEM106B. The majority of SPPL2c localizes in the ER. (E) A 
TMEM106B ICD composed of the first 101 amino acids retains its localization with 
lysosome membranes. (F) A truncated TMEM106B ICD composed of the first 96 
cytosolic residues is liberated from lysosomes and is diffusely localized throughout the 
cytosol and associated with the plasma membrane. 
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standards for experiments in which we expected to see ICD generation. As with the 
FLAG-ICD the 1-96 fragment ran slightly faster than the actual ICD, while 1-101 and 
1-106 appeared to run at nearly the same size, with 1-106 being the closest to the 
actual ICD in size (Figure 4.2A and B). All of these Western blots were run on 16% 
tricine gels in order to separate very small protein fragments with similar molecular 
weights. Interestingly, while the 1-106 fragment appeared the closest overall to the 
actual ICD in size, at least two extremely closely spaced bands were formed during the 
generation of the actual ICD, suggesting that there are multiple cut sites within close 
proximity to each other and centered around residue 106 (Figure 4.2A, 4.5A). This 
may suggest some degree of degeneracy in the cleavage site by SPPL2a.  TMEM106B 
is a highly conserved protein, detected throughout the vertebrate lineage. Sequence 
alignment shows that the transmembrane region is absolutely conserved in most 
mammals and is largely identical even in Danio rerio and Xenopus laevisi (Figure 
4.5B)(36). Similarly, intramembrane proteolysis is a ubiquitous mechanism across all 
domains of life. This points to the prospect that RIP of TMEM106B may also be an 
evolutionarily conserved event. 
Based on our data, we would expect to see the NTF on the lysosomal limiting 
membrane; however when overexpressed, FLAG-1-127 localizes exclusively to the 
cell surface, indicating that there are lumenal determinants, such as glycosylation, 
required for proper TMEM106B trafficking to lysosomes (16). While we could detect 
the 1-106 fragment via Western blot in HEK293T cells, it was difficult to distinguish 
from endogenous TMEM106B via immunofluorescence in N2a cells. Therefore, we 
looked at the very closely migrating 1-101 fragment, which appeared to localize 
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primarily to lysosomes, suggesting that the liberated ICD can remain associated with 
the lysosome membrane after RIP (Figure 4.3E). The 1-96 fragment which contains no 
transmembrane residues was nearly completely absent from lysosomes but still 
appeared membrane associated, potentially due to electrostatic interactions between 
the membrane and the string of basic residues at its C-terminus (Figure 4.3F).  
TMEM106A is processed in a similar manner on lysosome membranes  
To test the specificity of TMEM106B as a substrate for SPPL2a mediated 
intramembrane proteolysis, we decided to explore the localization and cleavage 
pattern of two paralogs of TMEM106B: TMEM106A and TMEM106C. N-terminally 
FLAG-tagged TMEM106A and TMEM106C constructs were used for staining and for 
assessing cleavage by SPPL2a and SPPL2b. Like TMEM106B, TMEM106A is 
primarily localized to lysosomes. TMEM106C does not localize to lysosomes but 
rather shows a reticulated pattern in staining, indicative of an ER localization. We 
treated HEK293T cells expressing TMEM106Aor TMEM106C with 3-MA in order to 
detect any potential N-terminal degradation products. Much like TMEM106B, both 
TMEM106A and TMEM106C had a characteristic pair of N-terminal cleavage 
products at approximately ~20-22 and 16-18 kDa as would be expected for 
homologous NTFs and ICDs. This processing pattern is intriguing as it suggests that 
the TMEM106 family may be sequentially degraded within their resident membranes 
in a similar manner. Since TMEM106A is also localized to lysosome membranes, we 
tested if SPPL2a could also enhance the cleavage of the TMEM106A NTF. We found 
no evidence for selective reduction in the NTF or enhancement of ICD formation 
when TMEM106A is co-expressed with SPPL2a (Figure 4.4C), indicating that  
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 Figure 4. 
Figure 4.4: The TMEM106B homologue TMEM106A localizes to lysosomes, but is 
not a substrate for SPPL2a. (A) FLAG-TMEM106A expressed in N2a cells is 
localized primarily to lysosomes, similar to TMEM106B. (B) FLAG-TMEM106C 
expressed in N2a cells does not localize to lysosomes and resides in the ER. (C-D) 
HEK293T cells transfected with FLAG-tagged TMEM106A (C) or TMEM106C (D) 
were treated with 5 mM 3-MA for 14 hours. Each TMEM106 family member has a 
similar molecular weight of full length protein and generates a characteristic predicted 
NTF(s) at ~20-22 and ICD(s) at ~16-18 kDa. Neither TMEM106A or TMEM106C is 
specifically cleaved by co-expression of SPPL2a-v5.  
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SPPL2a displays some degree of selectivity in cleavage of type II transmembrane 
stumps in the lysosomal compartment. Unsurprisingly, SPPL2a had no effect on 
TMEM106C NTF degradation (Figure 4.4D). Similarly, SPPL2b and SPPL2c had no 
effect on TMEM106A or TMEM106C NTF processing (data not shown). 
 
4.5 Discussion 
In this study we demonstrate the selective processing of the lysosome membrane 
protein TMEM106B via the sequential actions of lumenal domain shedding and RIP.  
We showed that inhibition of lysosomal hydrolases with either ammonium 
chloride and/or leupeptin reduces lumenal domain shedding. It is conceivable that this 
shedding event may be mediated by one of the multitude of soluble lysosomal 
proteases present within the lumen. Alternatively, this event may be mediated by an as 
of yet unidentified sheddase present within the lysosome membrane. Further 
experiments are needed to accurately identify the responsible enzyme. It will be 
interesting to understand if this shedding happens constitutively in response to 
elevated levels of TMEM106B, or if other factors regulate this process. 
We show that the GxGD proteases SPPL2a and SPPL2b are capable of 
cleaving TMEM106B when overexpressed; however SPPL2a appears to be more 
specifically inhibited by the SPP family inhibitor (ZLL)2-ketone, and it localizes much 
better to TMEM106B on the lysosomes, in agreement with previous reports showing 
that SPPL2a is predominantly trafficked to endosomes and lysosomes (22,35). 
SPPL2b localizes to the cell surface and was also observed to accumulate 
intracellularly in our immunofluorescence experiments. We speculate that this 
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overexpression may have saturated the machinery normally required for its trafficking 
to the cell surface, causing it to accumulate in the secretory pathway where it may be 
mediating the constitutive degradation of newly synthesized TMEM106B. Microarray 
studies performed by Friedmann and colleagues show that SPPL2b is expressed at low 
levels in most tissues except the adrenal cortex and mammary glands. SPPL2a, on the 
other hand, is expressed at high levels in a large number of tissues, with the highest 
levels detected in the brain (9). EST profiles of TMEM106B also show it to be 
expressed in a large number of tissues, including the brain 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.396358) 
(37). Due to these considerations, we predict SPPL2a, and not SPPL2b, to be the 
major physiologically relevant iCLiP responsible for processing the TMEM106B NTF 
in vivo. 
Our data indicates that SPPL2a cleavage is at least somewhat specific, as the 
highly conserved paralog TMEM106A does not appear to be robustly degraded by 
SPPL2a, despite having a similar localization and a similar degradation pattern in 
vitro. While iCLiPs can have a large array of potential substrates, they do appear to 
display some selectivity even for potentially very similar substrates. This modality is 
supported by experiments by Martin and colleagues in which they demonstrate that 
SPPL2b efficiently cleaves the Bri2 protein, but not the highly homologous Bri3, even 
after it is artificially truncated to mimic the NTF of Bri2 (11). Work by Lemberg and 
Martoglio supports the idea that helix breaking residues in the transmembrane region 
of SPP substrates are required for efficient catalysis and this model has been extended 
to include the SPPL2 family as well with regards to Bri2 degradation by SPPL2b 
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(38,39). Glycine is the second most helix destabilizing amino acid after proline and 
TMEM106B has a glycine residue at position 110 in its transmembrane domain (40). 
We mutated this glycine to alanine, which should yield a much more stable helical 
transmembrane region; however, we did not observe any differences in ICD 
generation
3
. This adds complexity to the picture and suggests that while helix breaking 
residues may be required in many circumstances, they are not an absolute requirement 
for all substrates. 
Our data supports the idea that SPPL2a cleaves the TMEM106B 
transmembrane region in the vicinity of amino acid 106. However, it also appears that 
more than one very closely spaced ICD bands are generated leading us to conclude 
that TMEM106B is cleaved at more than one location within its transmembrane helix. 
It has been shown by mass spectrometry that a similar pattern of multiple cleavage 
sites separated by several amino acids has been detected in the case of SPPL2b 
cleavage of TNFα (31). It has been argued that these multiple cleavage sites are 
required for the liberation of the TNFα ICD into the cytosol (7). This requirement of 
multiple intramembrane cleavage sites may explain why even our 1-101 amino acid 
TMEM106B ICD maintained its association with lysosome membranes. Additionally, 
this lack of absolute specificity of the intramembrane cleavage site may be a more 
general feature of the GxGD family of iCLiPs with ceratin substrates, as similar 
patterns of intramembrane cleavage are seen by proteases such as presenilin. The best 
characterized example of this is APP processing, which can result in multiple forms of 
β-amyloid which vary in length (41). Conversely, some presenilin substrates, such as 
Notch, have a single strictly defined cleavage site, suggesting that these patterns are to  
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Figure 4.5: The TMEM106B intramembrane cleavage site is highly conserved. (A) 
Schematic illustration of the predicted cleavage sites of TMEM106B by an as of yet 
unidentified sheddase at a lumenal juxtamembrane region near amino acid 127 and 
within the transmembrane region centered around amino acid 106. The transmembrane 
region is shown as a blue cylinder. (B) Sequence alignment of the TMEM106B 
transmembrane region from various species shows a high degree of conservation. The 
predicted region where SPPL2a mediated intramembrane cleavage may occur is 
indicated by a line above the absolutely conserved residues, “CLLL.” Sequence 
alignment was performed using Clustal Omega. 
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some degree substrate dependent (42,43). We propose a model in which TMEM106B 
sheds its lumenal domain at amino acid ~127, generating an NTF. This membrane-
retained stub then becomes accessible to cleavage by SPPL2a which can cleave in 
multiple closely spaced sites centered at approximately amino acid 106 (Figure 4.5A). 
Interestingly, this region is conserved in all species examined, highlighting the 
possibility that this TMEM106B membrane processing step is conserved through 
evolution (Figure 4.5B). 
 RIP generation of soluble ICDs has been proposed to mediate a large variety of 
signaling events both in the cytosol and in the nucleus to regulate transcription. Some 
ICDs generated in this manner, such as the ER to nucleus signaling of the SREBP 
proteins and ATF6 as well as the cell surface to nuclear signaling of Notch1, have 
been convincingly shown by a number of approaches (44-46). However, due to the 
extremely short lived nature of the vast majority of ICDs generated by RIP, many have 
yet to be detected in vivo. Hence, many experimentally reported effects of signaling by 
ICDs are only seen under artificial conditions such as reporter assays with 
supraphysiological levels of ICD expressed. Therefore claims of nuclear signaling by 
ICDs remain controversial for a number of RIP substrates. We see no evidence of the 
106 or 101 amino acid ICD fragments in the nucleus when overexpressed. 
Occasionally, we observed small amounts of our FLAG-1-96 construct in the nucleus; 
however, whether a fragment of this size is actually generated in vivo and if it can 
affect transcription are unknown. We cannot rule out that the TMEM106B ICD has a 
signaling function in the nucleus, but given the available evidence this seems unlikely. 
Whether TMEM106B lumenal domain shedding and/or RIP have functional 
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consequences with regards to lysosome function or intracellular/nuclear signaling 
remains to be determined. Perhaps an underappreciated role for some iCLiPs, 
including presenilin and the SPPL family of proteases, is as a membrane protein 
quality control mechanism, allowing the efficient removal of unneeded or damaged 
membrane proteins or for controlling their levels in order to down regulate their 
expression in response to other signals. This has led some to refer to these proteases as 
the proteasome of the membrane. Given the accumulating evidence linking elevated 
TMEM106B levels to FTLD risk, identifying pathways that regulate TMEM106B 
levels may represent an important avenue in developing strategies for therapeutic 
intervention. 
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CHAPTER 5 
 
CONCLUSIONS AND PERSPECTIVES 
 
 The work described here deals with the cellular and molecular basis of FTLD-
TDP pathogenesis as on overarching theme. In particular, I explored how the proteins 
that encode different genetic causes and disease risk modifiers affect various aspects 
of cellular proteostasis, with a focus on lysosomal function. 
 In Chapter 2, I described a role of the ubiquitin binding adaptor protein, p62, in 
mediating cellular clearance of aggregated TDP-43 via the UPS and autophagy-
lysosome pathways. Inclusions containing p62 have been reported in a number of 
neurodegenerative diseases including FTLD; however, their specific role in disease 
pathogenesis are unknown. Moreover, it is unclear if the presence of p62 in inclusions 
is a cause of or consequence of inclusion formation (1). To my knowledge, the data 
presented in chapter 2 is the first published demonstration that p62 can directly lead to 
reduced TDP-43 aggregation in vitro. These data were supported by a recent report 
that p62 directly binds TDP-43 in the brain and that this interaction is impaired in 
cases of FTLD-TDP, lending further weight that my study may be applicable in vivo 
as well. In addition, using phosphomimetic TDP-43 mutants in cell culture models of 
TDP-43 aggregation, I show that phosphorylation of TDP-43 may actually play a role 
in inhibiting further aggregation events, rather than promoting it, as had been proposed 
due to the observation that phosphorylation level is often proportional to the level of 
aggregation (2). Support for my observations came shortly after when another group 
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reported nearly identical results (3). Nonetheless, the data on this subject are still 
incompletely understood and seemingly contradictory dependent upon the system and 
different experimental setups and continues to be a vibrant area of research. This work 
has laid out an important foundation for further studies exploring the roles of other 
ubiquitin binding adaptor proteins such as UBQLN1 and UBQLN2 and the effects of 
other post-translational modifications including alternative phosphorylation sites and 
ubiquitination on TDP-43 aggregation, toxicity, and degradation. Building upon this 
data, this work is actively being pursued in our lab.  
 Chapters 3 and 4, along with the appendices represent the majority of my work 
here at Cornell. This work begins to illustrate a picture of the recently identified FTLD 
risk factor, TMEM106B, as a lysosomal membrane protein whose levels must be 
critically regulated for maintenance of lysosomal homeostasis. Chapter 3 and data in 
the appendices shows that TMEM106B overexpression in neuronal cell culture models 
leads to enlarged, dysmorphic lysosomes, which have defects in degradative capacity, 
lending support to the initial genetic data indicating that increased TMEM106B poses 
risk for FLTD-TDP patients with GRN mutations (4-7). Chapter 3 also demonstrates 
that elevated TMEM106B levels in and of itself is the likely cause of lysosome 
dysfunction and not a direct functional difference due to a coding variant in linkage 
disequilibrium with the risk allele. Interestingly, a recent article claims that the SNPs 
in the human TMEM106B risk allele confer partial resistance to regulation by another 
miRNA species and hence, higher mRNA levels lead to higher protein expression (8). 
Another recent report claims that the T185S coding variant, which is associated with 
the protective allele has a shorter protein half-life, potentially due to changes in a 
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consensus glycosylation site (9). Regardless if one or both of these mechanisms are in 
play in mediating the risk conferred by TMEM106B, mine and others’ data strongly 
supports a model in which increased TMEM106B protein levels confer risk for FTLD-
TDP through its effects on lysosomes. 
 Finally, data in chapter 3 suggests that elevated TMEM106B increases 
intracellular PGRN levels in a post-transcriptional manner, likely due to impaired 
lysosomal degradation. This data was supported to some degree by two 
contemporaneous papers exploring the cellular and molecular functions of 
TMEM106B, but have not been observed by all (8-10). In addition, there is some 
discrepancy as to the effects of elevated TMEM106B on PGRN levels seen in FTLD-
TDP patients and those seen in vitro (4,5,8-10). Hence, it will be important to follow 
up these experiments with more detailed assays to further distinguish the effects of 
TMEM106B on the levels of extracellular and intracellular as well as full-length and 
cleaved granulin species. It appears evident to me that intracellular full-length PGRN 
is elevated by TMEM106B overexpression; however, one limitation of the secreted 
PGRN data presented in this chapter is that it was measured using an ELISA with 
polyclonal antibodies and could theoretically be measuring a combination of full-
length and cleaved granulin species since PGRN is known to be processed 
extracellularly by a variety of proteases (11). Once possibility is that increased 
TMEM106B causes defects in PGRN processing to mature granulins within the 
lysosomes. Preliminary evidence in our lab indicates that co-expressing sortilin with 
PGRN leads to an increase in the levels of processed granulins detected intracellularly. 
Further, determining, PGRN and its granulin products functions in the lysosomes 
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remains a major goal of this lab, with work being done on this front using a 
combination of proteomics and traditional cell biology and biochemistry techniques. A 
more thorough understanding of PGRN processing and its roles in the cell may also 
shed light on why elevated TMEM106B is so deleterious.  
 Chapter 4 presents evidence that TMEM106B levels can be regulated in vitro, 
through successive proteolytic processing of TMEM106B within the lumen of 
lysosomes by an as of yet unidentified protease followed by cleavage within lysosome 
membranes by the iCLiP, SPPL2a. Whether or not, TMEM106B RIP demonstrated 
here results in a functional signaling event remains to be determined. Nonetheless, this 
data is significant as it demonstrates the existence of a pathway which can modulate 
TMEM106B protein levels. Activation of this pathway may be an attractive 
therapeutic target if it can be shown to decrease TMEM106B levels in vivo. The data 
presented in this chapter is currently undergoing revisions to address reviewer 
comments. A number of issues are being addressed as I write this dissertation and 
include more accurate mapping of the NTF and ICD generating cleavage sites using 
more TMEM106B fragment constructs as reference standards. I am also repeating all 
western blot experiments on tricine gels for more consistency in terms of sizes of 
fragments referred to. Figure 4.2 is being repeated for quantitation and statistical 
analysis. I will update the pictures in Figure 4.3 showing that SPPL2a-v5 localizes 
even better with endogenous TMEM106B than overexpressed TMEM106B, which 
tends to aggregate on lysosome membranes and will update information on the 
localization of the NTF and ICD fragments used. I have also repeated Figure 4.4 using 
an untagged TMEM106A construct and a homemade antibody against the 
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TMEM106A ICD showing that SPPL2a does not promote cleavage of TMEM106A. 
Finally, I will metabolically label proteins with 
35
S methionine and immunoprecipitate 
TMEM106B from various cells in an attempt to detect endogenously produced NTF 
and ICD products. This last experiment may prove difficult, as the cleavage is not 
detected at endogenous levels by western blot, but is seen in TMEM106B stable NSC-
34 cell lines and transiently overexpressed in HEK293T cells. It has been well 
established that ICDs generated by RIP from a large number of transmembrane protein 
precursors are usually turned over extremely rapidly, which makes endogenous 
detection difficult (12). I have also used a bioinformatic approach, using the 
SitePrediction software to identify several potential cathepsin cleavage sites in the 
lumenal domain of TMEM106B and generated mutants which may disrupt sites near 
the predicted NTF cleavage site (13). Cathepsins are a broad class of lysosomal 
peptidases with relatively degenerate protease consensus sites, however one feature in 
common with several of the cathepsins is the preference for cutting between paired 
hydrophobic residues on substrates, which was taken in to account when choosing 
sites for mutagenesis (14,15). In all, I have generated both FLAG-tagged and untagged 
Y125D, S130D, Y132D, and Y125D/Y132D TMEM106B mutants which are 
predicted to interrupt at least five potential cathepsin cleavage sites. Preliminary data 
indicates that expression of these mutants results in higher levels of full-length 
TMEM106B and lower levels of NTF, suggesting that at least some of these mutants 
disrupt lumenal domain shedding. SPP and SPPL iCLiPs have been shown to prefer 
substrates with helix-breaking residues in their transmembrane regions, although this 
may not be a universal requirement (16,17). Using a similar strategy, I have also 
 164 
 
generated TMEM106B C105A and P118A mutants which are predicted to increase the 
helical propensity of the transmembrane region and are currently being tested for their 
ability to be processed to TMEM106B ICDs by SPPL2a (18). 
 It is intriguing that in our experiments, overexpression of TMEM106B to a 
large enough degree appears to trigger its degradation via RIP. TMEM106B protein 
levels may be under very tight regulatory control and identifying these mechanisms 
remains an important avenue of research. In Appendix E, I show that ubiquitination at 
residue K3 in TMEM106B may play a role in regulating TMEM106B levels. These 
experiments should be followed up in more detail, in particular to test whether 
ubiquitination at this site affects TMEM106B internalization and degradation within 
lysosomes and if this is mediated through interaction with the ESCRT pathway, which 
has been shown to be disrupted in FTLD-UPS caused by mutations in CHMP2B. The 
levels of TMEM106B and its K3R mutant in the presence of dominant negative 
ESCRT subunit constructs such as disease causing CHMP2B mutants or an ATPase 
dead mutant of VPS4 could be examined. Additionally, ultrastructural examination of 
TMEM106B and the K3R mutant on the limiting membrane and within the lumen of 
lysosomes should be pursued using immuno-gold electron microscopy. 
 In our lab we have generated transgenic mice overexpressing human 
TMEM106B. These mice have been genotyped and confirmed to be expressing 
elevated levels of the human TMEM106B transcript by qPCR as well as confirmed to 
be expressing human TMEM106B protein via mass spectrometry. Despite all this, 
overall levels of TMEM106B detected in the brains and other tissues via western blot 
appear no different from controls, potentially indicating some sort of autoregulatory 
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mechanism at the protein level. While surprising to us, this mode of regulation is not 
unheard of. For example, human TDP-43 transgenic mice show dramatic suppression 
of expression from the endogenous locus (19). It will be interesting to see if 
TMEM106B expression levels change when these mice are crossed with a PGRN 
knockout mouse line to generate a TMEM106B overexpression/PGRN deficient line. 
Furthermore, PGRN knockout mice have been shown to recapitulate many of the 
features of FTLD-TDP, including reductions in social engagement and age-related 
deficits in learning and memory (20-22). Since TMEM106B risk alleles are most 
prominent in GRN mutant carriers, it will be important to test TMEM106B 
overexpressing mice crossed with Grn
+/-
 and Grn
-/-
  mice. The same behavioral tests 
used to assay these mice for FTLD-like phenotypes could be repeated in the context of 
a TMEM106B overexpressing background, which may more accurately recapitulate 
FTLD symptoms and serve as a better disease model for further studies, including the 
testing of therapeutics. 
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APPENDIX A 
LIVE CELL IMAGING OF TMEM106B REVEALS ITS DYANMIC NATURE 
AND POTENTIAL INVOLVEMENT IN MEMBRANE FUSION AND 
TUBULATION EVENTS 
 
A.1 Summary 
Preliminary evidence indicates that TMEM106B regulates lysosome size, number, and 
morphology. I performed a series of live-imaging experiments in order to more 
accurately describe lysosome dynamics which may govern this behavior in a 
TMEM106B overexpression model. 
 
A.2 Introduction 
We and others have recently shown that elevated TMEM106B causes defects in 
lysosome morphology and function. Specifically, overexpression of TMEM106B in 
cell culture models leads to an increase in the overall size of lysosomes and a 
concomitant decrease in the total number of lysosomes per cell. These changes were 
accompanied by increased aggregation of TMEM106B on the lysosome limiting 
membrane, and accumulation of TMEM106B within the lumen of the lysosomes. 
(1,2). Lysosomes are dynamic organelles which exhibit a variety of behaviors 
including fusion events, both with other lysosomes (homotypic fusion) and with 
related organelles such as MVBs and autophagosomes (heterotypic fusion). Both long-
term fusion events, and transient “kiss-and-run” events are known to occur (reviewed 
in ((3)). On the other side of the coin are fission and reformation events in which 
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lysosomes can split into two separate organelles or in which lysosomal membranes 
can reform from hybrid organelles such as autolysosomes, and MVB-Lysosome 
hybrids. This process typically involves a membrane tubule enriched in lysosome 
membrane proteins which buds off the hybrid organelle, and can be re-populated by 
lysosomal hydrolases by the typical mannose-6-phosphate receptor and related 
transport pathways (4,5). Conceptually, the lysosomal phenotype seen with 
TMEM106B overexpression could be due to several factors including: increased 
kinetics of fusion, decreased kinetics of fission or reformation events, or impaired 
degradation of lumenal contents resulting in swollen vacuoles, or some combination of 
these events. In these experiments, I attempted to characterize some of these events 
which may be occurring during TMEM106B overexpression conditions. 
 
A.3 Materials and Methods 
Cell culture and transfections 
 N2a cells were seeded to approximately 40% confluence in a 30 mm glass bottom cell 
culture dish (MatTek Corporation). 48 hours prior to image acquisition, cells were co-
transfected using PEI with GFP control, or GFP-TMEM106B and LAMP1-dsRed 
Monomer, sub-cloned from to LAMP1-YFP (Addgene# 1816) into pDsRed-Monomer 
N1 (Clontech). One hour prior to image acquisition, cells were washed with PBS and 
media replaced with DMEM with no phenol red (Invitrogen), 10% FBS (Sigma), and 
50 mM HEPES pH 7.4.  
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Live Cell Imaging 
 Plates were kept in a 37ºC heated environmental chamber with 5% CO2 atmosphere 
and images acquired at 2-6 second intervals for 10-20 minutes per capture, with 
multiple locations detected per acquisition using an automated stage. Images were 
collected with both a Zeiss LSM700 confocal microscope and a CSU-X spinning disc 
confocal microscope (Intelligent Imaging Innovations) with an HQ2 CCD camera 
(Photometrics) using a 100x objective. Image series were acquired at 24 hours and 48 
hours post-transfection. 
 
A.4 Results and Discussion 
GFP-TMEM106B overexpression causes increased lysosomal size and decreased 
mobility. Consistent with our earlier immunofluorescence experiments reported in (1), 
I observed a clear qualitative difference in the overall size distribution of GFP-
TMEM106B positive lysosomes compared to those from GFP control transfected cells 
(data not shown). Further, these differences were even more apparent at 48 hours post-
transfection than 24 hours, with apparently fewer, but larger GFP-TMEM106B 
positive lysosomes observed per cell. In addition, these engorged lysosomes appeared 
much less dynamic than the smaller ones observed earlier in the experiment and in 
control cells. While this may be due to continued synthesis of GFP-TMEM106B over 
the course of the experiment, it may also indicate a defect in lysosome fission 
dynamics. While these observations are preliminary, they provide an important proof 
of concept that we can image GFP-TMEM106B in combination with LAMP1-dsRed 
in vivo and may pave the way for a more systematic analysis of fusion vs. fission 
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dynamics, particularly in a stable N2a GFP-TMEM106B line that we have recently 
generated. 
 GFP-TMEM106B is a component of lysosomal membrane tubules. In some 
cases, particularly at 24 hours post-transfection, GFP-TMEM106B was seen on 
LAMP1 positive lysosomal tubules which emerged from some individual lysosomes. 
Figure A.1 shows multiple lysosomal tubules which were observed in our 
experiments. Interestingly, in some cases these tubules appeared to link multiple 
individual lysosomes together, possibly suggesting a tethering role or perhaps a way of 
transporting lumenal substrates to nearby lysosomes, analogous to the kiss-and-run 
dynamics seen in certain instances of lysosomal fusion. Perhaps more likely, is that 
these tubules are mediating fission events and the presence of TMEM106B on them 
may suggest a role in this dynamic process. On the other hand, TMEM106B may 
simply be a passenger on these tubules as a normal component of lysosomal 
membranes. Support for the previous notion occurs in a recent study by Rong, et al. in 
which purified autophagic lysosome reformation (ALR) tubules emerging from 
autolysosomes were purified and subjected to mass spectrometry to determine 
components enriched on these membranes. In every instance, TMEM106B was 
identified in their experiments, indicating that TMEM106B can indeed be a 
component of hybrid organelles and may play a role the process of lysosomal 
tubulation events (5). 
 GFP-TMEM106B puncta can be internalized into the lumen of lysosomes and 
may be transferred from the limiting membranes of adjacent lysosomes. At  
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Figure A.1: GFP-TMEM106B is present on lysosomal tubules. N2a cells were co-
transfected with GFP-TMEM106B and LAMP1-dsRed and imaged 24 hours post-
transfection. Scale bar = 10 µm, 2 µm in lower panel magnification. Images were 
acquired 12 seconds apart. An arrow indicates a roughly spherical lysosome which 
projects a TMEM106B positive tubule outwards towards neighboring lysosomes. A 
second tubulating lysosome can also be seen at the top of the inset. 
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endogenous levels at steady state, TMEM106B appears to evenly dot the limiting 
membrane in the form of small puncta. When overexpressed, we frequently observe an 
increase in the size of these puncta and a more polarized or even internalized 
distribution on the lysosome limiting membrane and lumen, respectively. Live-
imaging with high spatio-temporal resolution (time intervals ~2 seconds) reveals that 
these puncta are very dynamic on the limiting membranes of lysosomes. They 
continually track around the membranes and can be seen internalizing into the lumen 
and returning to the limiting membrane on individual lysosomes, compared to the 
much more static distribution of LAMP1-dsRed used in these experiments. An 
example of the former process is illustrated in Figure A.2, in which a GFP-
TMEM106B puncta translocates from the membrane to the lumen and back again, 
potentially highlighting a role for TMEM106B in the transport of membrane 
components to the lysosome for degradation. This is an intriguing possibility as 
CHMP2B, which is mutated in cases of FTLD-UPS is implicated in the budding of 
intralumenal vesicles into the lumen of MVBs.  
 Another feature of the GFP-TMEM106B puncta observed in these studies is 
that they tend to accumulate at the interface of adjacent lysosomes. With two puncta 
from different lysosomes frequently associating together. This is fascinating, as 
TMEM106B appears to homodimerize through its cytosolic intracellular domain 
(discussed in Appendix D), potentially indicating a role in mediating lysosome-
lysosome contacts and possibly homotypic fusion events. In some cases, it appears 
that individual puncta can “jump” between two adjacent lysosomes as shown in Figure 
A.3, further highlighting the extremely dynamic nature of this transmembrane protein. 
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Figure A.2: GFP-TMEM106B traverses the limiting membrane of lysosomes and 
undergoes internalization. The same cell shown in Figure A.1 is shown at a different 
time interval. Scale bar = 10 µm, 2 µm in lower panel magnification. The limiting 
membrane of the lysosome in the inset is highlighted with a dotted line. A single GFP-
TMEM106B puncta can be seen moving along the limiting membrane from 0 seconds 
to 12 seconds followed by internalization into the lysosome lumen from 12 seconds to 
24 seconds.  
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Figure A.3: GFP-TMEM106B is highly dynamic and accumulates at the interface 
between adjacent lysosomes. N2a cells were co-transfected with GFP-TMEM106B 
and LAMP1-dsRed and imaged 48 hours post-transfection. Scale bar = 10 µm, 2 µm 
in lower panel magnification. Images are separated by 2 seconds each. An individual 
lysosome’s limiting membrane is highlighted with a white line. Individual GFP-
TMEM106B puncta are capable of moving rapidly. The arrow highlights a single 
puncta which appears to originate from a neighboring lysosome to the upper right of 
the highlighted one. This GFP-TMEM106B appears at the interface of the two 
lysosomes and rapidly internalizes into the neighbor, in an apparent kiss-and-run 
event.  
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 Nonetheless, caution should be exhibited when interpreting these latter 
conclusions, as the resolution of the confocal microscope is insufficient to differentiate 
individual intralumenal vesicles and it is possible that these internalized puncta may 
still be on the limiting membrane or may be coming into focus from elsewhere on the 
same vesicle, and hence, these may be artifacts of our imaging capabilities. These 
conclusions should be confirmed, preferably with super-resolution microscopy or with 
immuno-electron microscopy to unequivocally demonstrate the presence of 
TMEM106B within the lysosome lumen and at lysosome contact sites.  
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APPENDIX B 
TMEM106B OVEREXPRESSION CAUSES DEFECTS IN LYSOSOMAL 
PROTEOLYSIS 
 
B.1 Summary 
In this experiment, I use a DQ-BSA proteolysis assay to clarify the lysosomal defects 
caused by TMEM106B overexpression. I demonstrate that terminal lysosomal 
proteolysis is impaired. 
 
B.2 Introduction 
We have previously shown that TMEM106B overexpression causes a kinetic delay in 
the degradation of endocytosed EGFR (1). Our results suggested that early and late 
endocytic trafficking is normal in this system, as measured by the kinetics of the 
downstream signaling through phospho-ERK. Another report by Chen-Plotkin and 
colleagues demonstrates impaired acidification in the lysosomes from cells 
overexpression TMEM106B (2). In this assay, we used the fluorogenic substrate DQ-
BSA, which contains a BODIPY dye conjugated to BSA. During proteolysis, the 
BODIPY becomes dequenched, resulting in a red fluorescence readout proportional to 
the amount of proteolytic activity occurring. 
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B.3 Materials and Methods 
Cell culture and transfections 
N2a cells were seeded at 40% confluence on coverslips in a 24-well plate. Cells were 
transiently transfected using PEI with pCMV-TMEM106B or Vector control. 24 hours 
after transfection, lysosomes were loaded with Red DQ-BSA (Invitrogen) by treating 
cells with 10 µg/ml DQ-BSA for 16 hours. A vector transfected well was treated with 
15mM ammonium chloride and 250 µM leupeptin for 16 hours to inhibit lysosomal 
proteases and served as a positive control. After treatment, cells were washed with 
PBS to remove excess DQ-BSA and fixed for 20 minutes with 4% paraformaldehyde. 
Cells on coverslips were permeabilized with PBS containing 0.05% saponin and 3% 
BSA blocking buffer. Primary rat anti-mouse LAMP1 (BD Biosciences) and rabbit 
anti-TMEM106B antibodies were incubated overnight in blocking buffer at 4º C. 
Coverslips were washed 3x with blocking buffer and incubated with anti-Rat 
fluorescein and anti-rabbit CF660 (Biotum) secondary antibodies at room temperature 
for 90 minutes. Cells were washed 3x with blocking buffer and again with PBS. 
Coverslips were mounted with Fluoromount G (Southern Biotech) and imaged on a 
CSU-X spinning disc confocal microscope (Intelligent Imaging Innovations) with an 
HQ2 CCD camera (Photometrics) with a 100x objective. 
Data analysis 
Maximum projection images through the center of the cells of interest were generated 
across two 0.28 µm slices from confocal Z-stacks using Slidebook software 
(Intelligent Imaging Innovations). All channels were background corrected and 
regions of interest drawn around individual cells. Regions were converted to masks 
 180 
 
and the mean intensity of DQ-BSA fluorescence contained within each mask was 
calculated. The mean fluorescence from a minimum of 8 cells from multiple fields of 
view per condition was analyzed for each of three independent transfections. 
Significance was determined with Student’s t-test. 
 
B.4 Results and Discussion 
Our DQ-BSA assay reveals that TMEM106B overexpression causes a statistically 
significant decrease in the level of DQ-BSA fluorescence observed, with levels at 
73.6% of vector controls as shown in Figure B.1 (n=3). Potent inhibition of lysosomal 
protease activity by treating cells with the alkalizing agent ammonium chloride and 
the broad-spectrum lysosomal protease inhibitor leupeptin caused a strong reduction in 
DQ-BSA fluorescence with levels at 47.6% of control cells (n=2), demonstrating the 
validity of our assay. This result confirms ours and others previous observation that 
increased TMEM106B levels are correlated with impaired lysosome function. Further, 
these experiments suggest that elevated TMEM106B causes a primary defect in 
lysosomal protein degradative function, rather than an indirect defect due to 
impairments in endocytic or autophagic trafficking to lysosomes. Interestingly, we 
also looked at the level of Filipin staining, a marker for cholesterol accumulation, 
which is a characteristic of some neurodegenerative lysosomal diseases such as 
Niemann-Pick disease (6). In these experiments, we saw no differences in Filipin 
staining in TMEM106B overexpressing cells versus control cells (data not shown), 
potentially indicating that certain degradative functions of the lysosome are 
differentially affected by elevated levels of TMEM106B. These experiments should be  
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Figure B.1: TMEM106B overexpression leads to impaired lysosomal proteolysis. (A) 
TMEM106B overexpression leads to a significant decrease in the proteolytic capacity 
of lysosomes as measured by the mean fluorescence intensity of cells pre-loaded with 
DQ-BSA. Values represent mean +/-SEM, n=3, *p < 0.05, paired Student’s t-test. (B) 
Representative image of vector transfected control N2a cells loaded for 16 hours with 
10 µg/ml DQ-BSA. Scale bar = 10 µm (C) Vector transfected N2a cells loaded with 
DQ-BSA and treated with 15 mM ammonium chloride and  250 µM Leupeptin to 
inhibit lysosomal proteases served as positive controls. Cells under these conditions 
exhibited strongly reduced DQ-BSA fluorescence. (D) Representative image of N2a 
cells overexpressing TMEM106B. Cells were loaded with DQ-BSA as in (B) and (C) 
and exhibited reduced fluorescence compared to controls. 
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followed up with more specific fluorogenic substrates in order to determine if certain 
proteases are specifically affected by TMEM106B overexpression. Examples of these 
more specific reagents include the specific cathepsin D substrate, Bodipy-FL-pepstatin 
A, and the Cathepsin B substrate, MR-CatB. 
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APPENDIX C 
TMEM106B TRAFFICKING TO LYSOSOMES DEPENDS ON BOTH 
INTRACELLULAR DOMAIN AND LUMENAL DOMAIN DETERMINANTS 
 
C.1 Summary 
In these experiments, I created a series of TMEM106B point mutants, truncations, and 
chimeric transmembrane proteins in order to dissect the molecular determinants of 
TMEM106B trafficking to lysosomes. These experiments reveal that both lumenal and 
intracellular domains of TMEM106B are essential for proper localization, and that 
TMEM106B traffics independently of classical lysosomal targeting motifs.  
 
C.2 Introduction 
Transmembrane proteins can be trafficked to the lysosome through a variety of 
different routes including direct Golgi to lysosome trafficking and indirect trafficking 
via the cell surface. Lumenal domain determinants of transmembrane protein 
trafficking include N-linked glycosylation signals which may be essential for proper 
folding and binding to lectin chaperones (7). Resident lysosome membrane proteins in 
particular, tend have heavily glycosylated lumenal domains to resist degradation by 
the acidic environment and hydrolytic enzymes present within lysosomes. 
TMEM106B contains 5 N-linked glycosylation sites which were previously shown to 
be essential for proper lysosomal targeting (8). The other major determinants of 
transmembrane protein targeting to lysosomes include the cytosolic trafficking motifs, 
most notably the YXXΦ, where Φ represents a bulky hydrophobic residue, and di-
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leucine type motifs, which are frequently preceded by one or two acidic residues at 
positions -3 or -4 and -5, respectively  (Reviewed in detail in (9)). These sequences 
typically bind clathrin binding adaptor proteins such as the µ subunits of the AP-2 and 
AP-3 adaptor complexes in the case of YXXΦ motifs or to the µ or β subunits of the 
AP complexes or the VHS domains of the Golgi-localized, -ear-containing, ARF-
binding (GGA) proteins, in the cases of di-leucine based sorting motifs. Many 
variations of these motifs have been described with the relative position of the motif in 
the cytosolic domain and different amino acids in nearby positions affecting the 
subunit preferences and targeting dynamics in subtle ways. 
 
C.3 Materials and Methods 
Plasmids and constructs 
TMEM106B sub-cloned into the pCMV3xFLAG7.1 vector (Sigma) provided the basis 
for most of these experiments. Mutagenesis was performed for indicated constructs 
using site-directed overlap-extension PCR. Chimeric constructs were generated by 
PCR of the appropriate fragments from indicated cDNAs and sub-cloned into 
pCMV3xFLAG7.1 with the conjugate TMEM106B fragment with overlapping 
restriction sites. TMEM106A, TMEM106C, TfR1, TMEM192 cDNAs were obtained 
from the ORFeome Collection (courtesy of Dr. Haiyuan Yu). TNF-α cDNA was a 
kind gift from Dr. Hening Lin. 
Cell culture and transfections 
N2a cells were seeded at 40% confluence on coverslips in a 24-well plate. Cells were 
transiently transfected using PEI with the indicated constructs. 48 hours post-
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transfection, cells were fixed, stained, and imaged as described above. Primary 
antibodies used were rat anti-mouse LAMP1 1D4B (BD Biosciences) and mouse anti-
FLAG (Sigma). Secondary antibodies were donkey anti-rat CF568 and donkey anti-
mouse CF488 (Biotum). 
Data analysis 
All primary data analysis was performed with Slidebook software (Intelligent Imaging 
Innovations). All images were background corrected to minimize secondary antibody 
cross-reactivity. Individual cells were analyzed by creating a mask around the region 
of interest corresponding to the entire Z-stack of each cell. Pearson correlation 
coefficients of LAMP1 and TMEM106B immunoreactivity were calculated for the 
voxels of individual cells in each condition. A minimum of 23 transfected cells from 
several fields of view were calculated for each condition. Cells were analyzed from a 
minimum of three independent transfections per condition and statistical significance 
determined with ANOVA and post-hoc analysis with Tukey's Multiple Comparison 
Test. 
 
C.4 Results and Discussion 
A C-terminal truncation  (1-241, Full length = 1-274) from the TMEM106B lumenal 
domain that removed the N5 glycosylation sites resulted in significantly impaired 
localization of TMEM106B to lysosomes, with the majority being retained in the ER. 
This is in agreement with results from Lang, et al. in which they show that point 
mutations of glycosylation site Asn residues impaired proper localization in their cell 
culture models (8). Further truncations that remove additional glycosylation sites 
 187 
 
yielded consistent results, with mislocalized TMEM106B fragments primarily at the 
cell surface (data not shown). These results strongly indicate intact N-linked 
glycosylation is required for proper TMEM106B trafficking. 
 The intracellular domain of TMEM106B is predicted to comprise amino acids 
1-96. An N-terminal truncation construct containing amino acids 70-274 exhibited a 
significant impairment in lysosomal localization, although this defect was not as 
severe as the C-terminal truncations. Interestingly, a small subset of cells expressing 
this construct appeared to have a lysosomal localization, suggesting alternative, but 
potentially less efficient routes to the lysosome. It should be noted that the levels of 
this protein product were significantly lower than full length TMEM106B and its C-
terminal truncations as determined by Western blotting (see Figure D.1B), suggesting 
that the ICD of TMEM106B may be important for its long-term stability within the 
cell. A further N-terminal truncation corresponding to amino acids 80-274 failed to be 
detected completely, further suggesting that an intact ICD is essential for protein 
stability. 
 The intracellular domain of TMEM106B has three potential consensus 
lysosomal trafficking motifs, including two YXXΦ motifs, and single degenerate di-
leucine like motif (18-YDGV-21, 50-YVEF-53, and 81-LI-82). In order to determine 
if any of these potential trafficking motifs mediate TMEM106B localization to 
lysosomes, they were mutated individually and combined, with the tyrosine and Φ 
residues from YXXΦ mutated to alanine and the leucine from the di-leucine like motif 
mutated to glycine. Surprisingly, none of these mutants resulted in a lysosomal 
trafficking defect, including when all three motifs were mutated in the same construct 
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(triple mutant), suggesting that the TMEM106B ICD may contain novel trafficking 
determinants independent of traditional targeting sequences. These results should be 
interpreted with caution, however, as TMEM160B is known to dimerize via its ICD 
(Appendix D), and it is conceivable that these mutant constructs were able to dimerize 
with endogenous TMEM106B and be trafficked to lysosomes indirectly through 
interaction with the trafficking motifs of endogenous TMEM106B. Hence, these 
results should be confirmed in cells with endogenous TMEM106B knocked out. 
 TMEM106B has two highly conserved paralogs, TMEM106A and 
TMEM106C, which were also analyzed for localization to lysosomes. TMEM106A 
had a localization pattern nearly identical to that of TMEM106B, potentially 
indicating a similar role in lysosome membranes. TMEM106C, on the other hand 
remained almost entirely within the ER. The results of these trafficking analyses are 
compiled in Figure C.1. 
 In order to more accurately determine if either the ICD or lumenal domain of 
TMEM106B is sufficient for lysosomal targeting, we generated a series of chimeric 
transmembrane proteins. All chimeras were constructed so as to maintain the type II 
transmembrane orientation of the relevant TMEM106B domain. A TMEM106B-TNF-
α chimera consisting of the lumenal domain of TMEM106B (127-274) and the 
intracellular and transmembrane region of the plasma membrane bound form of TNF-
α (1-55) reveals poor localization to lysosomes compared to TMEM106B alone. A 
cartoon schematic of this chimera is illustrated in Figure C.2B. Nonetheless, a small 
subpopulation of this chimeric transmembrane protein managed to localize to 
lysosomes, in addition to the cell surface as shown in Figure C.2B lower panel. This  
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Figure C.1: The lumenal domain and ICD of TMEM106B are both necessary for 
proper lysosomal localization. (A) Pearson correlation coefficients between FLAG and 
LAMP1 immunoreactivity in N2a cells. Values represent mean +/-SEM from a 
minimum of 23 cells split between at least 3 independent transfections. (**p<0.01, 
***p<0.001, one-way ANOVA with Tukey’s multiple comparison’s test) (B) N2a 
cells transfected with full length FLAG-TMEM106B shows high levels of lysosomal 
localization. (C) A C-terminal truncation of FLAG-TMEM106B (1-241) causes 
significant reduction in lysosomal localization, with most being retained in the ER. 
(D) An N-terminal truncation of FLAG-TMEM106B (70-274) also exhibits a 
significant reduction in lysosomal localization, with most located at the cell surface, 
although a small amount still localizes to lysosomes. (E) FLAG-TMEM106B with 
mutations in three predicted lysosomal targeting motifs localized to lysosomes at 
levels similar to WT controls. (F) The homologue, FLAG-TMEM016A is highly 
localized to lysosomes similar to FLAG-TMEM106B while the other homologue, (G) 
FLAG-TMEM106C is almost exclusively seen in the ER. Scale bars in B-G = 10µm.  
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suggests that the lumenal domain alone is not sufficient to mediate localization to 
lysosomes. Additionally, since the vast majority of this chimera appears at the cell 
surface, it is possible that the species that are seen localizing to lysosomes have 
trafficked there for degradation through the endocytic pathway. A separate chimera 
consisting of the TMEM106B ICD (1-96) and the transmembrane and lumenal 
domains of TfR1 (68-760), which normally localizes to the cell surface or early and 
recycling endosomes, was tested (Figure C.2C). Much like the previous chimera, this 
one also poorly localized to lysosomes, with some localizing to the cell surface and the 
majority being retained in the ER, which may suggest that this chimera is improperly 
folded. Similar to the TMEM106B-TNF-α chimera, a small population also localized 
to the lysosomes, potentially suggesting that the TMEM106B ICD may have some 
activity in lysosomal trafficking, although to a significantly impaired degree compared 
to full length TMEM106B. Another possibility is that a portion of these chimeras are 
being trafficked to the lysosomes for degradation, like many other membrane proteins 
along the endocytic pathway that are degraded in a regulated manner. Collectively, 
these two chimeras reveal that both an intact ICD and lumenal domain of TMEM106B 
are necessary for efficient trafficking to lysosomes, with neither domain alone 
sufficient to restore proper localization. 
 As a positive control for lysosomal targeting, I constructed a chimera 
containing a type II oriented intracellular domain composed of amino acids 1-42 of 
TMEM192, which contains two di-leucine motifs capable of potently and specifically 
trafficking to the lysosome (10). The rest of this chimera consisted of the 
transmembrane region and lumenal domain of TMEM106B (97-274). This chimera  
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Figure C.2: TMEM106B lumenal domain and ICD chimeras highlight the importance 
of both domains for correct lysosomal targeting. (A) Cartoon schematic of the domain 
structure and orientation of WT FLAG-TMEM106B. It localizes primarily on 
lysosomes in N2a cells as shown by overlap with LAMP1 staining (scale bar = 10 
µm.) (B) Domain structure and orientation of the FLAG-TNFα-ICD-TM/TMEM106B 
lumenal domain chimera. This construct localized poorly with lysosomes (top panel), 
but a sub-population did localize to lysosomes (bottom panel). (C) Domain structure 
and orientation of the FLAG-TMEM106B-ICD/Tfr1-TM-Ectodomain chimera. 
Overall, localization to lysosomes was very poor with a large amount retained in the 
ER as exemplified by the upper panel. A small population of this chimera did appear 
to partially co-localize with LAMP1 as shown in the lower panel. (D) As a positive 
control for lysosomal targeting, a chimera in which the TMEM106B ICD was replaced 
with the ICD from TMEM192, which contains known lysosomal targeting motifs, was 
generated (FLAG-TMEM192-ICD/TMEM106B-TM-lumenal domain). As expected, 
this chimera localized strongly to lysosomes as shown by co-localization with 
LAMP1. This chimera appeared to localize more potently and specifically to 
lysosomes than WT FLAG-TMEM106B. 
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actually targeted to the lysosomes with an even higher efficiency than WT 
TMEM106B as shown in Figure C.2D. This chimera was almost totally restricted to 
the lysosomes, with little to no staining at the cell surface, which is observed to some 
degree in most cells transfected with FLAG-TMEM106B. This is noteworthy, as it 
shows that specific lysosomal targeting motifs actually improve the localization of 
TMEM106B to the lysosomes, further strengthening the argument that TMEM106B 
lacks traditional YXXΦ or di-leucine trafficking motifs. Thus, TMEM106B lysosomal 
targeting may be represented by a novel trafficking mechanism, involving cooperation 
between the ICD and lumenal domains.  
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APPENDIX D 
TMEM106B EXISTS AS A DIMER AND BINDS HOMOTYPICALLY THROUGH 
ITS INTRACELLULAR DOMAIN 
 
D.1 Summary 
In this series of co-immunoprecipitation (co-IP) experiments, I analyze the domain 
determinants governing TMEM106B’s homodimerization and show that this 
interaction is mediated primarily through the ICD. Additionally, I show that 
TMEM106B is capable of forming heterodimers in vitro with its lysosomally localized 
paralog, TMEM106A.  
 
D.2 Introduction 
Western blots of TMEM106B reveal the presence of a heat sensitive species that runs 
at approximately twice the size of its monomeric ~43 kDa form, suggesting the 
presence of an SDS-resistant dimer (1,2). In order to determine the regions of 
TMEM106B that mediate this interaction, I performed co-IP experiments with various 
deletion constructs and chimeras. These experiments reveal that the ICD of 
TMEM106B is necessary and sufficient to bind to full length TMEM106B. 
TMEM106A, a highly conserved family member that also localizes to lysosomes is 
also shown to co-IP with TMEM106B, suggesting that heterodimers may exist in vivo. 
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D.3 Materials and Methods 
Plasmids and constructs 
Full-length TMEM106B and all N-terminal and C-terminal deletion constructs were 
sub-cloned into the pCMV3xFLAG7.1 vector. TMEM106B chimeras were generated 
as described in the previous appendix. GFP tagged TMEM106A and TMEM106B 
were used as prey proteins and were expressed in pEGFP-C1 (Clontech). 
Co-immunoprecipitations 
HEK293T cells in 6-well plates were co-transfected with the indicated constructs with 
PEI. 48 hours post-transfection, cells were washed with PBS and lysed in 500 µl IP-
lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10 
mM β-glycerophosphate, 5 mM sodium fluoride, and a Complete Mini protease 
inhibitor [Roche]). Lysates were cleared by centrifuging at 18,000 rcf for 20 minutes 
at 4º C. A fraction of the cleared supernatant was saved as input and the remaining 
supernatant was immunoprecipitated for four hours at 4º C with ANTI-FLAG M2 
Magnetic Beads (Sigma) or GFP Magnetic beads (ChromoTek). Beads were washed 
four times with lysis buffer, eluted with 15 µl of 3xFLAG peptide 200 ng/µl (Sigma) 
or 1% SDS in 50 mM Tris pH 8.0 elution buffer, then mixed with 2x Lamelli’s 
loading buffer and boiled two minutes. 
Western blots 
Inputs and eluates were run on 12% SDS-PAGE gels and transferred to PVDF 
membranes. Membranes were blocked with Odyssey blocking buffer (Li-Cor) for one 
hour. Mouse anti-FLAG M2 (Sigma) and homemade rabbit anti-GFP primary 
antibodies were added overnight at 4º C in Tris buffered saline pH 7.5 with 0.1% 
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Tween-20 (TBS-T). Membranes were washed three times with TBS-T, and incubated 
90 minutes at room temperature with donkey anti-mouse/rabbit conjugated to 
AlexaFluor 680 (Invitrogen) or IR DYE 800 (Li-Cor). Membranes were washed three 
more times with TBS-T and imaged with an Odyssey infrared scanner (Li-Cor). 
 
D.4 Results and Discussion 
GFP-TMEM106B co-IPed with full length FLAG-tagged and a series of C-terminal 
TMEM106B deletion constructs as shown in Figure D.1 (A and B). Deletion 
constructs as short as the first 96 amino acids, corresponding to the ICD of 
TMEM106B maintained the ability to bind GFP-TMEM106B in vitro. N-terminal 
deletion constructs on the other hand, failed to bind GFP-TMEM106B. A 
TMEM106B lumenal domain construct (127-274) failed to significantly interact with 
GFP-TMEM106B. A very faint band could be seen under these conditions; however 
its levels were comparable to those seen in a vector control IP. A shorter N-terminal 
deletion construct (70-274), which contains the transmembrane region and part of the 
ICD of TMEM106B also failed to interact with GFP-TMEM106B, suggesting that an 
intact ICD is necessary for homodimerization. One feature of the N-terminal deletion 
constructs is their lower apparent stability, as shown by the weaker immunoreactive 
bands seen in the inputs. In an attempt to control for these lowered protein levels, I 
used a chimeric protein consisting of the ICD and TM regions of membrane bound 
TNF-α (1-55) fused to the lumenal domain of TMEM106B (127-274) described in 
Appendix C. A sub-population of this chimera localizes to lysosomes as shown in 
Figure C.2B, yet it still fails to bind to GFP-TMEM106B in these co-IP experiments,  
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Figure D.1: TMEM106B homodimerizes through its ICD and can heterodimerize 
with TMEM106A. (A) Co-IPs from 293T cells transfected with GFP-TMEM106B and 
vector control or FLAG-TMEM106B and N- and C-terminal truncations. a chimera 
with its ICD from TNF-α (TNF-α 1-55/TMEM-127-274) (B) More TMEM106B co-
IPs with additional truncation construts and a chimeric TMEM106B with its ICD 
replaced with one from TNF-α (TNF-α 1-55/TMEM-127-274) demonstrate that the 
TMEM106B ICD is required for dimerization. (C) GFP-TMEM106B co-IPs FLAG-
TMEM106A and (D) FLAG-TMEM106A reciprocally co-IPs GFP-TMEM106B. 
  
 199 
 
suggesting that the TMEM106B ICD contains specific structural features governing its 
homodimerization. 
 I have previously demonstrated that the TMEM106B paralog, TMEM106A 
also localizes primarily to lysosomes (Figure 4.4A and Figure C.1F). In order to test if 
TMEM106B could form heterodimers in vitro, I performed reciprocal co-IPs with 
GFP-TMEM106B and FLAG-TMEM106A as shown in Figure D.1 (C and D). 
TMEM106B and TMEM106A bound strongly and specifically in these experiments, 
raising the possibility that they may form functional heterodimers in vivo. Since the 
primary functions of these membrane proteins still remains unknown, the 
physiological implications of this interaction remain to be determined. 
 The results of these experiments confirm that TMEM106B likely exists as a 
dimer in vivo to some degree. An extremely large number of membrane proteins have 
been shown to be able to dimerize and/or oligomerize and these self-interactions are 
thought to likely regulate a multitude of physiologically relevant protein functions in 
vivo, ranging from signal transduction events, regulation of channel activity, and as 
scaffolds for the formation of supramolecular complexes, among other functions (11). 
These results also have important implications for the interpretation of the trafficking 
experiments described in Appendix C. Since the ICD of TMEM106B is required for 
homodimerization, this may explain why the lysosomal targeting motif mutants did 
not have defects in localization, but the 70-274 deletion mutant, which cannot 
homodimerize, did have defects. Future experiments will have to be performed to 
address this discrepancy, preferably in a TMEM106B knockout background. Another 
question that needs to be addressed is if this homodimerization occurs in cis or in 
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trans; that is within the same membrane, or between adjacent membranes, 
respectively. Since the ICDs of TMEM106B embedded in lysosome membranes face 
the cytosol, it is conceivable that adjacent vesicles could bind to each other through 
the homophilic interaction of their respective ICDs. Interestingly, TMEM106B puncta 
were observed to accumulate between tightly packed, enlarged lysosomes in the live 
imaging experiments described in Appendix A. It is tempting to speculate that these 
interactions may play a role in mediating homotypic or heterotypic fusion events 
between lysosomes and/or other vesicles such as late endosomes and autophagosomes. 
These ideas could be tested more systematically and in depth in future studies. 
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APPENDIX E 
UBIQUITINATION OF TMEM106B ON ITS INTRACELLULAR DOMAIN 
CONTROLS ITS LEVELS 
E.1 Summary 
In this set of experiments I demonstrate that TMEM106B can be ubiquitinated in vitro 
with lysine residue 3, being particularly important. This ubiquitination event appears 
to modulate the levels of TMEM106B, but not its localization on lysosomes at steady 
state.  
 
E.2 Introduction 
Ubiquitin modifications to the cytosolic sides of membrane proteins provide a 
versatile way to regulate their trafficking and degradation (12). Because elevated 
levels of TMEM106B are strongly implicated as a risk factor for FTLD-TDP, 
identifying mechanisms by which its levels can be controlled will be critical for 
determining targets for therapeutic intervention. 
 
E.3 Materials and Methods 
Plasmids and constructs 
HA-ubiquitin in the pCDNA3.1 vector (Addgene # 18712) was used for all 
ubiquitination assays. TMEM106B constructs in the pCDNA3xFLAG7.1 vector were 
used to determine ubiquitinated domains and were: full length (1-274), NTF (1-127), 
ICD (1-96), and ΔICD (70-274). For determining the contribution of individual 
ubiquitination sites, untagged TMEM106B in pCMV-Sport6 was subjected to site-
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directed mutagenesis as described previously to generate K3R, K14R, and K3R/K14R 
double mutants.  
Ubiquitination assay 
HEK293T cells were co-transfected in 6-well plates with HA-ubiquitin and either 
FLAG-TMEM106B deletion constructs or pCMV-TMEM106B ubiquitination site 
mutants. Cells were washed with PBS and lysed in 500 µl RIPA buffer (50 mM Tris 
pH 7.5, 150 mM NaCl, 0.1% SDS, 0.05% sodium deoxycholate, 1% Triton X-100, 
and a Roche complete mini protease inhibitor). Lysates were cleared at 18,000 rcf for 
20 minutes at 4ºC. Inputs were saved and supernatants immunoprecipitated with either 
ANTI-FLAG M2 Beads (Sigma) or homemade Rabbit anti-ICD or Rabbit IgG control 
antibodies conjugated to sepharose resin. Purified TMEM106B was eluted with either 
FLAG peptide of 1% SDS elution buffer. 
Western blots 
Western blots were performed as previously described. Primary antibodies used were 
mouse anti-HA.11 (Covance) and homemade rabbit anti-ICD.  
Immunofluorescence 
Immunofluorescence was performed as previously described. 
 
E.4 Results and Discussion 
In order to determine if TMEM106B can be ubiquitinated in vitro and if so, which 
domains are modified, I performed immunoprecipitations with FLAG-TMEM106B 
and several domain deletion constructs co-transfected with HA-ubiquitin. These 
experiments reveal that full length TMEM106B is robustly ubiquitinated, with three 
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clear ubiquitin modifications visible as ICD and HA immunoreactive bands, each 
spaced ~7 kDa apart as shown by arrows in Figure E.1A. A 1-127 amino acid 
TMEM106B construct, which we have dubbed the NTF and includes a short region of 
the lumenal domain, the transmembrane region, and ICD also showed robust 
ubiquitination in this assay. Interestingly, the ICD alone (1-96) revealed no detectable 
ubiquitination, despite the fact that the majority of the ubiquitinatable lysine residues 
in the previous NTF construct are located in the ICD. This suggests that membrane 
anchoring is essential for TMEM106B to be properly targeted for ubiquitination by the 
appropriate E3 ligase. As predicted, a construct lacking the majority of the ICD (70-
274) failed to be ubiquitinated as well. Note, that this band does not appear on the 
western blot in Figure E.1A, as it was immunoprecipitated with FLAG-beads, but 
blotted with rabbit anti-ICD antibodies so as to be compatible with the mouse anti-HA 
antibodies used on the same membrane. I have previously shown that this construct is 
readily immunoprecipitated by FLAG-beads in Figure D.1B. 
 The previous experiment established that TMEM106B is most likely 
ubiquitinated somewhere in its ICD as long as it remains membrane bound. 
TMEM106B has three lysines in its ICD which can potentially be modified with 
ubiquitin at residues 3, 14, and 95 (K3, K14, and K95). K95 is directly adjacent to the 
start of the hydrophobic transmembrane helix and based on surrounding residues is 
likely a part of the type II signal anchor sequence (13). K3 and K14 appear to be prime 
targets for ubiquitination, and in fact TMEM106B ubiquitination at K14 has been 
detected as a ubiquitinated residue in a number of proteomic studies of global 
ubiquitination (14-17). The proteomic methods used in these studies involve trypsin  
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Figure E.1: TMEM106B is ubiquitinated in vitro to regulate its levels. (A) FLAG-
TMEM106B and truncation constructs were immunoprecipitated from HEK293T cells 
co-expressing HA-ubiquitin. Full length (1-274) and a membrane bound NTF (1-127) 
show robust ubiquitination, but not the soluble ICD domain alone (1-96) or an ICD 
truncation (70-274). (B) Untagged TMEM106B and various ICD ubiquitination 
defective mutants were co-transfected with HA-ubiquitin and immunoprecipitated. 
Constructs with K3R mutated consistently reveal higher levels of TMEM106B, 
suggesting that ubiquitination at K3 may mediate degradation of TMEM106B.  
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digestion of target proteins. Since trypsin cuts after lysine and arginine residues, it is 
highly likely that the small three amino acid peptide containing K3 was lost during 
chromatographic separation of peptides and was not detected in these studies. K3, 
K14, and K95 were mutated to arginine residues, both individually and in pairs. Also, 
since the FLAG tag has several lysines which can potentially be ubiquitinated, the 
next immunoprecipitation was performed with untagged wild type and mutant 
TMEM106B. As before, immunoprecipitation of each of these species yielded the 
characteristic ubiquitin ladder separated by ~7 kDa each and reactive to both ICD and 
HA antibodies as shown in Figure E.1B. All TMEM106B species tested showed this 
pattern, albeit in differing degrees, suggesting that TMEM106B is ubiquitinated 
redundantly. In particular, K95R appeared to be more heavily ubiquitinated, despite 
slightly lower levels of full-length TMEM106B in this sample. It is also possible that 
TMEM106B is ubiquitinated at its N-terminal amine, which cannot be controlled for 
through mutagenesis. Of particular interest is the fact that all mutants containing a 
K3R mutation (K3R, K3R/K14R, and K3R/K95R) showed more full-length 
TMEM106B in both input and immunoprecipitation fractions, strongly suggesting that 
ubiquitination at K3 may be a critical ubiquitination site that serves as a mode of 
regulating TMEM106B levels in vivo. 
 In order to test if these ubiquitination mutants had any defects in lysosomal 
localization, or effects on size and distribution of lysosomes, they were transfected 
into N2a cells and stained with rabbit anti-ICD and rat anti-LAMP1 antibodies. To our 
surprise, none of the mutants appeared to significantly affect the size or morphology 
of lysosomes and none had any apparent defects in internalization into the lysosomal  
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Figure E.2: TMEM106B ubiquitination mutants do not disrupt localization on 
lysosomes. N2a cells were transfected with WT TMEM106B and K3R TMEM106B, 
K14R TMEM106B, and K3R K14R TMEM106B ubiquitination defective mutants. 
No major differences in intracellular distribution on and within lysosomes were 
detected, suggesting that no single ubiquitination site is critical for internalization into 
lysosomes. (Scale bar = 10 µm, 2 µm in inset)   
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lumen, at least at steady state. Like most of these immunofluorescence experiments, 
the distribution of TMEM106B on and within lysosomes was somewhat 
heterogeneous, but no large scale differences could be detected (Figure E.2). 
Nonetheless, these results suggest that ubiquitination likely plays a major role in 
controlling TMEM106B levels and potentially its trafficking as well. As with the 
trafficking experiments described in Appendix C, one caveat is that TMEM106B is 
known to homo-dimerize, and it is possible that ubiquitination mutants such as 
K3R/K14R could bind to endogenous wild type TMEM106B, and be internalized into 
lysosomes through this interaction, rather than being solely dependent on ESCRT 
mediated internalization. These results warrant further investigation to more 
thoroughly characterize the causes and consequences of TMEM106B ubiquitination at 
the cellular level. 
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APPENDIX F 
TMEM106B PROTEIN-PROTEIN INTERACTION PARTNERS IDENTIFIED 
USING SILAC 
 
F.1 Summary 
The proteomic technique, stable isotope labeling by amino acids in cell culture 
(SILAC), was used to identify potential protein-protein interaction partners of 
TMEM106B. Several candidates were identified and confirmed biochemically with 
co-IP assays. Additionally, the localization of these putative binding partners was 
examined via immunofluorescence. 
 
F.2 Introduction 
SILAC describes a proteomic technique in which cells are grown in parallel with 
different isotopically labeled amino acids in order to identify protein-protein 
interaction partners (18). Briefly, cells are grown for several generations to fully 
incorporate the light and heavy isotopically labeled amino acids. The protein of 
interest, TMEM106B, was then expressed and affinity purified from the heavy isotope 
labeled cells, while the light isotope labeled cells were mock purified. Fractions from 
both populations were then combined and subjected to analysis with mass 
spectrometry. By selecting peptides identified by the mass spectrometer that have a 
high abundance and high heavy peptide to light peptide ratio, it is possible to predict 
potential interacting partners. Likely candidates were selected for further biochemical 
analysis in order to identify bona fide TMEM106B interacting partners. From these 
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experiments, we were able to identify four likely TMEM106B protein interacting 
partners: Motile Sperm Domain-Containing Protein (MOSPD2), clusterin, neural cell 
adhesion molecule 1 (NCAM1), and calnexin. These interactions were confirmed via 
co-IP and further analyzed for localization with TMEM106B using 
immunofluorescence.  
 
F.3 Materials and Methods 
SILAC 
NSC-34 cells were grown for a minimum of five generations in DMEM with 10% 
dialyzed FBS (Sigma) supplemented with either light (C
12
, N
14 
arginine and lysine) or 
heavy (C
13
, N
15 
arginine and lysine) amino acids. The heavy cells were transfected in 
two 15 cm dishes with GFP-TMEM106B while the light cells were transfected with 
pEGFP-C1 as a control. Cells were lysed in IP lysis buffer and clarified lysates were 
immunoprecipitated with GFP-beads (Chromo-Tek) as previously described.  
 The presence of GFP and GFP-TMEM106B in immunoprecipitated samples 
was confirmed by running SDS-PAGE and performing a silver stain. Samples were 
then mixed and boiled 5 minutes with 1% DTT followed by alkylation by treating 
samples with a final concentration of 28 mM iodoacetamide. Proteins were 
precipitated on ice for 30 minutes with a mixture of 50% acetone/49.9% ethanol/0.1% 
acetic acid. Protein was pelleted and washed with this buffer, re-precipitated on ice, 
and dissolved in 8M urea/50 mM Tris pH 8.0 followed by dilution with three volumes 
of 50 mM Tris pH 8.0/150 mM NaCl. Proteins were digested overnight at 37º C with 1 
µg mass-spec grade Trypsin (Promega). 
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 The resulting peptide samples were cleaned up for mass spectrometry by 
treatment with 10% formic acid and 10% trifluoroacetic acid (TFA) and washed twice 
with 0.1% acetic acid on pre-equilibrated Sep-Pak C18 cartridges (Waters). Samples 
were eluted with 80% acetonitrile (ACN)/0.1% acetic acid into silanized vials 
(National Scientific) and evaporated using a SpeedVac. Samples were re-dissolved in 
H2O with ~1% formic acid and 70% ACN. Peptides were separated using hydrophilic 
interaction liquid chromatography (HILIC) on an Ultimate 300 LC (Dionex). Each 
fraction was evaporated with a SpeedVac and resuspended in 0.1% TFA with 0.1 pM 
angiotensin internal standard. Samples were run on a Thermo LTQ Orbitrap XL mass 
spectrometer and data analyzed using the SORCERER system (Sage-N research). 
Co-immunoprecipitations 
co-IPs were performed in HEK 293T cells as previously described. In the case of 
cross-linking co-IP, cells were treated with Dimethyl 3,3´-dithiobispropionimidate 
(DTBP) (Pierce). DTBP was applied to cells at a final concentration of 500 µg/ml in 
DMSO and PBS at 37º C for 2 minutes. DTBP cross-linking was quenched by 
washing cells three times with TBS prior to lysis.  
Immunofluorescence 
Cells were transfected, fixed, and imaged, as described previously. YFP-Golgi and 
YFP-Tgn38 plasmids were kindly provided by Dr. Volker Vogt. 
 
F.4 Results and Discussion 
The proteins MOSPD2, clusterin, NCAM1, and calnexin were considered likely 
candidates for interaction with TMEM106B based on the SILAC mass spectrometry 
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data which measured the number and abundance of unique peptides detected in the 
heavy versus light fractions. These interactions were confirmed by co-transfecting 
GFP and GFP-TMEM106B baits with the indicated prey proteins. GFP-TMEM106B, 
but not GFP control co-IPed with each of these proteins in HEK 293T cells. Both 
GFP-TMEM106B (data not shown) and FLAG-TMEM106B were able to co-IP with 
detectable levels of endogenous calnexin. In order to further demonstrate that these 
protein-protein interactions are not an artifact of the GFP-tag, I repeated them with 
FLAG-TMEM106B in HEK 293T cells treated with the reversible protein cross-
linking reagent, DTBP (Pierce). These experiments revealed that FLAG-TMEM106B 
is also capable of binding MOSPD2, clusterin, and NCAM1 in vitro, albeit not as 
strongly as GFP-TMEM106B. The results of these co-IP experiments are summarized 
in Figure F.1. We have previously noted in Chapter 3 that GFP-TMEM106B appears 
to be expressed at higher levels compared to FLAG-TMEM106B, and this correlates 
with a more severe vacuolar phenotype in cell culture models of TMEM106B 
overexpression. We speculate that these differences in expression levels and their 
effect on lysosome morphology may partially explain the heightened binding between 
GFP-TMEM106B and these protein binding partners identified with SILAC.  
 The identities and distribution of these TMEM106B interacting partners may 
provide some insight towards the nature and function of these interactions. Calnexin is 
a membrane bound ER-resident chaperone that binds and facilitates the proper co-
translational folding of nascent glycoproteins (19). Hence, it is unsurprising that 
TMEM106B is one of the many substrates whose folding and stability are maintained 
by calnexin when traversing the ER.  
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Figure F.1: TMEM106B SILAC hits bind to TMEM106B in vitro. GFP-TMEM106B 
was co-transfected with (A) MOSPD2-v5, (B) clusterin-v5, or (C) NCAM1-v5 in 
HEK293T cells. GFP-TMEM106B potently co-IPs all of these proteins. Note, that in 
(B) GFP-TMEM106B also appears to pull down a higher MW band above the major 
clusterin band, indicated by *, suggesting potential enrichment of a post-translational 
modification. (D) FLAG-TMEM106B specifically co-IPs endogenous calnexin in 
HEK293T cells. (E) FLAG-TMEM106B co-IPs with MOSPD2, clusterin, and 
NCAM1 in HEK293T cells, albeit with lower efficiency than GFP-TMEM106B. 
These cells were treated with the cross-linking reagent DTBP, prior to 
immunoprecipitation.  
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 Clusterin strongly co-localizes with GFP-TMEM106B in N2a cells as shown 
in Figure F.2A. Clusterin is a multi-functional protein that has been shown to play a 
role in the clearance of extracellular misfolded proteins and promote their trafficking 
to and degradation in lysosomes, partially explaining the high degree of co-
localization with TMEM106B at lysosomes (20). Intriguingly, clusterin has recently 
been implicated as a modifying risk factor for Alzheimer’s disease in several studies 
(21-23). Due to its role in extracellular proteostasis and its documented linkage to at 
least one neurodegenerative disease, it will be interesting to explore the functional 
relationship between clusterin and TMEM106B in future studies. One could speculate 
a potential function of TMEM106B as a lysosomal receptor for extracellularly derived 
complexes of clusterin and misfolded proteins, akin to the role of LAMP2 in 
chaperone mediated autophagy, another lysosomal degradation pathway used for a 
subset of cytosolic proteins (24). 
 NCAM1 has numerous isoforms that are highly expressed in the nervous 
system where its homophilic interactions at the cell surface are thought to play roles in 
processes ranging from neurite outgrowth, axon guidance, and cell migration to 
regulating synaptic plasticity and long term potentiation (25,26). NCAM1 is highly 
expressed at the plasma membrane, although a significant fraction was also seen on 
lysosome membranes along with TMEM106B in our immunofluorescence 
experiments shown in Figure F.2B. NCAM1 has been shown to be endocytosed in a 
mono-ubiquitin dependent manner, with a small fraction being degraded in lysosomes 
(27). As a resident lysosome membrane protein, it is difficult to say if TMEM106B 
plays a direct role in regulating NCAM1 trafficking or retention at the lysosome or if  
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Figure F.2: GFP-TMEM106B co-localizes with clusterin and NCAM1. N2a cells 
were transfected with GFP-TMEM106B and clusterin-v5 (top panel) or NCAM1-v5 
(bottom panel) (scale bar = 10 µm, 2 µm in inset). Clusterin localizes very well with 
GFP-TMEM106B positive vesicles. NCAM1 is primarily expressed at the cell surface, 
but a portion localizes to the membranes of GFP-TMEM106B positive vesicles. 
Cathepsin D staining used to indicate lysosomes. 
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this interaction is simply a byproduct of the normal endocytic delivery of excess 
NCAM1 to lysosomes for degradation. Nevertheless, as a critical player in a number 
of essential neuronal processes, it would be of interest if it can be shown that 
TMEM106B plays a role in regulating NCAM1 degradation in vivo. 
 The final verified SILAC hit to be discussed here is MOSPD2, a poorly 
characterized protein with an MSP (major sperm protein) domain, a Sec14 domain, 
and a small C-terminal transmembrane region, as inferred from UniProtKB-KW. MSP 
domain proteins, named for the MSP protein in C. elegans are thought to be protein-
protein interaction domains capable of polymerizing into self-associating helical 
filaments (28). Sec14 domains from different proteins are known to bind to an array of 
different phospholipids, suggesting MOSPD2 may play a role dependent on membrane 
binding (29). MOSPD2 localizes strongly to GFP-TMEM106B positive membranes; 
however, the major pool appears to originate from the Golgi as evidenced by near 
perfect co-localization with the Golgi markers YFP-Golgi and YFP-Tgn38 shown in 
Figure F.3A. To our surprise, very little MOSPD2 co-localizes with untagged 
TMEM106B at lysosome membranes at steady state as shown in Figure F.3B. These 
differences in co-localization between the different forms of TMEM106B expressed 
may also explain the much higher affinity between GFP-TMEM106B and MOSPD2 
in our co-IP assays, with the GFP-TMEM106B form potentially dominantly binding to 
MOSPD2. Despite the much lower co-localization overall, small amounts of MOSPD2 
still localized with TMEM106B at steady state. Interestingly, when cells were treated 
over night with the lysosomotropic agent chloroquine, MOSPD2 was redistributed 
from the Golgi to lysosomes and showed a near perfect co-localization with  
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Figure F.3: MOSPD2 is primarily localized to the Golgi, but re-distributes to 
TMEM106B positive lysosomes under alkalizing conditions. (A) GFP-TMEM106B 
localizes somewhat well with MOSPD2-v5 in N2a cells (top panel). MOSPD2-v5 is 
located mainly within the Golgi at steady state, as shown by co-localization with YFP-
Golgi (middle panel) and YFP-Tgn38 (bottom panel) (scale bar = 10 µm). (B) Only a 
small amount of MOSD2-v5 localizes to untagged TMEM106B positive lysosomes at 
steady state (top panel). Upon treatment with the lysosome alkalizing agent, 
chloroquine, MOSPD2-v5 completely relocalizes to swollen, TMEM106B positive 
lysosomes (bottom panel). (C) Treatment with 100 nM Bafilomycin for 14 hours 
results in co-immunoprecipitation of  untagged TMEM106B and MOSPD2. 
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TMEM106B as shown in the lower panel of Figure F.3B. Similar results were 
obtained with another inhibitor of lysosome acidification, bafilomycin A1 (BafA1) 
(data not shown). Consistent with this re-loacalization of MOSPD2 to TMEM106B 
positive lysosomes under alkalizing conditions, we see a physical interaction between 
MOSPD2 and TMEM106B when cells are treated with BafA1, but not under untreated 
conditions as seen in Figure F.3C. These data suggests that MOSPD may shuttle back 
and forth between the Golgi and lysosomes and that elevated expression of 
TMEM106B, or inhibition of lysosome acidification may trap MOSPD2 at lysosomal 
membranes. MOSPD2 contains a putative phospholipid binding Sec14 domain and 
appears to be able to move back and forth between the Golgi and lysosomes, 
suggesting a potential role in regulating post-golgi membrane trafficking events. 
Further biochemical and live imaging experiments may help uncover a possible role 
for MOSPD2 that involves TMEM106B. 
 Taken together, these SILAC hits shed some light on potential roles of 
TMEM106B in lysosomal degradation of extracellular and membrane bound proteins 
as well as involvement in membrane trafficking. Nonetheless, it is difficult to tell the 
significance of some of these interactions. For example, calnexin is an ER-resident 
chaperone that binds a large variety of glycoprotein substrates. Clusterin also has well 
documented roles as a molecular chaperone and it is unclear if its binding to 
TMEM106B reflects a non-specific chaperone function or as a specific ligand-receptor 
interaction. Similarly, NCAM1 has been shown to be degraded in lysosomes and its 
appearance in our hits may reflect this normal turnover process. Finally, MOSPD2, 
while potentially interesting due to its domain structure, is completely uncharacterized 
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functionally, and any functional interaction with TMEM106B so far remains a 
mystery. Future SILAC experiments could be optimized to find more potential binding 
partners to give a clue towards TMEM106B function. Stable cell lines expressing 
closer to endogenous levels of TMEM106B could be used in conjunction with cross-
linking reagents in order to sensitively detect interactions with transient or low-
abundance binding partners. Additionally, lysosomal fractions could be purified prior 
to immunoprecipitation of TMEM106B in order to eliminate much of the non-specific 
binding and enrich the sample with lower abundance lysosomal proteins. These 
experiments have provided some insight into TMEM106B’s potential roles in the cell 
and should be followed up in order to more accurately determine TMEM106B’s 
physiological functions. 
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APPENDIX G 
TMEM106B IS A COMPONENT OF AUTOLYSOSOMES AND A SUBSTRATE 
FOR AUTOPHAGIC DEGRADATION 
 
G.1 Summary 
TMEM106B has been demonstrated to be a component of the membranes of late 
endosomes/lysosomes meaning it has the potential to be form hybrid organelles with 
autophagosomes. In this set of experiments, I demonstrate that TMEM106B is a 
component of autolysosome membranes and is turned over in response to starvation 
induced autophagy. 
 
G.2 Introduction 
Because TMEM106B has been shown to be a component of late endosome/lysosome 
membranes, I sought to determine if TMEM106B was incorporated into hybrid 
organelles such as amphisomes or autolysosomes, the formation of which are essential 
for neuronal health (30). The fate of membrane proteins incorporated into these hybrid 
organelles generally follows one of two patterns: intralysosomal degradation or 
membrane recycling in a process known as autophagic lysosome reformation (4). 
LC3-II, which decorates the double membrane of autophagic vacuoles is a 
prototypical example of a membrane bound protein which undergoes intralysosomal 
degradation while the lysosomal membrane protein LAMP1, typifies a membrane 
protein that is preferentially recycled from hybrid organelles into nascent 
protolysosomes (5,31). 
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 In the following experiments, I demonstrate that TMEM106B is indeed a 
component of starvation induced autolysosomes and that its levels appear to decrease 
concomitant with increased autophagy. This supports a model in which TMEM106B 
is at least partially degraded intralysosomally following autophagy. TMEM106B 
overexpression still allowed for the formation of autolysosomes, suggesting that 
elevated TMEM106B does not prevent lysosome-autophagosome fusion, as has been 
proposed to be the case for some FTLD causative proteins like mutant VCP and 
CHMP2B. 
 
G.3 Materials and Methods 
Cell culture and transfections 
N2a cells were transfected with GFP-TMEM106B, mCherry-LC3 as described in (32), 
and LAMP1-iRFP in which LAMP1 was sub-cloned into the piRFP vector (Addgene 
#31857) (33). For serum starvation conditions, cells were washed with PBS and grown 
in DMEM without FBS for the indicated time points. For amino acid starvation 
conditions, cells were washed with PBS and grown in Hank’s balanced salt solution 
(HBSS) for the indicated time period. All cells were kept at 37ºC in a 5% CO2 
incubator.  
Western blots 
Western blots were performed as previously described. 
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G.4 Results and Discussion 
We have previously shown that endogenous TMEM106B levels increase when cells 
are treated with the autophagy inhibitor, 3-MA, or with lysosomal alkalizing agents 
such as BafA1 (1). In order to further confirm that TMEM106B levels are regulated 
via autophagic turnover, N2a cells were serum starved for up to 10 hours and the 
levels of TMEM106B assayed at two hour intervals. TMEM106B levels were 
noticeably reduced and continued to decline throughout the time course. The most 
notable reduction occurred starting at ~4 hours and coincided with the beginning of 
the most prominent increase in autophagy as indicated by the levels of LC3-II relative 
to LC3-I. These results are displayed in Figure G.1A. 
 Since membrane proteins can be turned over through other mechanisms, 
including ERAD and in primary lysosomes that have not fused with autophagosomes, 
I sought to confirm that TMEM106B was indeed present on autolysosomes. 
Autophagy was rapidly induced by amino acid starvation of N2a cells expressing 
mCherry-LC3 and GFP-TMEM106B. In this assay mCherry-LC3 puncta are formed 
as LC3-I is converted to LC3-II and this is used as a readout for autophagosome 
formation. After one hour of amino acid starvation, numerous LC3 puncta could be 
detected, with a subset of them also positive for GFP-TMEM106B and cathepsin D, 
suggesting that even under overexpression conditions, TMEM106B can still be 
incorporated into autolysosomes. Treatment with BafA1 increases endogenous 
TMEM106B levels and is known to inhibit LC3-II turnover in autolysosomes. Based 
on this knowledge, I tested if it is possible to enhance the visualization of TMEM106B 
positive autolysosomes by treating amino acid starved cells with 50 nM BafA1  for 16  
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Figure G.1: TMEM106B is turned over via autophagy and is present on 
autolysosomes. (A) Western blot from N2a cells serum starved for the indicated times. 
Levels of endogenous TMEM106B decrease concomitant with starvation along with 
conversion of LC3-I to LC3-II which becomes most apparent from 6 hours and 
beyond. (B) N2a cells expressing mCherry-LC3 and GFP-TMEM106B were amino 
acid starved for 1 hour and stained for cathepsin D. GFP-TMEM106B appears on the 
same vesicles as mCherry-LC3 that stain for Cathepsin D in the lumen, indicating that 
TMEM106B is a component of autolysosomes.  A single autolysosome is indicated 
with an arrowhead and highlighted in the inset. (C) The same population of cells from 
(B) was amino acid starved and co-treated with BafA1 to inhibit the degradation of 
mCherry-LC3 and GFP-TMEM106B in autolysosomes. These conditions allow the 
visualization of numerous autolysosomes simultaneously. Several clustered 
autolysosomes are highlighted in the inset. Scale bars = 10 µm, 1 µm in inset. 
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hours. As expected, TMEM106B, LC3-II, and cathepsin positive vesicles were readily 
apparent, lending further support to the idea that TMEM106B is turned over in 
autolysosomes similarly to LC3-II. These results are shown in Figure G.1B. 
 These results confirm that TMEM106B is indeed a component of hybrid 
organelles and that it is at least partially degraded via autophagy. Collectively, the data 
argue against a model in which elevated TMEM106B causes defects in 
autophagosome-lysosome fusion. Nevertheless, at this point, it cannot be ruled out that 
subtle differences in the kinetics or efficiency of these fusion events may be affected 
until more carefully controlled experiments are performed which compare endogenous 
to overexpressed TMEM106B.  
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APPENDIX H 
TMEM106B mRNA IS UPREGULATED IN THE MICROGLIA OF PGRN 
KNOCKOUT MICE 
 
H.1 Summary 
TMEM106B mRNA levels have been reported to be elevated in FTLD-TDP, 
particularly those caused by GRN mutations, however these results have been 
controversial due to reproducibility issues and the reliance on post-mortem brain 
tissue. Here, we sought to compare the levels of TMEM106B and other lysosomal 
gene mRNAs in different populations of CNS cells from WT and PGRN knockout 
mice. In cells from newborn mice, TMEM106B mRNAs appears unaffected by Grn 
genotype status in neurons and astrocytes, whereas TMEM106B mRNA is 
significantly upregulated in microglia from Grn
-/-
 mice. 
 
H.2 Introduction 
Mounting evidence indicates that TMEM106B mRNA and protein levels are elevated 
in the brains of FTLD-TDP patients with GRN mutations; however some of these 
results are confounded by a reliance on post-mortem brain tissue, which can suffer 
from poor mRNA quality, as well as difficulties in reproducibility (2,34-36).  
 Using quantitative real-time PCR (qPCR), we sought to determine if PGRN 
knockout mice had elevated TMEM106B mRNA levels and if any effects were 
specific to any of the three major cell classes of the CNS: neurons, astrocytes, and 
microglia. To our surprise, mouse TMEM106B mRNA levels were unaffected in the 
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neurons and astrocytes of PGRN knockout mice; however levels were significantly 
upregulated in cells of microglial lineage. 
 
H.3 Materials and Methods 
Primary cell preparation  
Wild type C57BL/6 and Grn
-/-
 mice (Jackson Laboratory) were used for these 
experiments. For cortical neuron preparation, cortexes were rapidly dissected from the 
brains of postnatal day 1 (P1) mice in HBSS supplemented with B27 and 0.5 mM L-
glutamine (Invitrogen) on ice. Separated cortexes were digested with papain 
(Worthington) and DNase I (Sigma) at 37º C with gentle agitation.  Neurons were 
separated by trituration and passage through a flame polished glass pipette. The 
supernatant was then centrifuged at 225 rcf for 5 minutes and pellets washed with 
Neurobasal A medium (Invitrogen). Cells were separated through a 70 µm cell strainer 
and plated at a concentration of 1.0 x 10
6
 cells/ml on poly D-lysine coated cell culture 
plates (BD Biosciences). Cells were grown in Neurobasal A medium supplemented 
with B27, sodium pyruvate, and L-glutamine. After day 3, cells were treated with 1 
µM cytosine arabinoside (Sigma) to limit mitotic growth and to enrich for neurons. 
 Microglia and astrocytes were prepared by dissecting forebrains from P1 mice 
in PBS-5% FCS on ice. Cells were separated by trituration and passage through a 
flame polished pipette followed by separation with a cell strainer. Cells were pelleted 
and resuspended in DMEM with 10% FBS and penicillin-streptomycin (Sigma). Cells 
were seeded in 75 cm flasks and grown at 37º C and 5% CO2. After 4 days, culture 
medium was supplemented with 5 ng/ml GM-CSF (Sigma) and media changed every 
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4 days. At DIV12, flasks were shaken at 125 rpm at 37º C for 4-5 hours. Floating 
microglial cells were separated, pelleted, and re-plated on poly D-lysine coated cell 
culture plates while the remaining cells in the flask were comprised primarily of 
astrocytes.  
RT-PCR 
mRNA was collected and reverse transcribed followed by quantitative RT-PCR 
(qPCR) as described (1). All transcripts were normalized to the geometric mean of two 
reference genes, Tbp, and the 18S rRNA gene. Statistical significance between WT 
and PGRN-/- samples was determined with Student’s t-test. 
 
H.4 Results and Discussion 
Mouse TMEM106B mRNA levels from cortical neurons, astrocytes, and microglia 
from WT and PGRN
-/-
 mice were compared using qPCR. Surprisingly, TMEM106B 
mRNA levels were virtually unchanged in the neurons and astrocytes from WT versus 
Grn
-/-
 mice. Interestingly, microglia from Grn
-/-
 mice had a statistically significant 
>1.5 fold increase in TMEM106B mRNA compared to WT controls as shown in 
Figure H.1A. This is intriguing because along with neurons, microglia, are one of the 
major cellular sources of PGRN in the CNS, particularly in response to injury (37,38). 
When comparing PGRN between these three cell classes, microglia consistently 
showed the highest levels with virtually no PGRN mRNA detected in samples from 
PGRN knockout mice, confirming the specificity of our assay (data not shown). This 
may indicate that the effect of PGRN loss on transcription of targets such as 
TMEM106B is most acutely seen in cells with high basal PGRN expression.  
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Figure H.1: Microglia from Grn
-/-
 mice exhibit increased Tmem106b mRNA. (A) 
Cortical neurons, astrocytes, and microglia from WT and Grn
-/-
 newborn mice were 
analyzed using qPCR. Microglia, but not neurons or astrocytes, from Grn
-/- 
mice 
showed >1.5 fold increase over WT mice. (B) Microglia from Grn
-/-
 mice show 
upregulation of a number of lysosomal genes in addition to Tmem106b, including Ctsd 
and Psap. Not all lysosome genes were affected the same way as Ctss was not 
upregulated. Values represent mean +/-SEM (neurons and microglia n=3, astrocytes 
n=5, *p < 0.05, **p < 0.01 paired Student’s t-test). 
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Strikingly, in a microglia specific conditional PGRN knockout mouse model, 
neuroinflammation is increased and neuronal loss in response to injury is exaggerated, 
suggesting that neuronal loss in FTLD-TDP may occur in a cell non-autonomous 
manner (38). Based on this model, elevated TMEM106B in PGRN deficient microglia 
may potentially also exhibit effects on neurons in vivo. It should be noted that cortical 
neurons were selected for these experiments based on the types of neurons most 
affected in FTLD-TDP; however other populations of neurons may exhibit differing 
responses to loss of PGRN. Additionally, while microglia clearly showed a robust 
increase in TMEM106B mRNA due to PGRN loss, there was a slight upward trend in 
TMEM106B mRNA in our cortical neuron samples and it is possible that these data 
may be limited by small sample size. Finally, as an age-related dementia, FTLD-TPD 
typically manifests at middle age or later and this age-dependence is recapitulated in 
mouse models of FTLD caused by loss of PGRN (39-41). Hence, it is possible that we 
failed to see an increase in TMEM106B mRNA in neurons since they were cultured 
from newborn mice. Due to technical limitations, we did not analyze neuronal mRNA 
from aged mice, but future experiments could explore the effect of aging on levels of 
TMEM106B mRNA in the brains of WT and PGRN
 
knockout mice. 
 During the course of these experiments, we also looked at the mRNA levels of 
a number of other lysosomal genes. Interestingly, many of these lysosomal genes 
behaved similarly to TMEM106B, with levels being upregulated ~1.5-2 fold in PGRN 
knockout
 
mice. As before, this effect was by far the most prominent in microglia. 
Besides TMEM106B, lysosomal genes which were upregulated in Grn
-/- 
mice included 
Psap, which encodes the sphingolipid activator protein prosaposin, and Ctsd, which 
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encodes the lysosomal hydrolase cathepsin D. Another lysosomal hydrolase, cathepsin 
B (Ctsb) was upregulated and approached significance with a p-value = 0.501 and 
would likely become significant with a larger sample size. Interestingly, not all 
lysosomal genes were upregulated, with some completely unaffected, including 
another hydrolase, cathepsin S (Ctss), suggesting that there is some specificity in the 
lysosomal genes that are upregulated, and loss of PGRN does not result in a global 
upregulation of all lysosomal genes. Additionally mRNA levels of the PGRN receptor, 
sortilin (Sort1), which is responsible for delivering PGRN to lysosomes, were 
unaffected. The results from these experiments appear in Figure H.1B. 
 As discussed in previous chapters, PGRN appears intimately involved in 
lysosomal function and is one of the major transcriptional targets of the lysosomal 
master regulator, TFEB (42,43). A recent report supports the notion that PGRN 
suppresses at least some lysosomal gene expression, with PGRN knockout microglia 
exhibiting increased activation and increased transcription of many lysosomal genes in 
response to injury (44). This report and our data suggest that the increased 
TMEM106B mRNA levels seen in PGRN deficient backgrounds may represent a 
somewhat large scale perturbation of lysosome associated transcription. Furthermore, 
this may indicate that PGRN, itself a target of TFEB, acts in a negative feedback loop 
to suppress TFEB transcriptional events. The nature of this interaction still remains 
elusive and further research should investigate the signaling pathways and mechanistic 
aspects of PGRN and TFEB function and why certain subsets of lysosomal genes 
appear to be differentially affected. 
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